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ABSTRACT OF DISSERTATION 
 
 
 
PHASE BEHAVIOR OF AMORPHOUS SOLID DISPERSIONS: MISCIBILITY AND 
MOLECULAR INTERACTIONS 
 
 
Over the past few decades, amorphous solid dispersions (ASDs) have been of 
great interest to pharmaceutical scientists to address bioavailability issues associated with 
poorly water-soluble drugs. ASDs consist of an active pharmaceutical ingredient (API) 
that is typically dispersed in an inert polymeric matrix. Despite promising advantages, a 
major concern that has resulted in limited marketed formulations is the physical 
instability of these complex formulations. Physical instability is often manifested as 
phase heterogeneity, where the drug and carrier migrate and generate distinct phases, 
which can be a prelude to recrystallization. One important factor that dictates the physical 
stability of ASDs is the spatial distribution of API in the polymeric matrix. It is generally 
agreed that intimate mixing of the drug and polymer is necessary to achieve maximum 
stabilization, and thus understanding the factors controlling phase mixing and nano-
domain structure of ASDs is crucial to rational formulation design. The focus of this 
thesis work is to better understand the factors involved in phase mixing on the nanometric 
level and get insights on the role of excipients on overall stabilization of these systems. 
The central hypothesis of this research is that an intimately mixed ASD will have better 
physical stability as compared to a partially homogeneous or a non-homogeneous system. 
Our approach is to probe and correlate phase homogeneity and intermolecular drug-
excipient interactions to better understand the physical stability of ASDs primarily using 
solid-state nuclear magnetic resonance (SSNMR) spectroscopy and other solid-state 
characterization tools. A detailed investigation was carried out to understand the role of 
hydrogen bonding on compositional homogeneity on different model systems. A 
comprehensive characterization of ternary ASDs in terms of molecular interactions and 
physical stability was studied. Finally, long-term physical stability studies were 
conducted in order to understand the impact of different grades of a cellulosic polymer on 
phase homogeneity for two sets of samples prepared via different methods. Overall, 
through this research an attempt has been made to address some relevant questions 
pertaining to nano-phase heterogeneity in ASDs and provide a molecular level 
understanding of these complex systems to enable rational formulation design.  
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CHAPTER 1. INTRODUCTION: FUNDAMENTALS OF AMORPHOUS SOLID DISPERSIONS  
1.1 Introduction 
Oral route for drug delivery is considered the most preferred for its ease of 
administration, high patient compliance, cost effectiveness and flexible dosage design.1 
After oral ingestion of the solid dosage form, the drug is released in gastrointestinal (GI) 
tract, dissolved in GI fluids, then absorbed across the intestinal mucosa and passed 
through the liver to systemic circulation to reach its site of action.2 For the drug to 
dissolve in GI medium, appreciable aqueous solubility is required for adequate 
absorption and oral bioavailability. Thus, the two key properties of drug candidates that 
govern their extent of oral bioavailability are aqueous solubility and intestinal 
permeability. Based on these two properties, Amidon et al., proposed the 
biopharmaceutics classification system (BCS) in the year 1995.3 According to BCS, drug 
substances are classified into four classes based on their aqueous solubility and intestinal 
permeability (Figure 1.1). These four categories include drugs with high solubility/high 
permeability (class I), low solubility/high permeability (class II), high solubility/low 
permeability (class III), and low solubility/low permeability (class IV). A drug substance 
is considered “highly soluble” when the highest dosage strength is soluble in 250 mL or 
less in aqueous media (pH 1-7.5) whereas the drug is considered “highly permeable” 
when ≥ 90% of the administered dose is absorbed across GI barrier.4 
Combinatorial chemistry and high-throughput screening employed in drug 
discovery have significantly increased the number of poorly water soluble drug 
candidates.5,6 Poor aqueous solubility is responsible for a large number of attritions with 
the majority of new chemical entities (NCEs) with challenging physicochemical 
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properties. This has emerged as a major obstacle in drug discovery and development.7 It 
is estimated that approximately over 75 % of drug candidates, 60 % of NCEs, and 90 % 
of marketed drugs belong to either BCS class II or class IV.7-10 Thus, there is an 
increased interest in developing efficient formulation strategies for such drug candidates. 
This has resulted in progress of BCS class II compounds further along the drug 
development stages and several have become successful marketed drugs.2,5  
Some approaches that have been utilized successfully to address low drug 
solubility include salt formation, crystal modification, pH modification, cyclodextrin 
complexation, particle size reduction, lipid based systems, and amorphization.11,12 
Among the approaches stated above, amorphization is a prominent solubilization 
strategy. Amorphous solids are characterized by short range order and high internal 
energy.13 Generally, amorphous drugs have higher solubility than the corresponding 
crystalline form since the need of overcoming the lattice energy for the solubilization 
process is waived off.14 Studies point out that an amorphous form of a drug can generate 
1.1 to 1000 fold increase in solubility of the same drug compared to its crystalline 
form.15,16 These benefits come with a cost and the enhanced thermodynamic properties 
also accounts for higher chemical reactivity and crystallization tendency that can occur 
during manufacturing, storage or dissolution.17 Hence, an amorphous form of drug is 
seldom used alone. 
An important strategy for stabilizing an amorphous drug against crystallization is 
to disperse it into a polymer matrix, forming a solid dispersion.18,19 A solid dispersion 
can potentially enhance the physical stability by reducing the molecular mobility of a 
drug and increasing the diffusion length for the assembly of drug molecules into a drug 
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rich phase or recrystallization.20,21 In spite of the benefits offered by this formulation 
technology, developing a robust solid dispersion formulation still remains a daunting 
task for pharmaceutical scientists. Therefore, a significant part of pharmaceutical 
academic and industrial research is directed towards understanding the critical factors for 
physical stabilization of amorphous drugs. In this chapter, we will discuss the 
characteristics of amorphous state and factors affecting the physical stability and 
physicochemical properties of amorphous solid dispersion. In addition, preparation 
methods and the characterization techniques are also reviewed. Last but not least, a 
comprehensive overview of available literature on amorphous solid dispersions (ASDs) 
is presented here. 
1.2 The Amorphous State 
A convenient way to visualize the energetics of the amorphous state can be 
achieved through drawing the schematic representation of enthalpy (or volume) 
variations as a function of temperature (Figure 1.2). If we consider a situation where 
molten drug is cooled to the melting point (Tm) of the crystalline phase, which is a first-
order transition and leads to a decrease in free volume and enthalpy. However, if 
crystallization is not allowed to occur then the material enters the “supercooled” liquid 
state without depicting any discontinuity in H and V. The “supercooled” liquid state is 
often called a rubbery state due to the high viscosity of the material. Further cooling will 
result in substantial increase in viscosity and produce a glass at the glass transition state 
(Tg), accompanied by a change of slope. It should be noted that the “glassy state” is a 
non-equilibrium state and Tg can fluctuate with processing conditions and as a function 
of the history of the sample, which implies that Tg is a thermal event affected by kinetic 
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factors.13 At temperatures below Tg, the material becomes brittle and extremely viscous 
(>1012 Pa s).22 Moreover at temperatures below Tg, the real glass relaxes to reach 
asymptotically the equilibrium state and when the material is re-heated to the Tg, the lost 
enthalpy is recovered again.17 If the supercooled liquid curve is traced below Tg, there 
comes a point where it meets the crystal curve at temperature known as the Kauzmann 
temperature (TK). At TK, the configurational entropy of the system reaches zero and is 
believed to be a temperature with zero mobility ensuring sufficient physical stability for 
the sample.13 
The amorphous state is characterized by the absence of long-range three 
dimensional order and has enhanced thermodynamic properties in comparison to their 
crystalline counterparts as a result possess higher apparent solubility. Since the 
amorphous state is thermodynamically unstable, there is a tendency to approach a lower 
energy level through a process of relaxation.23 In theory, three types of relaxations are 
observed (α, β and γ relaxations). The slower, primary and universal motions involving 
Tg belong to α relaxations while β relaxations represent faster, secondary local motions 
of specific chemical groups or sequences and are dominant below the Tg. It is suggested 
that α relaxations are the key kinetic factor for crystallization, whereas β relaxations are 
responsible for crystallization below Tg for many systems.
24 Besides these two relaxation 
processes, γ relaxations are closely related to β relaxations but occur at lower 
temperatures.23  
1.3 Amorphous Solid Dispersions 
Historically the term “solid dispersion” was first used by Chiou and Riegelmann 
in 1971 who defined it as “a dispersion of one or more active ingredients in an inert 
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carrier at the solid state, prepared either by the melting, the solvent or the combined 
melting solvent methods”.25 However, the concept was first used earlier where the drug 
was delivered with a carrier as a eutectic mixture but it was Chiou and Riegelmann who 
first proposed a classification system for solid dispersions.25,26 Since then, this 
technology has been used as a viable formulation strategy to overcome the low oral-
bioavailability of BCS class II compounds. Before we discuss the other topics related to 
this important platform technology, it is relevant to study briefly its classification system. 
 
Figure 1.1. Biopharmaceutics classification system (BCS) and formulation approaches 
applicable for different classes. Adapted from reference.12  
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Figure 1.2. Schematic representation of thermodynamic relationship of amorphous and 
crystalline states. The green curve represents Tg curve of a solid dispersion. TK: 
Kauzmann temperature, Tg: glass transition, Tm: melting temperature. Modified from the 
reference.17 
1.3.1 Classification of Solid Dispersions 
Depending on the molecular structure of active pharmaceutical ingredient (API) 
in the carrier, the solid dispersions can be divided into crystalline solid dispersion and 
amorphous solid dispersion (ASD). Furthermore, within crystalline solid dispersion two 
classes exist: solid solution and eutectic mixture. Likewise, ASD group can be further 
divided into two sub-groups: glass solutions and glass suspensions. Here, we restrict 
ourselves to the ASD group, consisting of amorphous API and the carrier. The 
classification system for solid dispersions is shown in Table 1.1.  
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In the case of glass solutions, the carrier is amorphous while the drug molecules 
are molecularly dispersed in the amorphous matrix forming a homogenous single-phase 
system. These days polymers such as synthetic poly(vinylpyrrolidone) (PVP), 
semisynthetic hydroxypropyl methyl cellulose (HPMC) are employed as amorphous 
carriers.27 An intimate mixing between the drug and polymer ensures a physically stable 
system provided solubility of the drug in the polymer does not exceed. However, if drug 
is present at supersaturated concentration, recrystallization may occur. For a system to 
classify as a glass suspension, the drug is no longer dispersed molecularly within the 
amorphous polymer and multiple phases exist. In such system, the drug usually exists as 
a separate drug rich amorphous phase and may have higher tendency to recrystallize.  
More recently a different system of classification has been proposed based on the 
complexity of solid dispersions and their evolution over the time.19 Based on this 
classification system, solid dispersions can be categorized into four generations (Figure 
1.3). The generations highlight the advancement of knowledge and their composition.  
Figure 1.3. Classification of solid dispersions and their properties. Adapted from 
references.19,27 
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Table 1.1. Classification of solid dispersions. 
State of API 
Number of Phases 
1 2 
Crystalline Solid solution Eutectic mixture 
Amorphous Glass solution Glass suspension 
 
1.3.2 Preparation Methods 
Broadly, the preparation methods for ASDs can be classified into two major 
groups: solvent based or fusion based.27 Each group encompasses many technologies 
under it and the same is shown as a schematic in Figure 1.4.  
1.3.2.1 Fusion Based Technologies 
In general, fusion based approach involves heating the drug and carrier mixture 
above their melting point or Tg and then cooling the mixture to kinetically trap the 
amorphous form of the drug. The resultant solid sample is then crushed, pulverized and 
sieved to reduce the particle size. Even though this approach is solvent-free and 
frequently used, this method has some limitations such as thermolability of the drug and 
carrier at high temperatures.27 In addition, the drug and carrier need be to miscible at 
high temperatures as any immiscibility can potentially lead to phase separation from 
inhomogeneous distribution of drug in the matrix. 
Hot-melt extrusion (HME) is a popular fusion based technique that has been used 
for manufacturing ASDs on an industrial scale. The technique has its origin in plastic 
industry and known for its high scalability and applicability. In this method, the drug and 
carrier are mixed together and pumped through a heated barrel by one or two screws 
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under pressure and then discharging the extrudate through a die to get product in a 
specific shape such as a rod, pellet or tablet.28 The intense mixing and agitation forced by 
rotating screws ensure homogenous mixing and also make the process continuous.29 In 
order to lower the processing temperature or reduce the melt viscosity, low molecular 
weight additives such as plasticizers are added.23 This technique offers many advantages 
like solvent free method, efficient process, easy scale up and continuous manufacturing. 
Moreover, another important advantage of HME in comparison with other fusion based 
methods is the low residence time of the drug-polymer melt at higher temperature which 
diminishes the risk of degradation in the case of thermolabile drug. This technology has 
been successfully used for manufacturing marketed products like Kaletra, Onmel, 
Rezuin, Norvir, and Zoladex.30  
Other fusion based technologies that have been developed for ASDs include 
KinetiSol®. KinetiSol® is a new upcoming technology that is specifically suitable for 
thermolabile compounds as it uses shorter residence time than a regular HME process.30 
It can work better with viscous melts and thus the use of plasticizers can be avoided.31 
This technology is being developed for industrial manufacturing and there are no 
marketed products yet being manufactured via this process.  
1.3.2.2 Solvent Based Technologies 
The solvent based technologies include spray drying, freeze drying, rotary 
evaporation, supercritical fluid technology, fluid bed granulation, coprecipitation, spray 
freeze drying and electrospining.27 With solvent based technologies, the common steps 
involve preparation of drug carrier solution in a common solvent followed by 
evaporation of the solvent to produce a solid sample. This approach is devoid of any 
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melting at elevated temperature and hence most suited for thermolabile APIs. An 
important requirement for this approach is the sufficient solubility of API and the carrier 
in a common solvent, which can be challenging at times. Solvent like methanol, ethanol, 
methylene chloride, acetone, water or their mixtures have been employed and sometimes 
surfactants are also incorporated to aid in solubilization. The main disadvantage of this 
method is the issue of residual solvent, which is nearly impossible to remove completely 
and may pose toxicity based on solvent(s) used.30 Also, the residual solvent can act like a 
plasticizer and promote potential phase separation.32 Other challenges that are associated 
with this approach are high production cost, extra infrastructure for solvent removal, 
environmental concerns and potential explosion hazards.  
Spray drying is the most industrially applicable technique based on solvent based 
approach to be employed for ASDs manufacturing. It has been used in the field of 
pharmaceuticals since 1970s and is known for its efficient processing.33 This unit 
operation consists of drug-carrier solution or suspension that is atomized into fine 
droplets and evaporating the droplets rapidly using a drying hot gas inside the drying 
chamber followed by collection of solid particles in a cyclone. This technique has proven 
to be effective method for preparation of ASDs and offers better process control with 
desired particle properties.34 Compared to traditional solvent based methods like rotary 
evaporation, this approach ensure better mixing and hence molecularly dispersed ASDs 
are produced. It has been shown that phase separation in the final product can be 
controlled through processing conditions.35 A typical schematic of spray drying process 
is presented in Figure 1.5. Several marketed products prepared by this technology 
include InCivek, Kalydeco, Intelence and Torcetrapib.30  
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Figure 1.4. Commonly used methods in preparation of ASDs. 
 
Figure 1.5. Schematic representation of spray-drying equipment. Taken from source.82  
 
1.3.3 Characterization of Amorphous Solid Dispersions 
The characterization of ASDs is very crucial in order to study their phase 
behavior and require in-depth comprehensive characterization. A variety of 
characterization tools are available and multiple analytical techniques are used in 
conjunction to provide qualitative and quantitative information on crystallinity, phase 
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mixing, molecular mobility, intermolecular interactions, residual moisture/solvent 
content etc. In this section, the focus is given to techniques that are most widely applied 
such as differential scanning calorimetry (DSC), powder X-ray diffraction (PXRD), 
thermogravimetric analysis (TGA) and fourier transform infrared spectroscopy (FTIR). 
A comparative analysis of commonly employed technique is presented in Table 1.2. For 
this thesis work, special focus is given to solid-state nuclear magnetic resonance 
(SSNMR) spectroscopy, which is covered in-depth in Chapter 2. 
1.3.3.1 Differential Scanning Calorimetry 
DSC has been used as a very important technique for examining the thermal 
properties of ASDs like melting point, Tg event, enthalpy recovery, crystallinity, 
polymorphic transitions etc.36 The operating principle involves heating the sample and 
the empty reference pan inside the furnace and measuring the temperature difference 
between them. The total heat flow can be described by: 
 𝑑𝑄
𝑑𝑡
= 𝐶𝑝.
𝑑𝑇
𝑑𝑡
+ 𝑓(𝑡, 𝑇) (1.1) 
 
where dQ/dt is the total heat flow, Cp is the heat capacity of the sample, dT/dt is the 
heating rate and f(t, T) is the kinetic heat flow. It can be seen from the equation 1.1 that 
total heat flow contains two components: a specific heat component (non kinetic) and a 
kinetic component, which is a function of time and temperature.37 In a standard DSC 
setup, it is not possible to resolve these two components and hence modulated DSC 
(mDSC) is used. In mDSC experiments, a nonlinear waveform is superimposed on the 
linear heating rate. Thus, it possible to deconvolute the total heat flow into the reversing 
(Cp related ) and non reversing (kinetic) contributions, where non reversing heat flow 
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signal is the difference between the total and reversing heat flow as shown in equation 
1.2.38 
 𝑄𝑡𝑜𝑡𝑎𝑙 = 𝑄𝑟𝑒𝑣𝑒𝑟𝑠𝑖𝑛𝑔 + 𝑄𝑛𝑜𝑛𝑟𝑒𝑣𝑒𝑟𝑠𝑖𝑛𝑔 (1.2) 
 
mDSC improves the sensitivity and permits the investigation of important signals like Tg 
separately, which is usually depicted as a step change in heat capacity with a baseline 
shift in the thermogram. Reversing heat flow includes transitions like heat capacity, Tg, 
and melting, while non reversing heat flow includes transitions like enthalpic relaxation, 
cold crystallization, thermal decomposition, evaporation, etc.39 Since Tg is a kinetic 
phenomenon, it is strongly dependent on scanning rate and the thermal history of the 
sample.36 In practice, Tg is normally measured as the mid-point temperature at the half 
height of the step change. A typical mDSC thermogram is depicted in Figure 1.6.  
Another important piece of information that can be obtained from mDSC 
measurements is the phase homogeneity in ASDs. In multicomponent systems such as 
ASDs, it is important to assess phase mixing, which can be confirmed from the number 
of Tg events observed in a thermogram. In general, the presence of a single Tg is 
indicative of a homogenous sample, whereas multiple Tg events are consistent with 
possible phase separation.36 In addition, detecting phase mixing with mDSC requires 
individual Tg’s to be 10 °C apart and domains larger than 30 nm.
23,40 Theoretical Tg 
values can also be compared with the predicted Tg values based on number empirical 
mathematical models available. Among them, Gordon-Taylor relationship has been 
widely used and any deviation from the predicted Tg behavior is suggestive of the 
presence of specific interactions between components.41  
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In recent years, the field of DSC has seen new advancements especially when fast 
heating or cooling rates are performed. Fast DSC, hyper DSC or flash DSC is helpful for 
cases where heating or cooling rate faster than the time scale of the event in interest is 
required.42 Thus, fast cooling rates and fast heating rates can be useful for in situ 
amorphization of rapidly crystallizing drugs and thermally unstable materials, 
respectively. Moreover, hyper DSC measurements permit better assessment of 
miscibility in ASDs, as fast heating rates do not affect the miscibility of the drug and 
polymer in the sample.  
 
Figure 1.6. A typical mDSC plot showing the three signals corresponding to total heat 
flow (top), non reversible heat flow (middle), and reversible heat flow (bottom). The 
glass transition (Tg) is apparent in the reversible heat flow, whereas the crystallization 
exotherm is apparent both in reversible and non reversible heat flow. Melting is apparent 
in all three signals. 
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Table 1.2. Commonly used characterization techniques for ASDs. 
Properties DSC TGA FTIR/Raman PXRD SSNMR 
Glass Transition (Tg) 
temperature 
     
Crystallinity      
Mobility      
Drug-polymer interactions      
Moisture/ Residual content      
Number of phases      
Hydration/ Dehydration      
Sample destructiveness      
Abbreviations 
DSC Differential scanning calorimetry 
TGA Thermogravimetric analysis 
PXRD Powder X-ray diffraction 
FTIR/Raman 
Fourier transform infrared spectroscopy and Raman 
spectroscopy 
SSNMR Solid state nuclear magnetic resonance spectroscopy 
 
1.3.3.2 Thermogravimetric Analysis 
In TGA analysis, the change in sample weight is measured as a function of time 
and temperature. It is useful for studying the thermal stability of a material, total volatile 
content, kinetics of drying or desolvation, as well as dehydration.43 As with DSC, this 
method is sensitive to sample condition and experimental variables like heating rate. A 
typical TGA plot is illustrated in Figure 1.7. For spray dried ASDs, TGA is used 
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routinely to evaluate the residual solvent content in the samples.27 Another useful 
application is found for stability dispersions samples, where the moisture uptake can be 
measured easily following equilibration of the sample at a particular condition.  
 
Figure 1.7. A typical TGA plot showing weight % as a function of temperature for a 
spray dried dispersion sample. 
1.3.3.3 Powder X-ray Diffraction 
PXRD is the most common technique for detecting crystallinity in ASDs and 
confirms the amorphous nature of dispersion samples, since it is relatively simple to 
operate, non-destructive and can provide both qualitative and quantitative information.23 
Its principle is based on Bragg’s law, which can be described by the equation: 
 𝑛𝜆 = 2𝑑 𝑠𝑖𝑛𝜃 (1.3) 
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where n, λ, d and θ are an integer, the incident x-ray wavelength, the spacing between a 
set of lattice planes and the angle between the diffraction planes respectively. The 
common laboratory X-ray instruments use a monochromatic X-ray source (Cu or Mo) 
and measures a diffraction pattern by continuously increasing θ till the entire coverage of 
d satisfying Bragg’s condition for each plane. Furthermore, the measurements are 
conducted in either reflection mode (Bragg-Brentano geometry) or transmission mode 
(Debye-Scherrer geometry). In a typical powder diffractogram, diffraction intensity is 
plotted against 2θ. For crystalline powder samples, Bragg peaks related to particular 
space groups are observed and this pattern of peaks would typically correspond to a 
unique signature of the material. In contrast, analysis of amorphous powder samples 
gives broad, diffuse scattering signals without distinct Bragg peaks (Figure 1.8). 
Amorphous materials are characterized by lack of long-range order and exhibit short-
range periodicity (translational, orientational and/or conformational).44 Thus, amorphous 
samples including ASDs portray a continuous “halo” pattern, which is the mean response 
of the average local order of an ensemble of short-range orders. In characterizing ASDs 
samples, PXRD analysis is useful for determining the residual crystallinity in samples 
after manufacturing or during stability studies. It should be noted here that typical 
detection limit for crystalline content is 5-10 % (w/w).23 In addition, in recent years 
PXRD has been explored to characterize miscibility and phase structure in ASD using 
atomic pair distribution function (PDF).45 Another recent advancement permit 
measurements to be performed under non ambient conditions with the introduction of 
variable temperature (VT) or humidity control set up to assess structural changes 
associated with recrystallization under stressed conditions.46 
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Figure 1.8. PXRD patterns for crystalline (as-received) and amorphous celecoxib (CEL). 
Amorphous celecoxib is devoid of characteristic Bragg peaks as seen in as received 
celecoxib. 
1.3.3.4 Vibrational Spectroscopy 
FTIR and Raman spectroscopy are two well-established techniques for probing 
molecular vibrations in pharmaceutical samples. These two techniques are 
complementary and have been used extensively for evaluating intermolecular 
interactions, phase transitions, polymorph identification, crystallinity and phase 
separation. The signal is seen as a result of change in polarizability of molecules in 
Raman spectrum, whereas in IR spectrum it originates from the change in the dipole 
moment of the molecules.23 The IR spectrum consists of three regions: the near-IR (NIR) 
region between 0.78-2.5 μm, the mid-IR region between 2.5-50 μm and the far-IR region 
between 50-1000 μm. With the arrival of attenuated total reflectance (ATR) sampling 
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mode, it is possible to study bulk samples for routine analysis.47 The mid-IR region has 
been employed to probe drug-polymer specific interactions via variations in peak shape 
and or position that are involved in molecular interactions especially through the analysis 
of O-H, N-H and C=O stretching frequencies. For instance, the presence of hydrogen 
bonding between the donor and acceptor groups can be inferred from the shift to lower 
wavenumbers and or peak broadening.48 A number of publications highlight the 
applications of FTIR spectroscopy in the area of ASDs.49,50 Apart from the mid-IR 
region, NIR region has been found to be applicable especially for evaluating powder 
samples without saturation.51 In addition, NIR spectroscopy has been routinely used as a 
process analytical tool (PAT) for real time monitoring as well as for quantification of 
crystalline or amorphous content in a multi component system.52 
Raman spectroscopy is a powerful light scattering technique, which sometimes 
offers advantages in sampling and specificity when compared to IR spectroscopy.51 With 
shorter wavelengths of light being used it can be combined with microscopy. Confocal 
Raman microscopy has enabled detailed spatial analysis of pharmaceutical materials.53,54 
For this thesis work, focus is given to FTIR spectroscopy for its more convenient 
experimental setup and data collection.  
1.3.4 Physical Stability of Amorphous Solid Dispersions 
For a robust ASD formulation, it is desired that the dosage form remains stable 
during the manufacturing and the shelf life. Moreover, stability is preferred in solution 
phase as well when the formulation dissolves upon expose to the biological fluids. In 
solution phase, ASDs provide a “spring + parachute” effect, thereby sustaining the 
supersaturation achieved for longer times to elicit its action (Figure 1.9).55 If the “spring 
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+ parachute” effect fails, it is clear that the solubility advantage from ASDs will not be 
realized. Hence, it is of utmost importance to understand the factors affecting the 
physical stability of these enabling dosage forms. Before we list the factors affecting the 
physical stability, it is equally important to review the crystallization theory. 
 
Figure 1.9. Illustration of “spring and parachute” mechanism. Adapted from reference.30 
 
1.3.4.1 Theory of Crystallization 
Crystallization is a two-stage process: (1) nucleation and (2) crystal growth. 
During the nucleation stage, small number of molecules come together to form a nucleus. 
At the start of the nucleation process, the growth of the assembly is unfavorable. 
However, once the critical size is reached the process continues irreversibly.56 As per the 
classical nucleation theory, the Gibbs free energy of nucleation consists of two terms 
given by the equation: 
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 ∆𝐺(𝑟) = ∆𝐺𝑣 + ∆𝐺𝑠 (1.4) 
 
where ΔGv is the bulk free energy difference between the crystalline and amorphous 
phase and ΔGs is the energy required to make a new interface. Here, ΔGv is negative 
(favorable to nucleation) and ΔGs is positive (unfavorable to nucleation).
56,57 For a 
spherical nucleus, equation 1.4 can be written as: 
 
∆𝐺(𝑟) = −
4
3
𝜋𝑟3∆𝐺𝑣 + 4𝜋𝑟
2𝛾 (1.5) 
 
where r is the radius of nucleus and γ is the interfacial tension between the nucleus and 
the supercooled liquid. It is clear from equation 1.5 that ΔGv and ΔGs are proportional to 
r3 and r2 respectively. The relationship of ΔG versus r is illustrated in Figure 1.10. The 
maximum of ΔG(r) corresponds to the critical nucleus size r*, and defines the energy 
barrier for nucleation ΔG*. 
 
∆𝐺∗ =
16𝜋𝛾3
3∆𝐺𝑣
2  
(1.6) 
 
 
𝑟∗ =
2𝛾
∆𝐺𝑣
 
(1.7) 
 
It is apparent from the above discussion that once the size of assembly reaches the 
critical radius the process becomes thermodynamically favorable and continues. In 
addition, ΔGv can be estimated from enthalpy of fusion (ΔHfus) and the melting 
temperature of the crystal (Tm).
58  
 
∆𝐺𝑣 =
∆𝐻𝑓𝑢𝑠(𝑇𝑚 − 𝑇)𝑇
𝑇𝑚
2  
(1.8) 
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𝐼 = 𝐼0exp [−
∆𝐺∗
𝑘𝐵𝑇
] 
(1.9) 
 
It can be inferred from equation 1.9 that several variables influence the nucleation rate. 
Most importantly, the degree of undercooling (Tm-T) should increase the nucleation rate 
indefinitely. However, experimentally it is seen that the rate of nucleation increases with 
the degree of undercooling, reaches a maximum and then decreases (Figure 1.11). This 
behavior can be explained by the increase in the viscosity as the temperature decreases 
and thereby decreasing the molecular mobility.60 To account for this behavior, an 
additional kinetic term (ΔGa) is included in the equation 1.9, which defines the molecular 
mobility of crystallizing species.  
 
𝐼 = 𝐼0exp [−
∆𝐺∗ + ∆𝐺𝑎
𝑘𝐵𝑇
] 
(1.10) 
 
In practice, homogenous nucleation is seldom encountered and therefore presence of 
foreign bodies, impurities and surfaces may also influence the observed nucleation.60 
The second stage is the crystal growth, where the critical size nucleus increases in 
size resulting in the development of the crystalline phase. There are several ways 
molecules can join to the growing crystal surface. In the case of smooth crystal 
interfaces, models like screw-dislocation and two dimensional or surface nucleation 
growth have been employed. For pharmaceutical systems, the crystal growth rate U is 
given by61: 
 
𝑈 =
6𝑎𝐷
𝜆2
𝑓𝑒𝑥𝑝(−
∆𝑆
𝑘
)[1 − exp
∆𝐺𝑐
𝑘𝐵𝑇
] 
(1.11) 
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where a is the molecular diameter, D is the diffusion coefficient, λ is the diffusion jump 
distance, f is the fraction of interface sites that are active growth sites, ΔS is the entropy 
difference between the two phases, k is the Boltzmann’s constant, ΔGc is the 
thermodynamic driving force for crystal growth and T is the absolute temperature. The 
observed nucleation rate and crystal growth rate is dependent on factors such 
thermodynamic, kinetic and intermolecular. Additionally, the external conditions like 
humidity, method of preparation, stress may also impact the overall crystallization 
tendency of amorphous dosage forms.60 
 
 
Figure 1.10. Schematic representation of free energy ΔG as a function of nucleus radius 
r. Adapted from the reference.60  
 
 
 
24 
 
Figure 1.11. Schematic representation of nucleation rate and crystal growth rate as a 
function of temperature for undercooled melts. Adapted from reference.60 
 
1.3.4.2 Role of Polymers in Physical Stabilization 
There are wide varieties of polymers that are employed in formulation of ASDs. 
Chemically, polymers consist of structural units known as “monomers” which are 
combined together to form a chain-like structural backbone. They can be classified on 
the basis of their charge into: (a) nonionic or non pH dependent and (b) ionic or pH 
dependent. Additionally, nonionic polymers can further be categorized into 
polyvinyllactam polymers and cellulosic ethers. The ionic polymers are further 
subdivided into two sub groups: anionic and cationic polymers.62 A summary of common 
polymers with their important properties is listed in Table 1.3. Polymers can impact 
physical stability to a large extent and control factors like overall Tg of the system, 
mobility etc. Moreover, intermolecular interactions between the dug and polymer also 
play a crucial role in physical stabilization of ASDs.63,64 Thus, important performance 
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factors of polymers like Tg, thermal stability, solubility in solvents, drug-polymer 
miscibility should be considered in the polymer selection process. The list of 
commercially available solid dispersion products along with the polymer used is given in 
Table 1.4.  
1.3.4.3 Glass Transition Temperature 
ASDs are often characterized by their Tg, which is an important parameter 
dictating their physical stability.36 In general, high Tg for the system is desired as it 
guarantees better stability at room temperature and under typical storage conditions. For 
drug-polymer mixtures, it is possible to predict the Tg of the blend through many models, 
which have been widely studied for ASDs. One popular quantitative model for the 
prediction of Tg of a multicomponent system is the Gordon-Taylor relationship. It uses 
the Tg values of the individual components and predicts the Tg of the dispersion 
intermediate in value of Tg’s of each component. It is based on the assumption that the 
free volumes of both components are additive and that the system lacks any specific 
interactions.65 Based on these assumptions, the resultant Tg of the mix can be calculated 
by:  
 
𝑇𝑔𝑚𝑖𝑥 =
𝑤1𝑇𝑔1 + 𝑘𝑤2𝑇𝑔2
𝑤1 + 𝑘𝑤2
 
(1.12) 
 
where w1, w2 are weight fractions of each component, Tg1 and Tg2 are their glass 
transition temperatures. The constant k is related to density and expansion coefficient and 
may be approximated using Simha-Boyer rule.66 
 
𝑘 =
𝜌1∆𝛼1
𝜌2∆𝛼2
≈
𝜌1𝑇𝑔1
𝜌2𝑇𝑔2
 
(1.13) 
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The Gordon-Taylor equation can be modified with a different value of k to define 
Couchman-Karaz relationship with the value k being defined by heat capacity change at 
Tg.
67  
 
𝑘 =
∆𝐶𝑝1
∆𝐶𝑝2
 
(1.14) 
 
 1
𝑇𝑔𝑚𝑖𝑥
=
𝑤1
𝑇𝑔1
+
𝑤2
𝑇𝑔2
 
(1.15) 
 
The component with the lower Tg is called a plasticizer whereas the component 
with the higher Tg is called an antiplasticizer. Polymers generally have higher Tg values 
than the drug and therefore act as antiplasticizers and increase the overall Tg of the 
system. The presence of moisture in the system can reduce the Tg to a significant extent. 
Water is a great plasticizer (Tg ~ -140 °C) and can lead to physical and chemical 
instability of product.69  
In practice, deviations from ideality have been reported.13,36 This signifies that 
mixing of components is non ideal and are classified as: positive and negative deviations 
(Figure 1.12). In the case of positive deviations where experimental Tg values are greater 
than the predicted Tg values result from lower net excess free volume upon mixing or the 
drug-polymer interactions (D-P) are stronger than the drug-drug (D-D) and the polymer-
polymer (P-P) interactions. The negative deviations result from higher net excess free 
volume upon mixing or the drug-polymer interactions (D-P) are weaker than the drug-
drug (D-D) and the polymer-polymer (P-P) interactions, which leads to experimental Tg 
values being lower than the predicted Tg values.  
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Table 1.3. Physicochemical properties of the polymers commonly used in ASDs. 
Polymers Classification 
Tg 
(°C) 
Solubility 
Molecular 
weight 
(g/mol) 
Hygroscopicity 
Cellulosic Derivatives  
Hypromellose 
(HPMC) 
Nonionic 
170-
180 
Water 
Soluble 
85,000-
150,000 
High 
Hypromellose 
acetate 
succinate 
(HPMCAS) 
Anionic ~125 > pH 5.0 ~50,000 Low 
Hypromellose 
phthalate 
(HPMCP) 
Anionic 
133-
137 
> pH 5.0 
80,000-
130,000 
Medium 
Cellulose 
acetate 
phthalate 
(CAP) 
Anionic 
~160-
170 
> pH 6.0 ~2534 Medium 
Polyvinyl lactam (co)polymers 
Polyvinyl 
pyrrolidone 
(PVP) 
Nonionic 
150-
180 
Water 
Soluble 
30,000-
100,000 
High 
Copovidone 
(Kollidon® 
VA64) 
Nonionic 
105-
110 
Water 
Soluble 
45,000-
70,000 
High 
 Soluplus® Nonionic ~70 
Water 
Soluble 
118,000 Medium 
Methacrylate (co)polymers 
Eudragit® EPO Cationic ~48 < pH 5.0 ~47,000 Low 
Eudragit® 
L100 
Anionic > 150 > pH 6.0 ~125,000 Low 
Eudragit® 
L100-55 
Anionic ~110 > pH 5.5 ~320,000 Low 
Eudragit® 
S100 
Anionic > 130 > pH 7.0 ~123,000 Low 
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Comments 
Soluplus® Polyvinyl caprolactam-polyvinyl acetate-polyethylene copolymer  
Eudragit® EPO 
Poly(butylmethacrylate-co-(2-dimethylaminoethyl)methacrylate-co-
methyl methacrylate) 1:2:1 
Eudragit® 
L100-55 
Poly(methacrylic acid-co-ethylacrylate) 1:1 
Hypromellose Hydroxypropyl methyl cellulose 
Copovidone Poly(vinyl pyrrolidone-co-vinyl acetate) 
 
Furthermore, Tg is an important parameter for molecular mobility under typical 
storage conditions (15-30 °C). As a rule to predict the stability of ASDs under long term 
conditions, it has been suggested to store at 50 °C below Tg (Tg-50 rule).
13 This rule 
suggests that a Tg of at least 75-80 °C is preferred for storing ASD products at ambient 
storage conditions. 
1.3.4.4 Specific Interactions 
Intermolecular drug-polymer interactions play a significant role in making the 
matrix stable. Additionally, drug-polymer interactions prevent drug precipitation upon in 
vivo dissolution by maintaining supersaturation. The drug-polymer interactions can exist 
as ionic interactions, hydrogen bonding, dipole-dipole interactions and van der Waals 
interactions. These interactions differ in their relative strength with ionic and van der 
Waal interactions being the strongest and weakest respectively (Table 1.5).70 Many 
pharmaceutically grade polymers have hydrogen bond donors or acceptors in their 
structures, whereas many APIs also have chemical groups to form a hydrogen bond. 
Therefore, hydrogen bonding is one of the most common drug-polymer interactions 
observed in pharmaceutical systems.71-73 For instance, Matsumoto and Zografi 
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demonstrated the role of polymers like PVP in disruption of indomethacin dimers for 
enhanced stability.74 In a different study by Song et al., the role of polystyrene sulfonic 
acid was highlighted to stabilize two APIs, lapatinib and gefitinib, through ionic 
interactions.75 The stronger drug-polymer interactions will result in better miscibility and 
favor a single phase ASD. Moreover, it has been reported that specific interactions like 
hydrogen bonding can inhibit nucleation process, thereby rendering the system more 
stable.76  
Moisture uptake by hydrophilic polymers can interfere with physical stability by 
promoting demixing of the drug and polymer by weakening the existing interactions. In a 
study published by Rumondor et al., it was postulated that the physical stability of 
dispersions is based on the interplay of two factors, the strength of drug-polymer 
interactions and hygroscopicity.77 Additionally, water also reduces the Tg of the system 
and increase the mobility, which can further pose stability challenges.69  
 
Figure 1.12. Deviations from the Gordon-Taylor equation; D represents drug and P 
represents polymer. Adapted from reference.13  
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1.3.4.5 Drug-Polymer Miscibility 
The drug-polymer miscibility is one of the key factors that may impact the 
physical stability and performance of ASDs.36 Amorphous miscibility can be defined in 
terms of the level of mixing which results in a single-phase system. It must be kept in 
mind that even a miscible single-phase system can undergo crystallization, as the system 
is still metastable relative to its crystalline form. Consequently, it is important to review 
some key aspects related to miscibility. Here, we shall address some thermodynamics 
principles for binary amorphous systems. The Gibbs free energy of mixing, ΔGmix, at 
temperature T is given by: 
 ∆𝐺𝑚𝑖𝑥 = ∆𝐻𝑚𝑖𝑥 − 𝑇∆𝑆𝑚𝑖𝑥 (1.16) 
 
where ΔHmix and ΔSmix are the enthalpy and entropy of mixing respectively. In general, 
mixing increases the disorder of the system, which makes the entropic term positive. 
Hence, the sign of ΔHmix will dictate whether the mixing is favorable or unfavorable. 
Stronger drug-polymer interactions will result in loss of enthalpy, while stronger drug-
drug and polymer-polymer interactions will lead to an increase in enthalpy. Therefore, 
exothermic mixing is attained when adhesive interactions are stronger and/or more 
numerous than cohesive interactions. Athermal mixing results when adhesive 
interactions are similar and/or extent to the cohesive interactions.78 Thus, it is important 
to determine the nature of intermolecular interactions between the drug and polymer. 
Furthermore, it is desirable to predict the drug polymer miscibility based on predictive 
models such as the Flory-Huggins theory, which is a lattice based solution model 
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originally developed for polymers.79 Based on this model, the free energy of mixing, 
ΔGmix, can be described as: 
 ∆𝐺𝑚𝑖𝑥
𝑅𝑇
= 𝑛𝑑𝑙𝑛𝜙𝑑 + 𝑛𝑝𝑙𝑛𝜙𝑝 + 𝜒𝑑𝑝𝑛𝑑𝜙𝑝 
(1.17) 
 
where R is the gas constant, T is the absolute temperature, nd,p are the number of moles 
the drug and the polymer respectively, ϕd,p are the volume fractions of the drug and the 
polymer, and χdp is the Flory-Huggins interaction parameter. The first two terms on the 
right side describe the entropic contribution (combinatorial entropy) and the last term 
signifies the enthalpic contribution to the total fee energy of mixing of the binary 
system.80 The enthalpic contribution will dictate the sign of the ΔGmix and thus, the sign 
of χdp is the determining factor. It is therefore considered an indicator for drug-polymer 
miscibility. The smaller or more negative the Flory-Huggins interaction parameter, the 
stronger the intermolecular interaction between the drug and polymer. The value of χdp 
can be determined by the melting point depression approach and the solubility parameter 
approach.81 The details on how to obtain the value of χdp are discussed in Chapter 4. The 
drawbacks of the Flory-Huggins theory are that it does not account for the specific 
interactions and the energy for breaking the crystal lattice so that makes it only 
applicable for amorphous polymers. 
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Table 1.4. List of pharmaceutical solid dispersions available in the market. 
Product API 
Preparation 
Method 
Company 
Year of 
Approval 
Carrier 
Cesamet® Nabilone 
Solvent 
Evaporation 
Meda 
Pharmaceuticals 
1985 PVP 
Sporanox® Itraconazole 
Fluid Bed 
Bead 
Layering 
Janssen 
Pharmaceuticals 
1992 HPMC 
Prograf® Tacrolimus 
Spray 
Drying 
Astellas Pharma 1994 HPMC 
Kaletra® 
Lopinavir, 
Ritonavir 
Melt 
Extrusion 
AbbVie Inc. 2007 PVP/VA 
Intelence® Etravirine 
Spray 
Drying 
Janssen 
Pharmaceuticals 
2008 HPMC 
Zortress® Everolimus 
Spray 
Drying 
Novartis 
Pharmaceuticals 
2010 HPMC 
Norvir® Ritonavir 
Melt 
Extrusion 
AbbVie 2010 PVP/VA 
Onmel® Itraconazole 
Melt 
Extrusion 
Merz Pharma 2010 HPMC 
Incivek® Telaprevir 
Spray 
Drying 
Vertex 
Pharmaceuticals 
2011 HPMCAS 
Zelboraf® Vemurafenib 
Co-
precipitation 
Roche 2011 HPMCAS 
Kalydeco® Ivacaftor 
Spray 
Drying 
Vertex 
Pharmaceuticals 
2012 HPMCAS 
Orkambi® 
Lumacaftor, 
Ivacaftor 
Spray 
Drying 
Vertex 
Pharmaceuticals 
2015 
HPMCAS
/SLS 
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Table 1.5. Relative strength of drug-polymer interactions. Adapted from reference.70 
Type of Interaction Bond Energy (kJ/mol) 
Approximate Relative 
Strength 
Ionic Interactions 850-1700 1000 
Hydrogen Bonding 50-170 100 
Dipole-dipole 
Interactions 
2-8 10 
van der Waals 
Interactions 
~1 1 
 
1.4 Thesis Overview 
Chapter 1 deals with the introduction to the amorphous state, the importance of 
ASDs in drug development, the preparation methods, a brief outline of common 
analytical tools used for characterization of amorphous solids, and the factors affecting 
physical stability of ASDs. The central objective of my thesis research is to gain 
fundamental insights into the role of drug-polymer phase homogeneity and the factors 
impacting (specifically drug-polymer interactions) phase homogeneity and the physical 
stability of ASDs.  
1.4.1 Chapter 2 
In Chapter 2, the fundamentals and key features of SSNMR are introduced. It 
highlights the underlying principles of SSNMR, its advantages and limitations, and the 
applications pertaining to the field of ASDs. In addition, special focus has been given to 
the proton relaxation measurements and their importance in evaluating phase 
homogeneity in ASDs.  
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1.4.2 Chapter 3 
Chapter 3 presents a case study involving felodipine (FEL) as a model drug with 
three polymers, poly(vinylpyrrolidone), or PVP, poly(vinylpyrrolidone-co-vinylacetate), 
or PVP/VA, and polyvinylacetate or PVAc. In this investigation, the role of drug-
polymer hydrogen bonding and its impact on phase homogeneity is studied in-depth. A 
detailed comparative evaluation using DSC and SSNMR is presented on the model 
systems to investigate the phase homogeneity and hydrogen bonding interactions.  
1.4.3 Chapter 4 
Previously in Chapter 3, we studied the role of hydrogen bonding on phase 
homogeneity using felodipine as a model drug. Chapter 4 focuses on two structurally 
similar APIs nifedipine and felodipine, and their miscibility with Soluplus. In this 
chapter, both the aspects of miscibility: thermodynamic and kinetic are dealt with. 
Furthermore, differences in the hydrogen bonding patterns of two APIs will be 
discussed.  
1.4.4 Chapter 5 
So far through Chapters 3-4, we focused on the investigation of binary ASDs. In 
Chapter 5, we provide an in-depth comparative assessment of binary and ternary ASDs 
involving ketoconazole and two polymers, polyacrylic acid (PAA) and 
hydroxypropylmethyl cellulose (HPMC). The underlying molecular interactions are 
revealed in both the systems, which involved the identification and quantification of 
various species present. In addition, long-term physical stability is assessed for the 
samples at two different conditions. 
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1.4.5 Chapter 6 
Chapter 6 describes the impact of different grades of hydroxypropylmethyl 
cellulose acetate succinate (HPMCAS) on the phase behavior of itraconazole dispersions. 
The dispersions are prepared using two approaches and the role of preparation method is 
evaluated at various drug loadings. The samples are subjected to accelerated physical 
stability to investigate the influence of temperature and moisture on the dispersions. 
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CHAPTER 2. SOLID-STATE NMR OF PHARMACEUTICALS: AN OVERVIEW  
2.1 Introduction 
Nuclear magnetic resonance (NMR) spectroscopy has been used in 
pharmaceutical analysis typically for (a) structure elucidation1, (b) chirality analysis of 
drug substances2, (c) protein studies3, and (d) determination of cellular metabolism4. In 
most of these applications, solution NMR spectroscopy has been employed. However, 
since approximately 80-90% of pharmaceutical products on the market exist in the solid 
form,2 solid-state NMR spectroscopy has the potential to play a large role in the 
characterization of pharmaceutical solids, and recent developments in the field of 
SSNMR spectroscopy have made it amenable for a routine analysis for Pharm. Res. and 
development. 
In the area of solid-state characterization of pharmaceuticals, several techniques 
apart from SSNMR spectroscopy are utilized, such as PXRD, FTIR spectroscopy, 
Raman spectroscopy, DSC, optical and electron microscopies, and TGA. Usually, a 
combined application of many of these techniques is required, depending on the aim and 
the nature of the system under study. However, in this chapter, the focus is on SSNMR, 
where we want to highlight the advantages and limitations of this technique and its 
application in characterization of ASDs.  
It is important to mention that SSNMR is a non-destructive, non-invasive, 
flexible, quantitative, multinuclear technique that allows a variety of experiments to 
performed to examine the physical and chemical states of both API and the excipients.5 
Moreover, with the development of NMR crystallography, crystal structures may be 
solved through the combined use of X-ray diffraction and SSNMR.6 Furthermore, 
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SSNMR has the capability to selectively investigate individual component of ASDs and 
does not usually require any previous treatment of the sample.7 For all these aspects, 
SSNMR analysis can provide crucial and relevant information on pharmaceutical solids.  
Unfortunately, there are a few limitations associated with this technique, which 
arise from its complexity, long experimental times and high operation costs.8 However, 
with recent advancements in SSNMR hardware and software these disadvantages may be 
overcome. There are many excellent reviews on the pharmaceutical applications of 
SSNMR available in the literature.2,9-11 
2.2  NMR-General Introduction  
2.2.1 NMR Theory 
The NMR phenomenon is based on the Zeeman interaction between the magnetic 
moment of the nucleus (μ) and the external magnetic field (B0). The nuclear magnetic 
moment is described by the following equation: 
 
𝜇 =
𝛾𝐼ℎ
2𝜋
 
(2.1) 
 
where I is nuclear spin quantum number, γ is the magnetogyric ratio and h is Planck’s 
constant. The Zeeman interaction takes place with nuclei having a non zero spin 
quantum number (I). When nuclei having a magnetic moment are placed into a static 
magnetic field, they start to precess around their z-axis. The frequency of this movement 
is termed Larmor frequency ω0 and is proportional to the strength of B0 and the 
magnitude of γ. For instance, 1H in the magnetic field of 7.05 T will possess a Larmor 
 
 
38 
precession frequency of ~300 MHz, while 13C in the same static magnetic field will have 
a Larmor frequency of ~75 MHz. 
In the absence of external magnetic field, the nuclear magnetic moment is 
quantized into 2 I + 1 possible orientations or energy levels. Here, the discussion is 
limited to nuclei having spin I = 1/2 such as 1H and 13C. In this case, the nuclei can line 
up either parallel or antiparallel to B0. The low energy state is labeled α (+1/2) with 
magnetic moment aligned with the magnetic field, whereas the high energy state is 
labeled β (-1/2) with magnetic moment aligned opposite to the magnetic field (Figure 
2.1). The transition between these states give rise to observable NMR signal and the 
population difference between these states is governed by the Boltzmann distribution: 
 𝑁𝛽
𝑁𝛼
= 𝑒−∆𝐸/𝑘𝑇 
(2.2) 
 
where N is the number of nuclei present in each spin state, ΔE = γhB0/2π, k is the 
Boltzmann constant, and T is the absolute temperature. It can be seen from this relation 
that higher magnetic field spectrometers lead to a larger population difference and hence 
a stronger signal, and signal-to-noise ratio (S/N). 
The respective energy is provided by applying a radio frequency pulse (rf), B1, 
with a frequency of about ω0 along a direction perpendicular to B0. This causes the net 
magnetization to precess in the x-y plane of the laboratory frame at an angle governed by 
the intensity and duration of the rf pulse. This nuclear precession generates an alternating 
current in a coil surrounding the sample, whose evolution with time represents the NMR 
signal. The signal or free induction decay (FID) is collected in the time domain and then 
subjected to Fourier transformation to give rise to the NMR spectrum. 
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2.2.2 The Chemical Shift 
The nucleus is surrounded by electrons that generate a small local field and shield 
the local magnetic field experienced (Bloc) by the nucleus (Figure 2.2). The strength of 
the Bloc depends on the specific electron density and this shielding give rise to the 
phenomenon of chemical shift. Therefore, chemically non-equivalent nuclei experience 
different magnetic fields causing them to precess at different frequencies and in the 
NMR spectrum they are revealed as well separated peaks. In the NMR spectrum, the x-
axis is commonly expressed in terms of chemical shift (δ) having the units in parts per 
million (ppm). This scale is considered useful because it is independent of the strength of 
B0 and the location on the scale is relative to the location of a reference substance whose 
δ is conventionally taken to be zero. In the case of 13C and 1H, tetramethylsilane (TMS) 
is used as a reference.12 
Generally, Bloc is the product of B0 and (1- σ), where σ is the element of the 
shielding tensor. In a molecule, electrons are distributed anisotropically and that makes 
the value of σ dependent upon the molecular orientation with respect to B0. For 
molecules in liquid state, where fast and isotropic Brownian molecular tumbling exists, 
the anisotropy averages to zero. However, in solids where molecular tumbling is absent 
and consequently the resonance frequency for each nucleus is slightly different. This 
implies that for a “powder” sample, where all possible molecular orientations occur, the 
different δ values result in a very broad resonance lines and subsequent loss of 
resolution.  
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Figure 2.1. Schematic depicting the response of nuclear spins in the presence of the 
external magnetic field. The splitting of nuclear spin states is also shown. 
 
 
Figure 2.2. Illustration of the magnetic shielding of a nucleus by surrounding electrons 
and the effective magnetic field experienced by the nucleus.  
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2.3 SSNMR Principles and Techniques 
In the early 1950s, NMR spectroscopy was essentially used as a solution based 
technique, where unlike solids a high-resolution spectra could be acquired. Through the 
1950s and 1960s, researchers were devoted to advancing the field of SSNMR. As 
discussed in the previous section, the spectrum obtained for a solid sample showed line 
broadening, and that limited the application of SSNMR. It was not until the late 1970s 
that Schaefer et al. were able to demonstrate the utility of 13C SSNMR for solid polymer 
samples with the help of cross polarization (CP) and magic angle spinning (MAS).13,14 In 
this section, we will review the basic principles involving a SSNMR experiment and 
some other useful techniques, especially those used in ASDs research.  
2.3.1 Dipolar Coupling and High-Power Proton Decoupling 
On a molecular level, the magnetic dipoles of neighboring nuclei perturb the 
magnetic field experienced by surrounding nuclei. This result in the direct magnetic 
coupling of two nuclei directly thorough space and can occur on a heteronuclear and 
homonuclear base. It is important to note that the extent of this depends upon the 
magnetic moments of nuclei, the distance r between them, and their orientation with 
respect to B0. Thus, this interaction is significant for spin ½ nuclei with large magnetic 
moments such as 1H and 19F. In the pharmaceutical domain, samples are abundant in 
carbon and proton nuclei, and that makes heteronuclear 13C-1H coupling a significant 
contributor to line broadening (based on their natural abundance, Table 2.1). In fact, 
heteronuclear 13C-1H and homonuclear 1H-1H coupling in the solid state are generally in 
the order of 50 kHz and 100 kHz, respectively. The heteronuclear 13C-1H coupling can be 
suppressed by applying high decoupling fields at the 1H Larmor frequency, which cause 
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1H spins to flip between the α (+1/2) and β (-1/2) spin states so that the dipolar 
interactions are averaged to zero.9 Even after eliminating heteronuclear dipolar 
interactions 13C-1H, the broad lines are still seen in SSNMR spectrum primarily due to 
chemical shift anisotropy (CSA).  
2.3.2 Chemical Shift Anisotropy and Magic Angle Spinning 
As mentioned previously, the molecules in the solid state exist at fixed 
orientations relative to B0 and which results in distribution of chemical shifts termed as 
chmeical shift anisotropy (CSA). The concept of magic angle spinning (MAS) was 
originally proposed by Andrew et al. in 1958 to remove line broadening for solid 
samples.15 The idea can be understood by taking into account the nature of shielding 
tensor, σ, which can be divided into two components- an isotropic component and an 
isotropic component as described by the following equation: 
 𝜎𝑜𝑏𝑠 = 𝜎𝑖𝑠𝑜 + (3 cos
2 𝜃 − 1) 𝜎𝑎𝑛𝑖𝑠𝑜 (2.3) 
 
where θ is the angle made between the internuclear vector and B0. By spinning the 
sample at “magic angle” of 54.74 ° or 54°44` causes the anisotropic term to reduce to 
zero and only the isotropic chemical shift is retained. Thus, spinning the sample at an 
angle equal to the magic angle at sufficient high speed (sample rotation greater than the 
magnitude of CSA) will average the orientation dependent interactions (Figure 2.3).  
If the sample spinning rate is less than the width of CSA, spinning side bands 
(SSB) are generally observed at intervals equal to the spinning speed. These SSB contain 
intensity from the parent peak and can potentially overlap with the other signals, which 
complicate the spectral interpretation. Generally, they are easily identified by changing 
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the spinning rate and observing which signals change in frequency. Moreover, specific 
pulse sequences like total suppression of spinning sideband (TOSS) can be incorporated 
to minimize their occurrence.16  
Table 2.1. NMR frequency listing for a few common nuclei found in the pharmaceutical 
samples. 
Nucleotide Spin Natural Abundance 
NMR frequency (MHz) at a 
field (T) of 
5.87 11.74 
1H 1/2 99.98 250.00 500.00 
13C 1/2 1.10 38.38 76.75 
15N 1/2 0.37 25.33 50.66 
19F 1/2 100 235.19 470.39 
31P 1/2 100 101.20 202.40 
14N 1 99.63 18.06 36.12 
17O 5/2 3.7*10-2 33.89 67.78 
 
 
Figure 2.3. A schematic of magic-angle spinning. 
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2.3.3 Cross Polarization 
In general, SSNMR experiments lack sensitivity because of a nearly equal 
population distribution of the two spin states for spin 1/2 nuclei. Moreover, for solid 
samples, the sensitivity is decreased further due to the low natural abundance of the 13C 
nuclei (~1%), which constitute the majority of the sample chemically. In a SSNMR 
experiment, owing to the long T1 time of rare spin nuclei (
13C or 15N), very long 
acquisition times may be needed for a reasonable S/N ratio. In order to overcome this 
issue, the technique of cross polarization (CP) was first implemented by Pines et al.17,18 
The basic idea of this technique is that bulk magnetization is transferred from the 
abundant spin system having short T1 (
1H) to the rare spin system (13C or 15N) with long 
T1. 
As per the principles of quantum mechanics, any polarization transfer between 
the two spin systems can take place only when ΔE between the energy levels of the two 
participating spin systems be of equal magnitude. This is the case when the Hartmann-
Hahn condition is satisfied. 
 Δ𝐸𝐻 = 𝛾𝐻𝐵1𝐻 = 𝛾𝑋𝐵1𝑋 = Δ𝐸𝑋 (2.4) 
 
where, γH is the gyromagnetic ratio of 
1H and B1H is the 
1H-rf-field while B1X and γX are 
the respective parameters for X-spin system. The CP pulse sequence consists of 
simultaneous irradiation of the 1H and X spin systems by variable magnetic fields 
through a locked rf-pulse during contact time, tc (Figure 2.4). The magnitude of the spin 
locking fields B1H and B1X is chosen correctly to satisfy the Hartmann-Hahn condition. 
Once this condition is fulfilled, the dilute X spin system takes the magnetization from the 
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abundant 1H spins. As a last step in the sequence, the NMR signal of the X spins is then 
measured during the acquisition time under 1H high-power decoupling.  
The advantage from the CP pulse sequence is two fold: first, signal enhancement 
of X spins, which is determined by the gyromagnetic ratios of participating spin systems 
(~ 4x in 13C experiments); and second, reduction of the delay time between pulse 
sequences, since only the 1H spin-lattice relaxation remains relevant, which corresponds 
to a greater number of scans translating to higher S/N.9 
 
Figure 2.4. A scheme of cross polarization pulses sequence. The rectangles represent rf 
pulses, while the oscillating curve represents the FID. 
 
2.3.4 Relaxation 
After the termination of rf pulse the net magnetization of the ensemble of spins 
begins to relax back to their equilibrium values. The process of returning to equilibrium 
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is termed as relaxation.10 Broadly speaking, there are three important relaxation 
processes briefly described below: 
1. Spin-lattice relaxation (also known as longitudinal relaxation) – This is defined as 
the amount of time taken to regain equilibrium of the z component of M following 
a perturbation. The term “lattice” denotes the surroundings, which receive the 
energy in the process to re-establish the equilibrium. The process is generally 
described by an exponential relationship with a relaxation time constant, T1, given 
by the following equation: 
 
𝑀𝑧(𝑡) − 𝑀0 = [𝑀𝑧(0) − 𝑀0]exp (−
𝑡
𝑇1
) (2.5) 
 
where Mz(0) is the magnetization in the z direction after the perturbation. The time 
T1 is the inverse of a first-order rate constant for the relaxation process. For 
multipulse experiments, the optimum recycle delay of 5 x T1 is suggested in order 
to observe the fully relaxed signal after each pulse.19 
2. Spin-spin relaxation (also known as transverse relaxation) – This is related to the 
xy component of M and describes its decay to zero. It is given by the time 
constant, T2 and in general for solids T1 >> T2, but although in liquids they are 
often of the same order of magnitude. For example, for protons T2 is typically in 
the range of 10-100 μs whereas T1 is typically in the range 0.1-100 s.
10  
3. Spin-lattice relaxation in the rotating frame – This is described as the return to 
equilibrium of transverse magnetization kept aligned to a given direction by a 
“spin-lock” pulse. It is denoted by T1ρ. 
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2.4 Applications - Amorphous solid dispersions 
In the previous sections, we discussed the fundamentals of SSNMR and other key 
concepts related to the experiments. This section is devoted to the applications of 
SSNMR in the field of ASDs. In this regard, SSNMR stands out among currently 
available techniques in probing the structural and dynamic behavior of individual 
components, as well as the  intermolecular interactions and the phase mixing on a 
molecular level.5 With the advancements in the area, it is possible to investigate various 
subtle but important features pertaining to ASDs in terms of the state of the amorphous 
API, quantification of hydrogen bonding, distance of hydrogen bonds, and homogeneity 
on the nanometric scale.12,20-22 In the following sections, we will discuss and highlight 
various SSNMR methodologies utilized in exploring drug-polymer homogeneity and 
molecular interactions for complex systems like ASDs. 
2.4.1 Proton Relaxation Times and Spin Diffusion 
SSNMR provides very useful tools for measuring the degree of mixing among 
each component in systems like ASDs via proton relaxation times. The proton relaxation 
times: spin-lattice relaxation time (1H T1) and spin-lattice relaxation time in the rotating 
frame (1H T1ρ) are commonly used to provide valuable information about the 
heterogeneity of the sample. These relaxation times are affected by the process of spin 
diffusion.19 Basically, spin diffusion is an outcome of dipolar coupling and in a network 
of dipolar-coupled spins, the spatial diffusion of nuclear magnetization occurs from a 
locally excited site to distant sites. In case of two components close together spatially, 
proton magnetization within them is averaged by spin diffusion. Thus, for a 
homogeneous sample the proton relaxation times tend to average to a common value, 
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whereas a non-uniform relaxation behavior is detected for each component for a 
heterogeneous sample. The proton relaxation times are usually measured using a high-
resolution CP method and are conveniently detected via 13C nucleus to achieve spectral 
resolution of various components. The pulse sequences used to record 1H T1 and 
1H T1ρ 
are listed in Table 2.2. For methods employed to obtain 1H T1 times, the saturation 
recovery sequence was employed for the experiments described in this thesis work. In a 
typical saturation recovery experiment, the recovery of nuclear magnetization to the 
equilibrium after perturbation via a train of π/2 pulses is observed. In order to follow the 
build up of magnetization in the direction of external magnetic field B0, Mz is determined 
after various delay times t by applying π/2 pulses to flip the instantaneous magnetization 
Mz(t) in the xy plane and observe the subsequent signal. The signal recovery is fitted to 
the following function: 
 
𝑀𝑧(𝑡) = 𝑀0(1 − 𝑒
−
𝑡
𝑇1) 
(2.6) 
 
where, M0 is the equilibrium magnetization and T1 is the spin-lattice relaxation time 
constant. In the case of 1H T1ρ pulse sequence, spectra are recorded as function of the 
spin-lock time and the signal decay is fitted to the following function: 
 
𝑀𝑧(𝑡) = 𝑀0𝑒
−
𝑡
𝑇1𝜌 
(2.7) 
 
where, M0 is the equilibrium magnetization and T1ρ is the spin-lattice relaxation in 
rotating frame time constant. The pulse sequences for measuring 1H T1 and 
1H T1ρ are 
shown in Figure 2.5 and 2.6. 
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Table 2.2. List of pulse sequences used for measuring relaxation times. 
Pulse Sequence Relaxation Time Nucleus 
Inversion recovery T1 H or X 
Saturation recovery T1 H or X 
Inversion recovery with CP T1 H 
“Torchia” method T1 X 
Variable spin-lock T1ρ H or X 
Delayed contact T1ρ
 H 
Variable spin-lock with CP T1ρ X 
 
 
Figure 2.5. A scheme of pulse sequence for 1H T1 using saturation recovery.  
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Figure 2.6. A scheme for pulse sequence for measuring 1H T1ρ. 
 
A useful semiquantitative estimation of domain sizes can be obtained from the 
average diffusive path length L: 
 𝐿 = (6𝐷𝑇)1/2 (2.8) 
 
where, D is the spin diffusion coefficient and T is the time 1H T1 or 
1H T1ρ. In this 
relationship, D is dependent upon the average proton-proton distance and the strength of 
the dipolar interaction. In the current work, the value of D was taken to be 10-12 cm2/s.23 
If the diffusive path length is smaller than the domains in the sample, protons for each 
component will decay independently of one another and different values of relaxation 
time are measured for each component. Conversely, if the diffusive path length is larger 
than the size of domains in the sample, a single relaxation is obtained for each 
component. The main difference between 1H T1 and 
1H T1ρ is that they probe molecular 
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motion of different timescales. In general, 1H T1 relaxation time is sensitive to motions 
occurring on MHz scale, whereas 1H T1ρ is sensitive to motions occurring on kHz 
scale.10 Thus, 1H T1ρ << 
1H T1 so spin diffusion has an influence over smaller distances 
than it does for 1H T1.  
Since 1H T1 is typically of the order of 5 s and 
1H T1ρ of the order of 50 ms, the 
maximum diffusive path lengths are about 50 nm and 5 nm respectively.24 Based on 
these typical values and assuming that component relaxation times are sufficiently 
different, there exist three possibilities for phase homogeneity in ASDs: 
(1) An ASD is classified as “homogenous” when common values for 1H T1 and 1H 
T1ρ are observed and any domains must be smaller than 5 nm. 
(2) An ASD is classified as “partially homogenous” when a common 1H T1 but 
multiple 1H T1ρ values are obtained and for such a system the average domain size 
is between 5 and 50 nm.  
(3) An ASD is classified as “non-homogenous” when multiple 1H T1 and 1H T1ρ 
values are measured for each component and the average domain size is larger 
than 50 nm. 
The main advantages of using SSNMR to characterize phase homogeneity in ASDs are 
listed below: 
(1) The domain size accessible to SSNMR can go below 30 nm25, which is below 
DSC limit of detection. Hence, it is well-suited for investigating nano-phase 
separation in ASDs beyond the limits of thermal analysis. 
(2) The information obtained is usually very detailed and an accurate estimation of 
domains can be easily made. 
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(3) Using CP, it is easier to distinguish the relaxation behaviour of each component 
and can be resolved without decomposing the proton relaxation curves. 
2.4.2 Molecular Interactions 
In the study of ASDs, another important area for applications of SSNMR is 
molecular interactions. Very often, molecular interactions play a significant role in 
physical stabilization of ASDs and hence their detailed characterization is usually 
required. For complex systems like ASDs, SSNMR analysis can reveal the presence of 
interactions either directly through the changes in the high-resolution 13C spectra or 
indirectly via detecting the changes in parameters sensitive to the dynamics of the 
system. Usually changes in 13C CP/MAS spectra can reveal the presence of specific 
interactions such as hydrogen bonding between the groups when compared with neat 
drug and polymer or physical mixtures. In systems where hydrogen bonding exists, 
deshielding is observed in 1D 13C spectra as a result of change in local environment with 
isotropic chemical shift moving toward higher values.26 In pharmaceutical systems, 
typical hydrogen bonding involve groups such as –OH, -NH and –SH, where the labile 
protons attached to the heteroatoms act as donors. For such cases, X CP/MAS 
experiments can serve as a special probe to study drug-polymer H-bonding. The nucleus 
like 19F offers several advantages like 100% natural abundance, short accusation times, 
high sensitivity and no interference from excipients.27 This makes 19F MAS experiments 
highly desirable for fluorinated APIs. In this thesis work, we acquired 15N CPMAS 
spectra for ketoconazole dispersions, where changes in the local environment of nitrogen 
were monitored in the presence of polyacrylic acid. The drawbacks that come with 15N 
SSNMR experiments are long acquisition times and low sensitivity.28 This issue may be 
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solved by isotopic enrichment. The other potential option is to utilize quadrupolar nuclei 
like 14N to circumvent the need of isotopic labelling.29 Recently, quadrupolar nuclei (spin 
> 1/2) such as 14N, 35Cl, 17O have been used to study the change in hydrogen bond 
geometry in ASDs.30,31 In a study done by Vogt et al., a computational method involving 
the comparison of isotropic 1H chemical shift of a single molecule with that of its crystal 
structure was used to assess the relative strength of hydrogen bonding interactions in 
ASD of diflunisal.31 
The advancements in high resolution two-dimensional SSNMR involving 2D 
correlation experiments allow excellent opportunities to investigate spatial proximities 
between chemically distinguished nuclei. In these experiments, homonuclear and 
heteronuclear dipolar decoupling pulse sequences are used in order to obtain a much-
improved resolution in comparison to standard one-dimensional experiments. 
Homonuclear decoupling sequences such as frequency switched Lee-Goldburg (FSLG) 
or phase- modulated Lee-Goldburg (PMLG) are incorporated with MAS in CRAMPS 
(combined rotation and multiple pulse sequence) to obtain high resolution two 
dimensional spectra. Pham et al. demonstrated the applicability of HETCOR experiments 
in conjunction with TOSS for exploring miscibility and molecular interactions for 
multiple model systems involving binary and ternary ASDs.12  
2.4.3 Detection and Quantitation of Amorphous Phases 
One criterion to confirm the presence of amorphous phase is through broader 
resonances as shown in the Figure 2.7. In amorphous samples, molecules can exist in 
multiple conformations resulting in broad distribution of isotropic chemical shift values 
for each chemically inequivalent nuclear site. In addition, comparing line widths with the 
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crystalline phase may be useful evidence of amorphization. For the cases where 
crystalline and amorphous phase coexist within the same sample, the detection of 
amorphous phase may be difficult due to likely overlap with crystalline peaks and the 
weak intensity of the amorphous phase peaks. In such a situation, one potential strategy 
is to decrease the recycle day between two consecutive transients in a regular CP/MAS 
experiment. Decreasing the recycle delay results in a partial suppression of crystalline 
signals, and subsequently favoring the amorphous signals. 
 
Figure 2.7. A comparison of 13C CP/MAS spectra of crystalline and amorphous 
itraconazole (ITZ). 
 
Once the presence of the amorphous phase is confirmed, it is important to 
quantify it as well from a pharmaceutical standpoint. There are several case studies 
published in the literature where SSNMR has been used for the quantification of 
amorphous systems.32-34 The NMR signal is proportional to the number of nuclei, 
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provided that the spectrum is suitably recorded. Generally, it is assumed that CP/MAS 
spectra are not quantitative, as the transfer of magnetization does not occur uniformly for 
each carbon during the CP step.32 In order to obtain quantitative information from 13C 
CP/MAS spectra, it is important to carefully select the contact time for the CP pulse 
sequence. The intensity of the signal strongly depends on the contact time, which is 
usually specific to each chemically inequivalent nucleus, and can also change depending 
on the phase. Offerdahl et al. successfully quantified different forms of the artificial 
sweetener neotame.32 In the Figure 2.8, the experimental CP dynamics of the crystalline 
and the amorphous form of neotame is shown.  
 
Figure 2.8. 13C cross polarization dynamic curves for various forms of neotame, taken 
from reference.32 
 
In general, CP dynamics depend on the two rate constants, TCH and T1ρH as shown 
in the equation. This equation can be applied when T1ρC >> TCH. 
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𝑀(𝑡) =
𝑀0 [exp (−
𝑡
𝑇1𝜌𝐻
) − exp (−
𝑡
𝑇𝐶𝐻
)]
1 − (
𝑇𝐶𝐻
𝑇1𝜌𝐻
)
 
(2.9) 
where M(t) is the magnetization and t is the contact time. T1ρH is the spin-lattice 
relaxation times in the rotating frame for proton. TCH is the cross polarization time 
constant, which depends on the strength of the dipolar coupling between 13C and 1H. TCH 
time determines the rate of increase of 13C magnetization, whereas T1ρH dictates the decay 
of magnetization. By fitting the CP dynamics curve to the equation, it is possible to 
obtain the information on parameters T1ρH, TCH and M0 is the thermal equilibrium value 
of 13C magnetization. 
2.5 Conclusions 
In this chapter, a comprehensive overview of the basics of SSNMR was 
presented. The main focus of this chapter was to introduce some key concepts and 
experimental features pertaining to the use of SSNMR for pharmaceutical samples. In 
addition, some important applications of SSNMR with respect to the amorphous systems 
were highlighted. Special emphasis was given to the applications of proton relaxation 
time measurements for evaluating phase homogeneity in ASDs. 
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CHAPTER 3. PHASE BEHAVIOR OF AMORPHOUS SOLID DISPERSIONS OF FELODIPINE: 
HOMOGENEITY AND DRUG-POLYMER INTERACTIONS 
3.1 Introduction 
Over the past few decades, amorphous solid dispersions (ASDs) have been of 
great interest to pharmaceutical scientists to address the oral bioavailability issues 
associated with poorly water-soluble drugs.1-4 ASDs consist of an active pharmaceutical 
ingredient (API) that is typically dispersed in an inert polymeric matrix.5, 6 Despite 
promising advantages, a major concern that has resulted in limited marketed formulations 
is the physical instability of these complex formulations.7 Physical instability is often 
manifested as the API crystallizing in the formulation, which is often predicated on phase 
separation, where the drug and carrier migrate and generate distinct phases. Thus, phase 
separation can be a prelude to recrystallization.8 It is therefore important to understand 
phase homogeneity in ASDs to enable rational formulation design. 
One important factor that dictates the physical stability of ASDs is the spatial 
distribution of the API in the polymeric matrix.9 Three possibilities exist: (1) a 
homogenous system with a single phase where API is uniformly distributed throughout 
the polymeric matric, (2) a non-homogeneous system where API and polymer are totally 
phase separated, and (3) a partially homogeneous system with drug rich and polymer rich 
phases. From a pharmaceutical viewpoint, an intimately mixed ASD is usually preferred, 
as it is likely to have better physical stability and product efficacy.10 In addition to phase 
homogeneity, other factors to potentially impact physical stability include storage 
conditions, hygroscopicity of the polymer, solubility of the drug in polymer, and the glass 
transition temperature (Tg) of the system.
11-13 Regardless of the mechanism, it is generally 
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agreed that intimate mixing of the drug and the polymer is desired to achieve maximum 
stabilization14. Therefore, understanding the factors controlling phase behavior and nano-
domain structure of ASDs is crucial to rational formulation design.  
There are many analytical tools that have been used for determining drug-
polymer miscibility in ASDs. Differential scanning calorimetry (DSC) is one of the 
standard techniques for characterizing phase homogeneity in ASDs if the minimum size 
of phase separated domains is 30 nm or higher.15, 16 A single Tg, intermediate to those of 
an API and polymer is considered as a sign of a homogenous system. In contrast, 
multiple Tg values indicate a phase separated system but this criterion is not reliable. In 
several instances, it has been demonstrated that it is possible to observe a single Tg for a 
phase separated system, and vice versa.17, 18 Furthermore, detection of sub 30 nm 
domains may be challenging to characterize via DSC. Other analytical tools include 
Raman mapping, which has shown to be able to detect phase separation in systems where 
Tg is undetected by DSC.
19 Conventional high-resolution imaging techniques such as 
scanning electron microscopy (SEM), transmission electron microscopy (TEM), and 
atomic force microscopy (AFM) have also been employed to study miscibility.20-22 
However, these traditional characterization methods often have low spatial resolution 
with respect to the distribution of the components of ASD, and are unable to identify the 
chemical compositions of different microstructures. The lack of analytical methodology 
that can detect phase heterogeneity on the order of a few nanometers often leads to the 
difficulties in elucidation of phase behavior of ASDs at that level of resolution. 
Solid-state nuclear magnetic resonance (SSNMR) spectroscopy has recently 
emerged as a technique to investigate phase behavior of ASDs with atomic level 
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specificity and selectivity.23 SSNMR can provide valuable information on the 
heterogeneity of the sample at the nanometer level.24-28 It is especially useful for ASDs 
where nano heterogeneities can exist beyond the resolution limits of thermal analyses. 
Specifically, proton spin-lattice relaxation times (1H T1 and T1ρ) are measured to 
determine and understand phase homogeneity.29, 30 An intimately-mixed ASD is reflected 
in identical values of 1H T1 and T1ρ for the API and the polymer components. On the 
contrary, a detectable difference between the relaxation times for the API and the 
polymer provides the evidence for a heterogeneous or phase separated system.31, 32 In 
recent years, SSNMR has attracted increased attention in the field of ASDs to study 
phase homogeneity.24, 33-35 Policianova et al., probed homogeneity of acetylsalicylic acid 
dispersions on the scale of ca. 10-500 nm.36 In a study by Yuan et al., compositional 
dependent homogeneity was studied for nifedipine-PVP ASDs prepared by different 
methods. 1H T1ρ measurements indicated that 95:5 and 90:10 nifedipine-PVP ASDs 
prepared by melt-quenching were non-homogeneous on the molecular level.27 Most 
recently, Yang et al. demonstrated that at extrusion temperature higher than 160 ˚C better 
miscibility was achieved for the drug and polymer with length scale of mixing of 20-80 
nm for nifedipine-copovidone dispersions prepared via hot melt extrusion.33 In spite of 
these previous studies, little SSNMR work has been reported on the systematic study of 
the factors affecting the compositional homogeneity in ASDs.  
The domains are affected by the composition of the drug-polymer mixture and the 
underlying molecular interactions. The level of mixing between API and the polymer is 
maximized when the individual components are involved in intermolecular interactions 
such as hydrogen bonding (H-bonding).37-39 There are several examples in the literature 
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where pharmaceutical polymers containing H-bond donor/acceptors have shown to form 
H-bond with drug molecules containing acceptor/donor groups. The formation drug-
polymer interactions can lead to better physical stability and dissolution properties.40, 41 
Routinely, H-bonding interactions between the drug and polymer are studied by fourier 
transform infrared (FT-IR) spectroscopy. There are numerous examples in literature 
where presence of H-bonding has been shown by FT-IR measurements.42-47 Even though 
widespread, FT-IR technique has its drawbacks. It is possible to achieve unreliable results 
due to broad and overlapping absorption bands. SSNMR can offer better resolution 
between the components of ASDs and reveal the nature of interactions between H-bond 
donors and acceptors quantitatively. Yuan et al., demonstrated the use of high resolution 
13C SSNMR measurements to monitor H-bonding interactions in amorphous 
indomethacin and its ASDs.35  
For the current study, we hypothesize that the systems with stronger and more 
extensive drug-polymer H-bonding interactions will exhibit better compositional 
homogeneity than the systems with weaker and less extensive drug-polymer interactions. 
We used a BCS class II API felodipine (FEL) as our model drug and three different 
polymers poly(vinylpyrrolidone) (PVP), poly(vinylpyrrolidone)/vinyl acetate (PVP/VA), 
and poly(vinylacetate) (PVAc). FEL is a dihydropyridine derivative with one H-bond 
donor and several acceptors in its structure. The polymers have only H-bond acceptors in 
their backbone thereby offering different possibilities for H-bonding interactions with 
FEL, thus helping us establish our hypothesis. In H-bonded systems, the phase behavior 
of resulting dispersions is determined by the extent and strength of H-bonds between the 
donor and acceptor groups. We are aware of no previous SSNMR studies regarding the 
 
 
61 
role of H-bonding on compositional homogeneity. The chemical structure of all the 
compounds along with the physicochemical properties is shown in Table 3.1. The first 
part of this article is devoted to investigate the phase behavior of FEL dispersions using 
DSC. In the second part of this article, SSNMR is used to elucidate the extent of H-
bonding and correlate that to phase homogeneity. We show that SSNMR methods can be 
used to study comprehensively the phase behavior and speciation in ASDs, which cannot 
be achieved using conventional analytical tools. 
3.2 Experimental Section 
3.2.1 Materials 
Felodipine (FEL; purum 99%) was purchased from BOC Sciences (Shirley, NY). 
PVP K25 (Kollidon 25, Mw = 28-34 kg/mol) and PVP/VA (Kollidon VA 64, Mw = 45-70 
kg/mol) were kindly donated by BASF Corp. (Edison, NJ). PVP and PVP/VA were dried 
at 70 ˚C under vacuum to remove residual moisture before use. PVAc (average Mw = 100 
kg/mol) was purchased from Sigma-Aldrich (St. Louis, MO). Polymer samples were 
stored over Drierite at all the times. 
3.2.2 Preparation of Amorphous Materials 
Preparation of Amorphous Felodipine. Amorphous felodipine was prepared by 
in situ melt quenching inside the spinning NMR rotor. Sample was packed into 7.5 mm 
zirconia rotors with Teflon or Kel-F end caps (Revolution NMR, LLC., Fort Collins, 
CO). The rotor was heated in the NMR probe equipped with a variable-temperature 
accessory stack (Varian, Palo Alto, CA) at 155 ˚C for approximately 10 min while 
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spinning at 4 kHz. The rotor was then rapidly cooled to room temperature to generate 
glassy felodipine.  
Preparation of Felodipine Amorphous Solid Dispersions. Amorphous solid 
dispersions of felodipine with PVP, PVP/VA, and PVAc were prepared by melt 
quenching in the lab setting. To prepare dispersions via this approach, one gram samples 
at various drug:polymer weight ratios ranging from 50:50 to 90:10 (on weight basis) 
were cryomilled at 10 Hz (SPEX SamplePrep 6770 Freezer/Mill, SPEX SamplePrep 
LLC., Metuchen, NJ) for five cycles, each comprising 2 min of milling and 2 min of 
cooling. Liquid nitrogen was employed as a coolant. The cryomilling procedure was 
used to ensure optimally mixed drug-polymer mixtures before melting. The cryo-milled 
mixtures were then transferred into a Teflon beaker and heated in an oil bath at 160 ˚C 
for 10 min or until completely melted. The melted mixtures were then quenched-cooled 
using liquid nitrogen to generate dispersions. The resulting dispersions were vacuum-
dried at room temperature overnight to remove any residual moisture. All dispersions 
samples were confirmed amorphous by powder X-ray (Figure 3.5). All amorphous 
samples were stored in glass vials over Drierite in the freezer when not analyzed. 
3.2.3 Differential Scanning Calorimetry (DSC) 
DSC analyses were performed using a Q2000 (TA Instruments, New Castle, DE) 
equipped with a RCS90 refrigerated cooling system (TA Instruments; New Castle, DE). 
The instrument was calibrated for temperature and heat flow using indium as a standard. 
Approximately 5-7 mg of sample was hermetically sealed in an aluminum pan with one 
pinhole in the lid. All the dispersion samples were analyzed via heat-cool-heat cycle 
under nitrogen purge (50 mL/min). A typical thermal cycle consisted of following stages: 
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1) heating from 20 ˚C to 165 ˚C (first heating); 2) isothermal for 10 min followed by 
cooling to -10 ˚C (cooling stage); 3) reheating to 165 ˚C (second heating). For the heating 
cycles, an underlying heating rate of 2 ˚C/min was used with modulation amplitude of 
±0.21 ˚C applied every 40 s. For each sample, measurements were conducted in 
duplicate. The data were analyzed by Universal Analysis software (Version 4.7, TA 
Instruments, New Castle, DE). The value of Tg reported was the half height of the 
transition in the reversing heat flow signal.  
3.2.4 Solid-State NMR Spectroscopy 
13C SSNMR spectra were acquired using a Tecmag Redstone spectrometer 
(Tecmag Inc., Houston, TX) operating at approximately 300 MHz for 1H and 75 MHz for 
13C. Samples were packed into 7.5 mm zirconia rotors and sealed with Teflon or Kel-F 
end-caps (Revolution NMR LLC., Fort Collins, CO). One dimensional 13C spectra were 
acquired using cross polarization magic angle spinning (CP/MAS) at 4 kHz, using total 
sideband suppression (TOSS)48 and SPINAL6449 decoupling. The 1H 90˚ pulse width was 
set to 4.0 μs and the contact time of 1.5 ms was used in all the measurements. The 13C 
chemical shift scale was referenced with the methyl peak of 3-methylglutaric acid, which 
was set to 18.84 ppm.50 
The proton relaxation times were detected via 13C nucleus to resolve the 
resonances for respective components. The chemical shift regions unique to FEL and the 
polymers were integrated to obtain the proton relaxation times (details in Results and 
Discussion). Proton spin-lattice relaxation time in the laboratory frame (1H T1) was 
measured using a 13C-detected saturation recovery pulse sequence with TOSS. 1H T1 
obtained by fitting intensity-recovery time data by the following equation: 
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𝑀(𝑡) = 𝑀0(1 − 𝑒
−
𝑡
𝑇1) 
(3.1) 
 
where M(t) is the integrated signal intensity at delay time t, M0 is an amplitude parameter 
from the fit, and T1 is the obtained spin-lattice relaxation time. Proton relaxation time in 
the rotating frame (1H T1ρ) was measured by varying the spin lock duration time after a 
90˚ pulse. The T1ρ decay times were obtained by analyzing the integrated carbon signal 
intensity according to the following equation: 
 
𝑀(𝑡) = 𝑀0𝑒
−
𝑡
𝑇1𝜌 
(3.2) 
 
where M(t) is the integrated peak intensity and t is the spin-lock duration time. M0 is an 
amplitude parameter from the fit, and T1ρ is the fitted spin-lattice relaxation time in the 
rotating frame. All data fitting was done using GraphPad Prism (GraphPad Saoftware, 
Inc., La Jolla, CA). 
The NMR spectra of amorphous FEL and the dispersions samples were 
deconvoluted using MNOVA software (MestreLab Research, Version 10.0, Santiago de 
Compostela, Spain) in the carbonyl region. For the dispersion samples, the spectra were 
fitted with three or four peaks depending on the system. The parameters like the peak 
width and the Gaussian/Lorentzian ratio were kept fixed across samples in the same 
system. The area percentages for the various species were calculated from the total area 
of the deconvoluted peaks and the area for FEL peaks were then normalized to the total 
area of its carbonyl peaks. 
 
 
 
65 
Table 3.1. Chemical Structures showing H-bond donors (in blue) and acceptors (in red) 
of model compounds along with their physicochemical properties. 
Compound Structure Tm (⁰C) Tg (⁰C) 
H-Bond 
Donors/Acceptors 
Felodipine 
 
144.4 46.2 
Donor and 
Acceptors 
PVP K25 
 
-- 170.0 Acceptor 
PVP/VA 
 
-- 109.0 Acceptors 
PVAc 
 
-- 44.4 Acceptor 
 
3.2.5 Theoretical Calculations 
Gas-phase calculations were completed with the Gaussian09 software package,51 
utilizing the B3PW9152 density functional and the 6-311G(2d2p)53 basis set for structural 
optimizations. This particular theory was chosen based upon its performance as reported 
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by Chen et. al.,54 and its performance on the systems studied herein. All gas-phase 
calculations used molecular structures extracted from the single crystal X-ray data 
retrieved from the CCDC as starting points. All geometry optimizations allowed the 
molecules to fully relax with no symmetry restrictions, while the single-point energy 
calculations held the molecules in rigid conformations. The default total energy 
convergence criteria for was used (ΔE < 10-6 hartree) for geometry optimizations. The 
DFT grid was set to program option “ultrafine” for all simulations. The NMR chemical 
shifts were predicted using HF/6-31G(d)55, 56 level of theory and the GIAO command in 
Gaussian09. 
3.3 Results and Discussion 
The most common approach to analyze homogeneity at the molecular level is 
DSC. The presence of a Tg in a dispersion of drug and polymer has been suggested to 
indicate that the sample is homogeneous at a molecular domain size of ≥ 30 nm. When 
studying homogeneity at smaller domain sizes, more advanced techniques such as 
SSNMR are needed that can probe down the 2-5 nm range. For this reason, the samples 
were initially analyzed using DSC to probe whether any differences in homogeneity 
could be observed based upon multiple Tg values or deviations from the predicted values. 
3.3.1 DSC Results 
3.3.1.1 DSC Heating Cycles 
As noted in the above paragraph, thermal analysis is one of the most convenient 
approaches to assess the homogeneity and thermal behavior of dispersions.57 
Inhomogeneity is often marked by two Tg values, corresponding to the Tg values of the 
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individual components.58 The DSC analysis of the neat polymers showed a Tg of 170 ⁰C 
for PVP, 109 ⁰C for PVP/VA and 44.4 ⁰C for PVAc (Table 3.1). Amorphous FEL 
showed a Tg of 46.2 ⁰C, accompanied by an exothermic crystallization, and followed by 
melting with an endothermic peak at 144 ⁰C, which is consistent with previously-
reported results.43 It is worth noting that PVAc has slightly lower Tg than the amorphous 
FEL. 
The DSC thermograms from the first heating cycle for FEL:Polymer dispersions 
with various compositions are shown in Figure 3.1. For each set of ASDs, a single 
composition-dependent Tg was observed in the reversing heat flow traces, which implies 
that the FEL and polymers were homogeneous over the composition range. Melting 
endotherms were observed for certain compositions (samples containing less than or 
equal 20% PVP, 20% PVP/VA and 40% PVAc) in each system. The presence of a 
melting endotherm can be attributed to either the presence of residual crystallinity in the 
sample, or to crystallization taking place at temperatures above Tg. Because a 
crystallization exotherm was observed in the non-reversing heat flow (vide infra), the 
latter explanation is more likely. This suggests that there is some degree of nano 
heterogeneity and the amorphous drug-rich domains can rearrange into crystalline phases 
due to increased mobility of the system above Tg. This phenomenon of crystallization 
above Tg is polymer dependent and the details will be discussed in the later section. In 
order to further investigate this phenomenon, a second DSC scan was performed on these 
samples to see if the crystallization exotherm/melting endotherm was observed for 
samples when the thermal history was removed as a variable. 
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The characteristics seen in first heating cycle represent the state of the samples as 
they were prepared, which was by melt quenching. After the first heating scan, both the 
thermal history of the samples and any residual moisture content are removed from the 
samples, and this can result in the samples being more homogenous for accurate 
measurement of Tg of a homogeneous system. The DSC thermograms of the second 
heating scans were slightly different than the first heating scan, with sharper Tg step 
changes and the absence of any melting endotherms. The absence of melting endotherms 
signifies that quench cooling in the DSC pan after the first heating scan was sufficient to 
eliminate the crystal formation during the cooling cycle. As it can be seen from Figure 
3.2, only one Tg was detected in each set of dispersions for the composition range 
studied, with the Tg value being a function of the drug to polymer ratio. In order to 
understand the impact of this crystallization appearing in the first heating scan but not the 
second, the data was analyzed first to see if there was any drug-polymer interactions that 
might be observed in the DSC data, specifically in the form of a change in the Tg values. 
A change in the Tg from the first to second scan could indicate a change in the 
homogeneity of the samples, where the second scan may result in a more homogeneous 
sample, and therefore less susceptible to crystallization. 
The DSC thermograms (first and second) had similar mean Tg values from both 
the cycles. Even though these dispersions appear to be homogeneous, since they 
exhibited a single Tg for both the heating runs that was very close in value, this does not 
necessarily ensure that they are homogenous below the 30 nm scale as noted above for 
DSC homogeneity measurements. 
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Figure 3.1. DSC thermograms from first heating scan for FEL:Polymer dispersions A) 
FEL:PVP B) FEL:PVP/VA and C) FEL:PVAc. The values reported here are the mean 
glass transition temperatures. 
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Figure 3.2. DSC thermograms from second heating scan for FEL:Polymer dispersions A) 
FEL:PVP B) FEL:PVP/VA and C) FEL:PVAc. The values reported here are the mean 
glass transition temperatures. 
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3.3.1.2 Fitting DSC Data to Gordon-Taylor Equation 
DSC data can be plotted as a function of composition to determine if there are 
potential interactions between the drug and the polymer, where deviations from linearity 
suggest that there may be drug/polymer interactions. A number of empirical models have 
been proposed to study the Tg composition dependence of dispersions. Among the 
equations proposed, the Gordon-Taylor equation is widely used.59 It is described as 
follows: 
 
𝑇𝑔 =
[(𝑤1𝑇𝑔1) + (𝑘𝑇𝑔2)]
[𝑤1 + (𝑘𝑤2)]
 
(3.3) 
 
where Tg is the glass transition of the dispersion, Tg1 and Tg2 are those of pure 
components, w1 and w2 are the weight fractions of each component, and the constant k is 
an adjustable fitting constant. The mean Tg values from the second heating scans were 
used for the Gordon-Taylor equation. For fitting the data it is convenient to linearize and 
rewrite the original Gordon-Taylor equation as: 
 𝑇𝑔 − 𝑇𝑔1 = k ∗ (Tg2 − 𝑇𝑔) ∗ (
𝑤2
w1
) (3.4) 
 
A plot of Tg-Tg1 versus (Tg2-Tg)*(w2/w1) will yield k via linear regression. Using this 
approach, we get k values of 0.81, 1.18, 0.91 for FEL:PVP, FEL:PVP/VA, and 
FEL:PVAc dispersions respectively. 
Figure 3.3 shows the plot of Tg values obtained after the second heating scan vs. 
the weight fraction of polymer for the three polymer systems. The broken lines in Figure 
3.3 were obtained by inserting the resulting values of k into equation (3) and plotting the 
corresponding Tg values. A slight negative deviation is seen for FEL:PVP and 
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FEL:PVP/VA dispersions, which likely reflects the presence of weak specific 
interactions. Compared to FEL:PVP and FEL:PV/VA dispersions, FEL:PVAc system 
had no deviations from the predicted Gordon-Taylor curve. This ideal behavior could be 
due to negligible presence of any specific intermolecular interactions, or that the 
intermolecular FEL-FEL interactions were replaced with the similar strength of 
intermolecular FEL:PVAc interactions. It is worth mentioning that the Tg of amorphous 
FEL and PVAc were almost similar, which caused Tg values of resulting dispersions to 
change very slightly for the composition range studied. 
 
Figure 3.3. Tg-composition relationship for FEL:Polymer dispersions. Mean 
experimental Tg values are denoted by symbols (red circle for FEL:PVP, green square for 
FEL:PVP/VA, and FEL:PVAc). The respective Gordon-Taylor curves are shown in 
colored broken lines. 
 
3.3.1.3 Drug Crystallization-First Heating Scan 
Figure 3.1 showed that for samples containing less than or equal to 20 % polymer 
for FEL:PVP and FEL:PVP/VA ASDs, FEL crystallized upon heating. For FEL:PVAc 
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ASDs, samples containing less than 50% polymer showed signs of FEL crystallizing 
upon heating. To support the idea that the crystallinity was produced during heating and 
was not present prior to analysis via DSC, PXRD (Figure 3.5) and 13CP/MAS (vide infra) 
clearly pointed to the absence of any crystallinity present within their detection limit. 
The reversible heat flow data shown in Figure 3.1 is useful for determining the Tg 
values, but the non-reversible heat flow events can provide insight into events such as 
crystallization occurring in the samples. Figure 3.4 shows DSC thermograms for the non-
reversing heat flow for the 90:10 (Plot 3.4 A) and 80:20 (Plot 3.4 B) compositions. 
Amorphous FEL exhibited a crystallization exotherm at 80.9 ⁰C. The crystallization 
temperature of amorphous FEL increased with polymer loading for all three polymers. In 
addition, it can be seen that the crystallization temperature was the highest with PVP for 
both of the polymer loadings. Overall, the stabilization potential of a polymer is rank 
ordered as PVP>PVP/VA>PVAc. In fact, the rank ordering correlates well with the 
results reported by Bhugra et.al.60 The authors showed that crystallization temperature 
could be an indicator of the strength of drug-polymer interaction. For their case study 
with nifedipine, a similar trend was seen and the authors concluded that PVP had the 
most potential to retard crystallization in comparison with other polymers studied. This is 
also consistent with the study performed by Yuan et.al, where the authors showed that 
PVP systems had a stronger interaction with indomethacin as compared to systems with 
PVP/VA35. 
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Figure 3.4. DSC thermograms showing non reversing heat flow versus temperature as a 
function of polymer loading: A) 10% polymer B) 20% polymer. 
 
3.3.1.4 Summary – DSC Results 
The DSC data in the previous sections highlighted several trends. First, there 
were differences between the first and second heating cycles in the DSC thermograms, 
suggesting that the samples as initially prepared were different than the samples that 
were heated above the melting point of the drug, cooled, and then reheated. The most 
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likely explanation we have pointed out is that there was some degree of phase 
heterogeneity present when the samples were initially prepared. However, the most 
definitive evidence for that could be the observation of two glass transition temperatures 
in the DSC thermograms, or even a change in the Tg of the samples from the first and 
second heating curves, which was not observed. There was no direct evidence for phase 
heterogeneity from the DSC results. Second, the strength of drug-polymer interactions 
was consistent with PVP having the strongest H-bonding interaction with FEL, followed 
by PVP/VA and PVAc in that order. However, the relative strength of this interaction 
was not quantified, except by the change in the crystallization temperature. 
To answer these questions, SSNMR was used to study the homogeneity of the 
samples as a function of polymer composition, and for a select sample, the equivalent of 
a second heating scan was done in situ in the SSNMR rotor. In addition, SSNMR was 
employed to investigate the structural changes in the drug as a function of polymer 
loading to better understand the strength and extent of the drug-polymer H-bonding 
interactions. 
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Figure 3.5. X-ray powder diffraction patterns of FEL:Polymer dispersions for A) 
FEL:PVP, B) FEL:PVP/VA and C) FEL:PVAc. 
 
3.3.2 13C CP/MAS Solid-State NMR Results – Miscibility 
3.3.2.1 SSNMR Spectra and Interpretation 
The 13C CP/MAS spectra of as-received FEL and amorphous FEL are shown in 
Figure 3.6. The assignments of resonances as given in Table 3.1 for various carbons of 
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as-received FEL were done based on previous literature reports.61 In the recorded 13C 
CP/MAS spectrum, the crystalline material could be easily be identified and 
distinguished from the amorphous state based on its narrow and well resolved resonances 
in contrast to broad NMR signals seen for the amorphous FEL. The 13C CP/MAS spectra 
for the polymers are displayed in Figure 3.6. All the three polymers depicted amorphous 
characteristics as exhibited by their broad resonances. For pure PVP, four distinct peaks 
were observed although it has six carbons in its structure. This is owing to the overlaps 
observed in the carbon resonances. The resonance at 175 ppm corresponded to the 
carbonyl group (C=O) of PVP pyrrolidone backbone. Similarly for neat PVP/VA, only 
eight resonances could be resolved in the spectrum. The carbonyl region of the spectrum 
of PVP/VA consisted of resonances at 175 ppm and 170.9 ppm, which arose from two 
carbonyl carbons one from the pyrrolidone moiety and other from the acetate 
functionality. In the PVAc spectrum, four resonances were seen with no overlap in the 
resonances. Peaks at 40 ppm and 66 ppm corresponded to the polymer backbone. 
Meanwhile, the other resonance at 170.2 ppm came from the carbonyl group. 
The 13C CP/MAS spectra of FEL dispersions with various polymers are shown in 
Figure 3.7 (Plots A, B and C). The spectra confirmed the amorphous nature of the 
dispersions formulated via melt quenching. For the spectra of dispersions, it was noted 
that there were some non-overlapping resonances for the drug and polymers. The carbon 
signals around 146 ppm, 128 ppm and 104 ppm were selective for FEL (red dashed 
boxes in Figure 3.7). Meanwhile, the carbon signals around 175 ppm served as non-
overlapping peak for PVP and the carbon resonance around 68 ppm was selective for 
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both PVP/VA and PVAc (blue dashed boxes in Figure 3.7). These specific peaks act as a 
unique probe to follow the relaxation behavior of FEL and polymers in the dispersions. 
 
Figure 3.6. Stacked plot of 13C CP/MAS spectra for (A) Felodipine (as received) (B) 
amorphous felodipine (C) PVP (D) PVP/VA and (E) PVAc. The 13C resonances relate to 
the numbering scheme presented in Table 3.1. 
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Figure 3.7. 13C CP/MAS spectra of (A) FEL:PVP dispersions (B) FEL:PVP/VA and (C) 
FEL:PVAc. In each stacked plot the spectra from top to bottom include amorphous FEL, 
FEL:Polymer dispersions with 50-90% drug load and neat polymer. The central aromatic 
peaks at 146 ppm, 128 ppm and 104 ppm (indicated by the red box; plot A-C) were 
attributed to FEL specific resonances while the peaks at 175 ppm (indicated by blue box; 
plot A), 68 ppm (indicated by blue box; plots B and C) were identified as non-
overlapping regions for PVP, PVP/VA and PVAc respectively. 
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3.3.2.2 SSNMR Relaxation Times - Investigation of Phase Behavior 
In order to obtain more detailed information on the compositional homogeneity 
and phase behavior of dispersions, the proton relaxation experiments were performed, 
which consisted of measuring the spin-lattice relaxation time in the laboratory frame (1H 
T1), and in the rotating frame (
1H T1ρ) for both the drug and polymer peaks. The 
measurements are usually performed via 13C resonances to be able to determine the 
relaxation time values for the drug separately from the polymer. As depicted in Table 
3.2, the neat samples of FEL (as-received and amorphous) and polymers were 
characterized by different 1H T1 and T1ρ times. An examination of experimental 
1H T1 
and T1ρ data for FEL showed that amorphous state has shorter relaxation times than the 
crystalline FEL, which is characteristic of disordered materials. From Table 3.2, a single 
proton relaxation value was observed for pure polymers, indicating a single-phase 
amorphous system. The experimental 1H T1 and T1ρ values are rank ordered as 
PVAc>PVP/VA>PVP. 
For a system containing multiple components, such as a drug and a polymer, the 
scale of compositional homogeneity can be estimated from the relaxation behavior of the 
individual components. Three possibilities exist for the phase behavior classification of 
dispersions, namely a homogeneous, a partially homogeneous, and a non-homogeneous 
system, corresponding to a uniformly mixed system, a partially-mixed system, and a 
phase separated system. In case of a homogeneous system on the molecular scale, the 
protons of different components spin diffuse and relax at an identical rate. For a phase-
separated system, the drug and polymer have different relaxation behavior is observed 
owing to domain sizes of the drug and polymer being so large that there is incomplete 
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spin diffusion between the drug and polymer at the largest domain size measured. It 
should be noted that when a difference in relaxation times is observed, it simply indicates 
that the entire sample is not fully homogeneous over that domain size, and there could 
easily be domains that are homogeneous, along with some domains that are only partially 
or completely phase separated. Since any degree of phase heterogeneity can potentially 
indicate that there is a propensity for the sample to crystallize, the observation of a lack 
of homogeneity is more important than determining if the sample is completely phase 
separated. In most cases, solid-state NMR spectroscopy will indicate a lack of full 
homogeneity of the sample, rather than total phase separation.  
Table 3.2. 1H T1 and T1ρ values along with the standard errors associated with the fit for 
FEL (as-received and amorphous) and Polymers measured via 13C resonances. 
 
Proton 
Relaxation 
Time 
Felodipine Polymers 
As received Amorphous PVP PVP/VA PVAc 
T
1
 (s) 61.34±1.56 4.82±0.13 1.73±0.02 2.15±0.04 3.73±0.03 
T
1ρ
 (ms) 305.00±6.44 140.70±5.95 23.68±0.13 25.56±0.16 39.86±0.24 
 
The characteristic 13C resonances for FEL and polymers were identified from the 
13C CP/MAS spectra (Figure 3.7). It should be noted that the absolute values for 1H T1 
and T1ρ relaxation times depend on the many factors like water content, particle size, 
etc.62, 63 The absolute relaxation times for the dispersions were intermediate in values 
when compared to those for the neat components (data not shown). For the current 
investigation, the differences in the relaxation times between FEL and polymer were 
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compared for samples in each system. The plots of 1H T1 differential between FEL and a 
given polymer are shown in Figure 3.8. As displayed in Figure 3.8, no apparent trend 
could be seen in the plot of 1H T1 differentials for all the systems. The FEL:PVP system 
had the same values for 1H T1 for FEL and polymer across all the compositions within the 
error of the measurement. The FEL:PVP/VA also had similar values across all 
compositions, although the higher drug concentrations (80% and 90%) were slightly 
different, still within the 95% confidence intervals. Thus, these systems are essentially 
homogenous on the length scale measured by 1H T1, except potentially the higher drug 
loading samples. In the case of FEL:PVAc dispersions, no significant differences in 1H 
T1 were observed between FEL and PVAc at PVAc > 10% w/w, confirming phase 
uniformity at 1H T1 length scale of mixing for those compositions.  
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Figure 3.8. 1HT1 differential between FEL and polymer in dispersions for A) FEL:PVP, 
B) FEL:PVP/VA and C) FEL:PVAc as a function of weight fraction of polymer. The 
error bar signifies 95% confidence interval associated with the fit. The dashed line 
represents the zero. 
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The relaxation time constant 1H T1, which is usually a few seconds for ASDs and 
is usually about two orders of magnitude longer than 1H T1ρ, is averaged out over a large 
distance (tens of nanometer) while 1H T1ρ is typically a few tens of milliseconds and is 
averaged out to over few nanometers.64, 65 This makes 1H T1ρ a way to determine 
homogeneity over a much smaller domain size compared to 1H T1 values. The 
differential 1H T1ρ plots between FEL and a given polymer are presented in Figure 3.9. 
For all polymers, there was a change in the 1H T1ρ values, where the differential values 
increased with decreasing polymer concentration. It was observed  that the FEL:PVP had 
the lowest differentials, followed by the FEL:PVP/VA and finally the FEL:PVAc. This 
trend is consistent with the crystallization trends observed in the DSC data. The samples 
with less than or equal to 10% PVP, 20% PVP/VA and 30% PVAc exhibited non 
identical 1H T1ρ times within the error of measurement. This clearly indicates nano-phase 
separation existing for these compositions on the length scale of 1HT1ρ. 
We also investigated whether the molecular weight of the PVP had an impact on 
phase miscibility as studied by 1H T1ρ. The differential 
1H T1ρ plots between FEL and 
different grades of PVP polymer for 90% drug loading sample are shown in Figure 3.10. 
It is apparent from Figure 3.10 that the 1H T1ρ were different for FEL and PVP grades, 
suggesting the presence of drug rich nano domains. The extent of phase heterogeneity 
can be confirmed by the magnitude of the differential. The differential is larger for the 
higher molecular weight polymers, which is consistent with poorer mixing and less 
homogeneity due to the lower mobility of polymers for higher molecular weight grades. 
All of these samples showed a single glass transition, crystallization in the first heating 
cycle, and no endotherm in the second DSC scan (data not shown). 
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3.3.2.3 SSNMR Relaxation Times - Determination of Domain Sizes 
If the diffusion path length is smaller than the dimensions of the domains in the 
dispersions, two different relaxation times will be observed, one for the drug and the 
other for the polymer, or also different relative compositions of drug and polymer, or 
some combination of these. However, if the diffusion path length is larger than the 
dimensions of domains in the dispersions, effective spin diffusion causes single average 
relaxation time for both the components or various domains.65 The upper limit of the 
length scale of mixing can be approximated by the one dimensional Fickian diffusion 
equation, which is given as: 
 < 𝐿2 ≥ (6𝐷𝑇𝑖) (3.5) 
 
where D is the spin diffusion coefficient, which depends on the average proton to proton 
distance as well as a dipolar interaction. Although the coefficient can vary somewhat, a 
typical value of 10-12 cm2/s is often used for rigid organic solids with a moderate proton 
spin density.32, 66 Ti is the relaxation time, T1 or T1ρ. Using this approach, a reasonable 
estimation of spatial heterogeneities can be made, which is order of magnitude different 
than DSC, where it is hard to confirm existence of phase homogeneity based on a single 
Tg. In addition, the length scale of DSC measurements is usually 10-30 nm,
15 and any 
heterogeneity which may be present on a smaller scale will go undetected by thermal 
analysis. From this SSNMR study and the previous DSC study on the dispersions, the 
scales of domain sizes for the samples are summarized in Table 3.3. It can be clearly seen 
that FEL:PVP and FEL:PVP/VA dispersions were all homogeneous on a scale below 7 
nm for the samples with drug loading less than 90% and 80% respectively. Additionally, 
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the samples with higher drug loading(s) (90% for FEL:PVP and 80% and 90 % for 
FEL:PVP/VA) were characterized by larger domains. From the results observed for 
FEL:PVAc dispersions, we see variation in the homogeneity profile across the 
compositions studied. The dispersions at PVAc > 30% were found to be intimately mixed 
on the scale of less than 5 nm. For the compositions with PVAc at 30% and 20%, we 
observed that domain sizes between 5-40 nm. These findings suggest that these 
compositions are only partially homogeneous. As to the composition with PVAc at 10%, 
exhibited non-homogeneous behavior with domains larger than 40 nm. 
The data shown here is consistent with the presence of nano-domains being 
present in the samples prior to the first heating scan, and then being removed by melting 
in the DSC pan and reheating a second time. Unfortunately, the traditional method of 
determining phase homogeneity using DSC, i.e. the presence of multiple Tg events, is not 
useful for these samples, as all showed only a single Tg that was consistent between the 
first and second heating scans. However, the NMR data so far does not indicate whether 
the sample becomes homogeneous upon the equivalent of a second heating scan. Figure 
3.11 shows the differential 1H T1ρ plots between a FEL:PVP sample at 90% drug loading 
before and after heating in the NMR rotor, which is essentially equivalent to a first and 
second DSC scan. The sample prior to heating had a significant difference in 1H T1ρ 
values, whereas the sample after second heating had almost identical 1H T1ρ values, 
indicating that the sample was now more homogeneous. This observation is consistent 
with the first and second heating scans DSC data and supports the presence of nano 
heterogeneities in as prepared samples. 
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Figure 3.9. 1HT1ρ differential between FEL and polymer in dispersions for A) FEL-PVP, 
B) FEL:PVP/VA and C) FEL:PVAc as a function of weight fraction of polymer. The 
error bar signifies 95% confidence interval associated with the fit. The dashed line 
represents the zero. 
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Figure 3.10. 1HT1ρ differential for 90:10 FEL:PVP ratio as the function of PVP grade. 
The error bar signifies 95% confidence interval associated with the fit. The dashed line 
represents the zero. 
 
 
Figure 3.11. 1HT1ρ differential for 90:10 FEL:PVP before and after heating in situ in 
NMR rotor. The error bar signifies 95% confidence interval associated with the fit. The 
dashed line represents the zero. 
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3.3.3 13C CP/MAS Solid-State NMR Results – Molecular Interactions 
In the SSNMR spectra shown in Figure 3.7, the peak intensities for the carbonyl 
carbons of both FEL and the various polymers change depending upon drug to polymer 
ratios. In addition, the chemical shifts of the carbonyl carbon (C=O) of PVP and 
PVP/VA change monotonically with composition (Table 3.4). In general, variation in 
chemical shifts is seen when the groups are in involved H-bonding.67 This is based on the 
fact that the specific interactions influences the electronic density around a given carbon 
comprising interacting functionalities, which can induce changes in magnetic shielding 
due to increase or decrease in its electron density and hence the variation in the chemical 
shift. For FEL:PVP and FEL:PVP/VA dispersions, the formation of H-bond between the 
carbonyl group in polymers and an amine group in FEL resulted in a downfield shift in 
the resonance of the C=O carbon atom of the polymer as the amount of FEL increased in 
the dispersions. A downfield shift of 1 ppm relative to that of pure PVP was seen for the 
carbonyl carbon in the 90:10 FEL:PVP dispersion. For the 90:10 FEL:PVP/VA 
dispersion, a downfield shift of 0.6 ppm relative to that of pure PVP/VA was observed. 
In the case of FEL:PVAc dispersions, however, no detectable differences in the chemical 
shift was seen. This result reflects that the acetate group appears to interact very weakly 
with FEL. Based on the variation in the chemical shift of the carbonyl carbon of 
polymers, the strength of the H-bonding interactions can be rank ordered as 
PVP>PVP/VA>PVAc. 
In order to study the extent of FEL-polymer interactions, the 13C CP/MAS spectra 
were subjected to deconvolution procedure based on Gaussian-Lorenzian function to 
decompose the multiple overlapping peaks emerging from the composition dependent 
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FEL:Polymer interactions. In the current investigation, we employed the relative areas of 
the individual species present in the carbonyl region to estimate the percentage of each 
component. The deconvoluted spectrum of amorphous FEL in the carbonyl region is 
illustrated in Figure 3.12. The spectrum revealed a main peak at 167 ppm and a shoulder 
at 169 ppm. The main peak was attributed to the H-bonded carbonyl group 
(dimer/bonded) while the shoulder was assigned to the non H-bonded carbonyl group 
(free/non-bonded) of FEL. These assignments agree well the results from the simulation 
studies (discussed in later section). 
 
Table 3.3. Domain Sizes in amorphous solid dispersions for FEL:Polymer systems as 
estimated by SSNMR and DSC. Composition represents felodipine to polymer ratio.  
System Composition 
Domain Size (nm) Classification 
Type SSNMR DSC 
FEL:PVP 
50:50 < 4-5 < 30 Homogeneous 
60:40 < 4-5 < 30 Homogeneous 
70:30 < 4-5 < 30 Homogeneous 
80:20 < 4-5 < 30 Homogeneous 
90:10 5-30 < 30 
Partially 
Homogeneous 
FEL:PVP/VA 
50:50 < 4-7 < 30 Homogeneous 
60:40 < 4-7 < 30 Homogeneous 
70:30 < 4-7 < 30 Homogeneous 
80:20 4-40 < 30 
Partially 
Homogeneous 
90:10 6-45 <30 
Partially 
Homogeneous 
FEL:PVAc 
50:50 < 4-5 < 30 Homogeneous 
60:40 < 4-5 < 30 Homogeneous 
70:30 5-40 < 30 
Partially 
Homogeneous 
80:20 5-40 < 30 
Partially 
Homogeneous 
90:10 >40 < 30 
Non 
homogeneous 
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Table 3.4. 13C chemical shifts (ppm) of carbonyl carbon of polymer in FEL:Polymer 
dispersions. 
System 
Resonance C=O group of polymer 
Composition (Drug:Polymer) 
0:100 50:50 60:40 70:30 80:20 90:10 
FEL:PVP 174.9 175.3 175.4 175.5 175.7 175.9 
FEL:PVP/VA 175.2 175.3 175.4 175.5 175.7 175.8 
FEL:PVAc 170.2 170.1 170.1 170.2 170.2 170.3 
 
 
 
Figure 3.12. Deconvolution of carbonyl region of amorphous FEL. The experimental 
spectrum is shown in brown; the simulated spectrum is shown in magenta while the 
residual spectrum is depicted in red.  The blue lines represent the fitted individual species 
used in deconvolution. 
 
 
 
167.2 ppm Non-bonded 
carboxyl (Free) (60.9%) 
169.7ppm Bonded carboxyl 
(Dimer) (39.1%) 
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Amorphous FEL can exist as dimer by forming self-association via H-bond 
between the NH group of one molecule with the carbonyl group of the other molecule.68 
The free C=O fraction comprised 61% while the dimer C=O fraction constituted 39% of 
the total area. Our experimental results are in good agreement with what Xiang et al. 
found using molecular dynamic simulations.68 Additionally, the carbonyl region of 
FEL:Polymer dispersion was deconvoluted to explore the molecular interactions of FEL 
with the polymers for quantitative purpose (Figure 3.13). In this study, the 13C carbonyl 
carbon region was resolved into three (PVP, PVAc) or four (PVP/VA) peaks depending 
on the polymer type for the systems under study. The intensity of H-bonded (dimer) 
carbonyl peak of FEL decreased with the increase in the polymer content in the 
dispersion. It was expected that a large portion of these dimer carbonyl groups of FEL 
were consumed by formation of the intermolecular H-bonds between FEL and the 
polymer. This phenomenon revealed that a new distribution of H-bonds was taking place 
resulting from the competition between dimer and FEL:Polymer H-bonded fractions. By 
calculating the total area from the contributing components corresponding to the dimer 
and free carbonyl of FEL, their respective fractions could be obtained. The fraction of 
dimer and free carbonyl carbon of FEL obtained from peak fitting exercise with the 
polymers is compared in Figure 3.14. Several observations can be made from the data 
presented in Figure 3.14. Across this composition range, the dimer fraction of FEL 
decreased, together with the simultaneous increase in the free fraction. This trend was 
same for all the three polymers. However, there is a difference in the extent of H-bonding 
interactions with the three polymers. In the dispersion with 50% polymer load, the dimer 
fraction was smallest for PVP when compared with PVP/VA and PVAc, suggesting that 
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the highest number of FEL molecules were bonded with PVP at the same polymer weight 
percentage. The extent of H-bonding interactions were in decreasing order of 
PVP>PVP/VA>PVAc. PVP/VA is a copolymer of 60% water-soluble vinyl pyrrolidone 
and 40% water-insoluble vinyl acetate by weight. Therefore, PVP/VA presents lesser 
interactions sites for FEL in comparison to PVP for a given weight percent of polymer. 
PVAc is least effective in breaking the self-association between FEL molecules owing to 
the fact that the vinyl acetate moiety interacts via relatively weak H-bonding.  
FEL has a weak NH donor group.69 Using our deconvolution studies, we were 
able to quantify the extent of H-bonding in weakly bonded systems. Usually, 15N 
SSNMR experiments would have been more apt to study the local environment of NH 
donor group. Song at al. investigated H-bonding interaction in 30% FEL spray dried 
dispersion with PVP/VA using 15N solid-state NMR.70 For the dispersion sample, the 
authors found slight change (~ 3 ppm) in 15N chemical shift with respect to pure drug, 
which was attributed to the presence of intermolecular H-bonding between FEL and 
PVP/VA in dispersion. However, the authors mentioned that 15N chemical shifts were not 
conclusive because of broad nature of peaks. Furthermore, the authors confirmed H-
bonding via 1H DUMBO NMR experiments. 15N SSNMR study has its own challenges. 
15N is very low natural abundance with low magnetogyric ratio, and overall low 
sensitivity. In order to avoid use of 15N SSNMR experiments, which might not prove to 
be useful with a compound like FEL, we quantified the extent of H-bonding by 
monitoring the changes in the 13C spectra in the carbonyl region. The polymers were rank 
ordered as PVP>PVP/VA>PVAc for their strength and extent of H bonding with FEL. 
The rank ordering presented here is in agreement with the results obtained by FTIR 
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spectroscopy for FEL dispersions.71 This trend could also be understood by taking into 
consideration basicity of proton acceptor. Wegiel et al. studied the potential of chemically 
diverse polymers as crystallization inhibitors for resveratrol based on the basicity of 
proton acceptor as one of the factors. Through their results, it is apparent that PVP 
carbonyl has the strongest acceptor group (the pKBHX value of 1-methyl-2-prrolidone as 
an acceptor is 2.38) while PVAc has the weakest acceptor group in the polymers studied 
(the pKBHX value of ethyl acetate as an acceptor is 1.07).
72 Our SSNMR stimulation 
results also corroborated these findings (vide infra). Through this case study, it is evident 
that knowledge of phase behavior on a nanometric is needed to explain the presence of 
heterogeneities in ASDs. 
Another interesting aspect to consider here is to understand that the disruption of 
the dimers is due to the formation of H-bonding interactions between the drug and 
polymer. In order to test this, we formulated a dispersion of FEL with inert polymer 
polystyrene with 50% drug loading. Polystyrene (PS) can help us understand this 
because it lacks any H-bond acceptors in its structure. Therefore, it has almost no 
capability to interact with FEL via H-bonding. From the data obtained it can be seen, 
there is very less change seen in the dimer and free fractions when compared to 
amorphous FEL for the sample with polystyrene whereas a drastic reduction in dimer 
fraction was observed in the case of polymers PVP, PVP/VA, and PVAc in that order 
(Figure 3.15). This clearly explains that in the three systems studied, disappearance of 
dimers is not due to dilution effect rather it can be accounted through H-bond formation. 
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Figure 3.13. 13C SSNMR sub spectra of FEL:Polymer dispersions in the carbonyl region 
for A) FEL:PVP, B) FEL:PVP/VA and C) FEL:PVAc. The experimental spectrum is 
shown in brown; the simulated spectrum is shown magenta while the residual spectrum is 
depicted in red. The blue lines represent the fitted individual species used in 
deconvolution. 
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Figure 3.14. The fraction of dimer and free FEL carbonyl carbon for FEL:Polymer 
dispersions with A) PVP, B) PVP/VA and C) PVAc as a function of polymer weight 
fraction. 
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Figure 3.15. The comparison of dimer and free fractions for 50:50 FEL:Polymer 
samples.  
 
3.3.4 NMR Chemical Shift Calculations for Proposed Species 
Several species have been proposed in this paper, including free FEL and dimers 
of FEL. For this reason, DFT calculations of the proposed species were carried out to 
ensure that the calculated chemical shifts agreed at least qualitatively with those observed 
experimentally. Pure FEL was simulated as a single molecule and as dimers, with 
interactions between the amine and methyl-ester, and the amine and ethyl-ester as 
separate starting structures. The DFT-calculated chemical shifts were 170 ppm for the H-
bonded ester group and 166 ppm for the non H-bonded ester, while the experimental 
chemical shifts were 169 ppm and 167 ppm, respectively. The results from these 
simulations helped to confirm the experimental 13C SSNMR spectral assignment of the 
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pure drug, while also indicating the difference in carbonyl peak location in the 
presence/absence of H-bonding interactions. While the absolute values obtained from the 
simulation were not the same as the experimental chemical shifts, the relative positions 
are the same. Since the calculations of the pure FEL were consistent with the 
experimentally observed values, an investigation of the FEL-polymer interactions was 
explored. 
In this study, all polymers were created as shortened versions (3-5 monomers) 
with 3 FEL molecules placed around in favorable positions to allow for completion of 
the calculations in a timely manner. The calculations illustrated the strength of H-
bonding between the FEL and polymer similar to those seen in the experimental data 
with the theoretical rankings by chemical shift changes being the same: 
PVP>PVP/VA>PVAc. Although the relative ordering is the same, the absolute values for 
the chemical shifts are not. The theory tended to over predict the chemical shift change, 
suggesting stronger hydrogen bond interactions than the experimental data illustrated. 
This behavior can be explained by the number of H-bonded polymer monomers in the 
theory vs the experiment. In the calculations, all H-bond acceptor sites in the polymers 
were forced to H-bond, whereas in the experiment the steric hindrances from having 
some drug molecules so closely packed would overcome the tendency to H-bond. The 
ability for the short-chain polymer to bend freely allowed the three monomers to get as 
far apart, spatially, as they could. In a real-world polymer, the monomers would not all 
be even spaced out, with parts of the polymer being squeezed or bent based on the solid-
state shape. 
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Another indicator of H-bond strength is the H-bond length (shorter H-bonds 
usually correlates with stronger H-bonds73), and can be obtained from the optimization 
output files. The H-bond length (N-O bond) for the FEL-PVP, FEL-PVP/VA, and FEL-
PVAc dispersions was 2.980  0.007, 3.009  0.023, and 3.077  0.039, respectively. 
Using these values and the standard deviations from three H-bond donor-acceptor pairs 
per calculation, the rank ordering of the polymers by H-bond strength follows the same 
rank order as found by chemical shift change (PVP>PVP/VA>PVA). According to 
Jeffrey, the length of H-bond in these three dispersion indicates medium strength, mostly 
electrostatic interactions (4-14 kcal/mol).73 The distances show similarity between the 
PVP and PVP/VA dispersion interactions, suggesting the inclusion of vinyl acetate does 
not inhibit the propensity to H-bond in the PVP/VA even though the number of acceptor 
sites has decreased. The PVAc does not have as strong of interactions with the FEL as 
the PVP monomer and the larger standard deviation suggests the location of the 
monomer on the polymer chain affects the interactions more in the PVAc than the PVP 
and PVP/VA. 
3.4 Conclusions 
With a wide variety of analytical tools available to characterize ASDs, a major 
challenge lies in detecting phase heterogeneity and speciation. From this case study, it 
was shown how characterization via DSC alone might not be sufficient in order to 
understand phase heterogeneity on a nanometer level in ASDs. The results from SSNMR 
were able to explain the existence of nano domains with the matrix more efficiently. 
However, overall these two approaches agreed in their general trends. Additionally, we 
demonstrated how SSNMR can be used to quantify drug-polymer H-bonding. We 
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observed that the strength and extent of FEL:Polymer H-bonding could be ranked order 
as PVP>PVP/VA>PVAc. Our findings suggest that the phase behavior of ASDs is 
governed by the nature of H-bonding interactions between the drug and polymer. 
Moreover, our results from the current exercise have practical value in both 
understanding and formulating stable ASDs. 
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CHAPTER 4.  UNDERSTANDING DRUG-POLYMER MISCIBILITY IN TWO 
STRUCTURALLY SIMILAR MOLECULES 
4.1 Introduction 
Over the last decade, amorphous forms of active pharmaceutical ingredients 
(APIs) have been used successfully as a platform technology to enhance the oral 
bioavailability of poorly water soluble drug candidates.1-4 However, the amorphous state 
is inherently unstable and possesses the risk of converting to the more stable crystalline 
form during storage, manufacturing, and/or dissolution. To overcome this physical 
instability, a polymer is usually used as a carrier matrix to disperse the API to form an 
amorphous solid dispersion (ASD).5 The physical stabilization achieved through the use 
of polymers have been attributed to a combination of restricted mobility, increased glass 
transition temperature (Tg), and intermolecular interactions such as hydrogen bonding, 
van der Waals forces, and electrostatic interactions.6, 7 In order to develop a robust ASD, 
a homogenous solid dispersion is desired where the drug and polymer are mixed 
intimately. Since even partial phase separation can be a prelude to recrystallization, a 
partially mixed or completely phase separated system can potentially negate the 
advantages obtained from ASDs. Hence, in recent years drug-polymer miscibility has 
been an area of extensive research.8-10 There are two aspects to consider when it comes to 
drug-polymer miscibility: thermodynamic miscibility and kinetic miscibility. Both are 
equally important while ensuring the robust development of complex systems like ASDs. 
From thermodynamics standpoint, a system is considered miscible when the free 
energy of mixing (ΔGmix) of the two components is negative, where ΔGmix is given by: 
 Δ𝐺𝑚𝑖𝑥 = Δ𝐻𝑚𝑖𝑥 − 𝑇Δ𝑆𝑚𝑖𝑥 (4.1) 
 
 
 
102 
where ΔHmix is the enthalpy of mixing, ΔSmix is the entropy of mixing and T is the 
absolute temperature. In contrast, a positive value of ΔGmix signifies unfavorable mixing 
and potential phase separation. The Flory-Huggins theory, which based on lattice-based 
solution models, has been used extensively to assess miscibility in drug-polymer 
blends.11, 12 According to this classical approach, ΔGmix can be described as: 
 
ΔGmix = 𝑅𝑇(𝜙𝑑𝑟𝑢𝑔𝑙𝑛𝜙𝑑𝑟𝑢𝑔 +
𝜙𝑝𝑜𝑙𝑦𝑚𝑒𝑟
𝑚
𝑙𝑛𝜙𝑝𝑜𝑙𝑦𝑚𝑒𝑟
+ 𝜒𝑑𝑟𝑢𝑔−𝑝𝑜𝑙𝑦𝑚𝑒𝑟𝜙𝑑𝑟𝑢𝑔𝜙𝑝𝑜𝑙𝑦𝑚𝑒𝑟) 
(4.2) 
 
where R is the gas constant, T is the absolute temperature, ϕdrug and ϕpolymer are the 
volume fraction of drug and polymer respectively, m is the ratio of the volume of a 
polymer chain to drug molecular volume and χdrug-polymer is the Flory-Huggins interaction 
parameter between the drug and polymer. The first two terms on the right hand side 
defines the entropic contribution, and the last term defines the enthalpic part of the 
equation to the total free energy of mixing. Given that the entropic contribution is always 
favorable, the enthalpic contribution will therefore determine the sign of ΔGmix and that 
makes χdrug-polymer an important factor. A negative value of χdrug-polymer favors mixing by 
making the overall value of ΔGmix negative. The Flory-Huggins interaction parameter can 
be estimated through several methods.13 The most-studied approach is based on melting 
point depression, which was first used by Marsac et al. for pharmaceutical systems and 
has been used for several drug-polymer systems.14-17 In this approach, the depression in 
melting point of the drug in the presence of polymer is used to predict the interaction 
parameter using the following relationship: 
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 1
𝑇𝑚𝑖𝑥
−
1
𝑇𝑝𝑢𝑟𝑒
= −
𝑅
ΔHfus
[ln𝜙𝑑𝑟𝑢𝑔 + (1 −
1
𝑚
) 𝜙𝑝𝑜𝑙𝑦𝑚𝑒𝑟
+ 𝜒𝑑𝑟𝑢𝑔−𝑝𝑜𝑙𝑦𝑚𝑒𝑟𝜙
2
𝑝𝑜𝑙𝑦𝑚𝑒𝑟] 
(4.3) 
 
where Tmix and Tpure are the melting points of the drug in the binary drug polymer 
mixture and the pure drug respectively, ΔHfus is the heat of fusion of the pure drug, R is 
the gas constant, ϕdrug and ϕpolymer are the volume fractions of drug and polymer 
respectively, m is the ratio of the volume of polymer chain to drug molecular volume and 
χdrug-polymer is the Flory-Huggins interaction parameter between the drug and polymer. 
While using this approach for calculating χdrug-polymer, several points are to be considered. 
Firstly, this method requires the drug and polymer to be stable over the temperature 
range of interest and that they form a miscibile system for the melting point depression to 
be observed. Secondly, this approach works the best for systems where the polymer Tg is 
significantly lower than the melting point of the pure drug. In addition, it should be noted 
that this approach does not provides a universal value of χdrug-polymer but an estimation 
close to the melting point of the drug. Although this approach has its own limitations, it 
has shown to give a reasonable and reliable estimate of χdrug-polymer in comparison to 
theoretical approach based on solubility parameters. 
The thermodynamic drug-polymer miscibility relates to the phase behavior in the 
equilibrium state. However, in many real situations the drug molecules in the polymeric 
matric may never achieve thermodynamic equilibrium but remain kinetically stable. 
Hence, it is imperative to assess the kinetic miscibility as well. The kinetic miscibility 
can be assessed using calorimetric approaches or spectroscopic methods. DSC has been 
used traditionally to evaluate kinetic miscibility based on the number of Tg events. A 
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single Tg denotes a miscible system whereas multiple Tg denotes an immiscible system.
18 
It has been shown that the rule of a single Tg does not necessarily imply phase 
homogeneity.19 Moreover, since the resolution scale for a DSC measurement is generally 
taken to be > 30 nm, any heterogeneity, which may be present on a smaller scale, may go 
undetected by DSC analysis. In recent years, spectroscopic techniques like SSNMR has 
been used to study phase homogeneity on a molecular level based on the proton 
relaxation time measurements (1H T1 and 
1H T1ρ).
20-22 Through these measurements, it is 
possible to study phase homogeneity on two length scales of mixing. In theory, they can 
be used to give semi quantitative information on domain sizes and can study phase 
mixing at domain sizes < 5 nm. In addition, SSNMR can also provide additional 
information on molecular interactions and mobility.23 We have earlier shown how in 
depth analysis can be performed through SSNMR with respect to phase homogeneity and 
molecular interactions in Chapter 3. 
Considering the growing interest in understanding drug-polymer miscibility and 
how important is to the overall stability of the system, it is useful to evaluate both the 
aspects miscibility. From this perspective, it would be interesting to use this dual 
approach to perform a comparative study of two common model BCS class II drugs: 
nifedipne (NIF) and felodipine (FEL) when formulated as an ASD with Soluplus®. Both 
drugs have similar structural features and properties like Tg
24 and it therefore important 
to understand the differences if any between them in terms of drug polymer miscibility 
and interactions. We have previously studied FEL with polymers like PVP, PVP/VA, 
PVAc and NIF has also been studied in the Munson group before. Thus, we have prior 
baseline knowledge of these APIs. Recently, Soluplus® has been used as a polymeric 
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matrix and solubilizer for ASDs.15, 25 Its low Tg and good thermal stability makes it 
especially amenable for hot melt extrusion processes and spray drying.26 Chemically, 
Soluplus® is a polyvinyl caprolactam–polyvinylacetate–polyethylene glycol graft 
copolymer, which was first launched by BASF in 2009. 
In this chapter, the melting point depression approach was used to estimate χ 
value for NIF/FEL-Soluplus systems. Also, Gibb’s free energy of mixing was calculated 
using χ at respective temperatures and phase diagrams were predicted from data obtained 
from thermal analysis. Moreover, SSNMR was employed to evaluate kinetic miscibility 
for both systems at different compositions and a comparison of intermolecular 
interactions was achieved by analyzing 13C SSNMR spectra. 
4.2 Experimental 
4.2.1 Materials 
Nifedipine and felodipine were purchased from TCI America (Portland, OR) and 
BOC Sciences (Shirley, NY) respectively. Soluplus was a generous gift from BASF 
(Edison, NJ). Soluplus was stored over Drierite at all times and vacuum dried at 40 °C 
overnight every time before use. NIF is photo labile and hence was protected from light 
whenever possible. The chemical structures of raw materials and their physiochemical 
properties are listed in Table 4.1. 
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Table 4.1. Physicochemical properties of raw materials. 
Compound Chemical Structure 
Tg 
( °C) 
Molecular 
Weight 
(g/mol) 
Density 
(g/cm3) 
Felodipine 
 
47.1 384.26 1.28 
Nifedipine 
  
46.7 346.34 1.2 
Soluplus 
 
77.7 118000 1.2 
 
4.2.2 Solubility Parameter Calculation 
The solubility parameters were calculated using the Hoftzer-Van Krevelen group 
contribution method27, which is expressed as: 
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 𝛿2 = 𝛿𝑑
2 + 𝛿𝑝
2 +  𝛿ℎ
2 (4.4) 
 
where δd, δp and δh are contribution from dispersive forces, polar forces and hydrogen 
bonding respectively. These may be individually defined as: 
 
𝛿𝑑 =
Σ𝐹𝑑𝑖
𝑉
 
(4.5) 
 
𝛿𝑝 =
√ΣF𝑝𝑖
2
𝑉
 
(4.6) 
 
𝛿ℎ = √
ΣEhi
𝑉
 
(4.7) 
Fdi is the molar attraction constant due to dispersion component, Fpi is the molar 
attraction constant due to polar component, Eh is the group contribution to hydrogen 
bonding energy and V is the molar volume. 
4.2.3 Preparation of Amorphous Materials 
Amorphous FEL and NIF were prepared by melting crystalline as received 
materials (5 °C above their respective melting points) in a Teflon beaker over an hot oil 
bath. Once melted, the molten mass was quenched cooled using liquid N2 to generate the 
glassy form and was lightly ground in a mortar and pestle. The pure amorphous samples 
were analyzed immediately to prevent crystallization. The dispersions samples were 
prepared at various drug loadings from 50% to 90% w/w via melt quenching. To ensure 
optimum mixing between the drug and polymer, the physical mixtures were first 
cryomilled (SPEX SamplePrep 6770 Freezer Mill, SPEX SamplePrep, Metuchen, NJ) at 
10 Hz for five cycles, each comprising 2 min of milling and 2 min of cooling in a liquid 
N2 environment. The cryomilled mixtures were then further treated for melt quenching 
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with the same procedure as used for the neat amorphous drugs. The dispersion samples 
thus generated were then vacuum dried at room temperature and stored at -20 °C in 
desiccators containing Drierite until further analyzed. 
4.2.4 Thermal Analysis 
DSC experiments were performed using a Q2000 (TA Instruments, New Castle, 
DEI equipped with a refrigerated cooling accessory (RCS90). Nitrogen gas at a flow rate 
of 50 mL/min used to maintain the inert atmosphere. The instrument was calibrated 
using indium and sapphire. 
Melting Point Depression Measurement. Mixtures of NIF/FEL with Soluplus 
were prepared with via cryo milling at 10 Hz for three cycles, each comprising 2 min of 
milling and 2 min of cooling in a liquid N2 environment at various weight ratios. These 
mixtures were then packed in Tzero aluminum pans (5-7 mg) and heated at 1 °C/min from 
20 to 200 °C. All samples were analyzed in duplicate and the mean values of melting 
peak was used. 
Measurement of Tg. The samples were subjected to modulated DSC experiments 
with modulation of 0.5 °C every 60 s. To record the Tg values of pure drugs, the 
amorphous form was generated in situ DSC by heating the samples at 10 °C/min from 20 
to 180 °C, cooled at a rate of 30 °C/min to -10 °C, and then reheated at 2 °C/min to just 
above their melting points. For the dispersion samples prepared via melt quenching, the 
samples (5-7 mg) were packed in Tzero aluminum pans and treated with heat-cool-heat 
cycle. The samples were first heated at the rate of 5 °C/min to 185 °C followed by 
cooling to -10 °C at a cooling rate of -30 °C/min and reheated at the rate of 5 °C/min to 
185 °C. The Tg values were recorded from the second heating cycle and determined by 
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half height at mid point using the Universal Analysis software (TA Instruments, 
Newcastle, DE). All samples were run in duplicate and the mean Tg values were 
reported. 
Theoretical prediction of Tg. The Tg values of solid dispersions were predicted 
using the Gordon Taylor equation28, which is expressed as: 
 
𝑇𝑔 =
[(𝑤1𝑇𝑔1) + (𝑘𝑇𝑔2)]
[𝑤1 + (𝑘𝑤2)]
 
(4.8) 
 
 
𝑘 =
𝑇𝑔1 ∗ 𝜌1
𝑇𝑔2 ∗ 𝜌2
 
(4.9) 
 
where Tg is the glass transition of the dispersions, Tg1 and Tg2 are those of pure 
components, w1 and w2 are the weight fractions of each component, and ρ1,2 are the true 
densities of each component. The corresponding ρ values were obtained from literature.  
4.2.5 13C Solid-state NMR Spectroscopy 
13C SSNMR spectra were acquired using a Tecmag Redstone spectrometer 
(Tecmag Inc., Houston, TX) operating at approximately 300 MHz for 1H and 75 MHz 
for 13C. Samples were packed into 7.5 mm zirconia rotors and sealed with Teflon or Kel-
F end-caps (Revolution NMR LLC. Fort Collins, CO). One dimensional 13C spectra were 
acquired using cross polarization magic angle spinning (CP/MAS) at 4 kHz, using total 
sideband suppression (TOSS)29 and SPINAL6430 decoupling. The 1H 90˚ pulse width 
was set to 4.0 μs and contact time of 1.5 ms was used in all the measurements. The 13C 
chemical shift scale was referenced with the methyl peak of 3-methylglutaric acid, which 
was set to 18.84 ppm.31 
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The NMR spectra of pure amorphous drugs and the dispersion samples were 
subsequently deconvoluted using MNOVA software (Mestrelab Research, Version 10.0) 
in the carbonyl region. The parameters for peak width and Gaussian/Lorentzian ratio 
were kept same while the constraint for peak position was kept at ± 5%. The area 
percentages for the various species were calculated from the total area of the peaks 
deconvoluted and the drug peaks were then normalized to their respective carbonyl 
peaks. 
The proton relaxation times were detected via 13C nucleus to facilitate the 
identification of regions for respective components. The chemical shift regions specific 
to FEL/NIF and Soluplus were integrated to obtain the relaxation times. Proton spin-
lattice relaxation times in the laboratory frame (1H T1) were measured using a 
13C-
detected saturation recovery pulse sequence with TOSS. 1H T1 was obtained by fitting 
integral-recovery time data by the following equation: 
 
𝑀(𝑡) = 𝑀0(1 − 𝑒
−
𝑡
𝑇1) 
(4.10) 
 
where M(t) is the integrated signal intensity at delay time t, M0 is an amplitude parameter 
from the fit, and T1 is the spin-lattice relaxation time in the laboratory frame. Proton 
relaxation times in the rotating frame (1H T1ρ) were measured by varying the spin lock 
duration time after a 90˚ pulse. The T1ρ decay time was obtained by analyzing the 
integrated carbon signal intensity according to the following equation: 
 
𝑀(𝑡) = 𝑀0𝑒
−
𝑡
𝑇1𝜌 
(4.11) 
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where M(t) is the integrated peak intensity and t is the spin-lock duration time. M0 is an 
amplitude parameter from the fit, and T1ρ is the fitted spin-lattice relaxation time in the 
rotating frame. Data was fitted using GraphPad Prism software (GraphPad Software, 
Inc., La Jolla, CA). 
4.3 Results and Discussion 
4.3.1 Baseline Characterization 
The melt quenched amorphous drugs were observed to be X-ray amorphous (data 
not shown). The Tg values of model drugs were obtained by generating the amorphous 
form in situ in the DSC pan. The as-prepared dispersion samples were also observed to 
be X-ray amorphous (data not shown) and the same observation was confirmed by 13C 
SSNMR spectra (vide infra). 
4.3.2 Solubility Parameters 
In order to understand and predict miscibility between FEL/NIF and Soluplus, 
theoretical solubility parameters (δ) were calculated via Hoftyzer-Van Krevelen group 
contribution approach. Solubility parameter values for the materials used in the current 
study are listed in Table 4.2. The difference of the solubility parameter (Δδ) of two 
materials is suggestive of miscibility or immiscibility. For systems having Δδ < 7.0 
MPa1/2 are likely to be miscible whereas Δδ > 10.0 MPa1/2 are likely to be immiscible.32 
In the present case, the solubility parameters for FEL and NIF were calculated to be 
20.53 and 19.43 respectively. Meanwhile, the solubility parameter for Soluplus was 
reported to be 21.79.33 The Δδ values for FEL:SOL and NIF:SOL were less than 7.0 
MPa1/2.  
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Table 4.2. Calculation showing solubility parameters of felodipine and nifedipine based 
on the Hoftyzer-Van Krevelen group contribution method. 
Group Frequency Fdi (J1/2 cm3/2 mol-1) F2pi (J cm3 mol-2) Ehi (J/mol) 
Felodipine 
CH3 4 1680 0 0 
CH2 1 270 0 0 
NH 1 160 44100 3100 
Cl 2 900 605000 800 
COO 2 780 480200 14000 
Phenylene 1 1270 12100 0 
C= 4 280 0 0 
ring (6) 1 190 0 0 
CH 1 80 0 0 
Sum - 5610 1141400 17900 
δ = 22.74 - 20.86 3.97 8.16 
Nifedipine 
CH3 4 1680 0 0 
CH2 0 0 0 0 
NH 1 160 44100 3100 
NO2 1 500 1144900 1500 
COO 2 780 480200 14000 
Phenylene 1 1270 12100 0 
C= 4 280 0 0 
ring (6) 1 190 0 0 
CH 1 80 0 0 
Sum - 4940 1681300 18600 
δ = 19.43 - 17.12 4.49 8.03 
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Thus, it can be predicted that both the drugs should exhibit miscibility with 
Soluplus. This approach has been widely used in literature but comes with several 
limitations.14, 18 For instance, in the case of drug-polymer mixtures expected to form 
hydrogen bonding or ionic bonding, this method can result in erroneous outcomes. 
Nonetheless, this approach could be useful as a means for initial miscibility assessment 
and needs further confirmation from other experimental based methods. 
4.3.3 Differential Scanning Calorimetry 
4.3.3.1 Estimation of Drug-Polymer Miscibility 
The melting point depression approach was used to estimate the Flory-Huggins 
interaction parameter between FEL/NIF and Soluplus. The depression in melting point of 
the drug is usually observed in the case of a miscible drug-polymer system and has been 
used as an indicator of drug-polymer miscibility. This phenomenon results from the 
negative free energy of mixing linked with the spontaneous mixing of the polymer with 
the drug and the chemical potential of the drug in the mixture is lowered than the pure 
drug melt.14 The extent of melting point depression observed for FEL and NIF systems is 
used here to distinguish their propensities to mix with Soluplus. From the analysis of the 
melting point depression data (Figure 4.1) it is shown that melting point of both FEL and 
NIF decreased with increase in Soluplus content, which is indicative of both the drugs 
being miscible with Soluplus. However, larger depression in melting point was observed 
in NIF-SOL system in comparison to FEL-SOL system especially at higher Soluplus 
concentrations, which potentially resulted from higher miscibility of NIF with Soluplus 
than FEL. The interaction parameter was estimated from the slopes of (1/Tmix-1/Tpure) * 
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(ΔHfus/-R)-ln(ϕdrug)-(1-1/m)ϕpolymer plots against the second power of the polymer volume 
fraction (ϕ2polymer) by rearranging the Flory-Huggins equation (Figure 4.2). The linear 
regression analysis was done for the data points with low Soluplus weight fractions, as at 
higher concentrations the linearity was lost. Marsac et al. have earlier reported the 
phenomenon of nonlinear relationship at higher polymer weight fractions.14 For NIF-SOL 
and FEL-SOL systems, interaction parameters with a value of -1.413 (r2 = 0.991) and -
0.743 (r2 = 0.998) were obtained respectively. The negative value of the interaction 
parameter for both the systems is suggestive of miscibility and an endothermic heat of 
mixing. It should be noted that the value obtained with NIF is more negative than FEL, 
which is reflective of more favorable mixing of Soluplus with the former. In addition, it 
is also important to mention that the Flory-Huggins interaction parameter is not constant 
but a function of temperature34, which can be empirically described by: 
 
𝜒𝑑𝑟𝑢𝑔−𝑝𝑜𝑙𝑦𝑚𝑒𝑟 = 𝐴 +
𝐵
𝑇
 
(4.12) 
 
where A and B are constants. In order to further understand miscibility between the two 
components, the melting point depression data was then used to construct a plot χdrug-
polymer versus 1/Tm for each system. The plots were used to obtain the values of the 
entropic (A) and enthapic (B) contributions to χdrug-polymer for both the systems. The 
values of constants “A” and “B” are listed in Table 4.3. Through this analysis, a series of 
χdrug-polymer values could be calculated at different temperatures. In addition, this also 
enabled construction of Gibb’s free energy diagrams as a function of both temperature 
and composition for each system by combining eqs 4.2 and 4.3 with eq 4.12. The Gibb’s 
free energy of mixing diagrams for FEL-SOL and NIF-SOL as a function of temperature 
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and composition are shown in Figure 4.3. It has been pointed out that a negative ΔGmix 
value is reflective of a miscible system, whereas a positive value signifies a likely partial 
miscible or immiscible system.11 As shown in Figure 4.3 A, it is apparent that at 
temperatures ≥ 120 °C the value of ΔGmix/RT was negative at all compositions for FEL-
SOL system. It is interesting to note that at temperatures ≤ 100 °C all compositions were 
found to have a positive value of ΔGmix/RT and especially at 25 °C larger positive values 
were obtained. Accordingly, at 25 °C the calculated solubility (% wt) of FEL in Soluplus 
was found to be extremely low (~ 8.29*10-9). It is clear from Figure 4.3 B that at 
temperatures ≥ 100 °C resulted in a negative value of ΔGmix/RT, suggesting miscibility at 
all compositions in the case of NIF-SOL system. Furthermore, at 25 °C a positive value 
of ΔGmix/RT was observed at all compositions. Consequently, the calculated solubility 
(% wt) of NIF in Soluplus at 25 °C was estimated to be 8.54*10-3. Overall, it can be 
predicted that NIF has better miscibility and solubility than FEL in Soluplus. This 
exercise is useful in selection of the components during ASD formulation development 
and also help in optimizing process parameters for processes like hot melt extrusion. 
Table 4.3. F-H interaction constants A and B as obtained from melting point depression 
data. 
Constant NIF:SOL FEL:SOL 
A -11.23 -56.49 
B 22499 4270.1 
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Figure 4.1. Melting temperatures (Tm) of NIF (black circles) and FEL (red diamonds) as 
a function of drug weight percent. The data points represent the average of two separate 
runs and errors bars represent the standard deviation.  
 
 
Figure 4.2. Plot used to calculate the Flory-Huggins interaction parameter for NIF:SOL 
(green circles) and FEL:SOL (blue circles). The slope would represent the value of the 
Flory-Huggins interaction parameter. The respective values of slope were obtained using 
linear regression.  
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Figure 4.3. A plot of ΔGmix/RT as a function of volume fraction of drug (ϕdrug) for (A) 
FEL:SOL and (B) NIF-SOL.  
 
Another important piece of information that can be further generated here is the 
temperature-composition phase diagram. In theory, phase diagrams can allow estimation 
of regions of stability, instability and metastability. Typically, temperature phase 
diagrams consists of two curves: binodal and spinodal. The binodal curve represents the 
phase boundary between the stable and metastable region, whereas the spinodal curve 
represents the phase boundary between the unstable and metastable region. To the right 
side of spinodal curve, phase separation is expected to occur spontaneously. On the other 
hand in the metastable region, the system will start to phase separate only after large 
fluctuation in drug density.35 Moreover, the spinodal phase separation curve can be 
calculated by equating the second derivative of the free energy to zero as described by: 
 
𝑇𝑠 =
2𝐵
(
1
𝜙𝑑𝑟𝑢𝑔
) + (
1
𝑚𝜙𝑝𝑜𝑙𝑦𝑚𝑒𝑟
) − 2𝐴
 
(4.13) 
 
The phase diagrams for each system are shown in Figure 4.4. It is evident from 
Figure 4.4 that both the systems showed temperature dependent solubility and miscibility 
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but relative to FEL-SOL system, the phase diagram of NIF-SOL shifted towards the 
higher composition range. Moreover, with NIF-SOL system larger gap was observed 
between the solubility and miscibility curves. This suggests that NIF has higher 
solubility and miscibility in Soluplus than FEL. The construction of phase diagrams is a 
useful exercise since detailed information could be extracted with regards to potential 
processing conditions, identification of metastable regions, achievable drug loadings and 
storage temperature.12, 35 
4.3.3.2 Glass Transition Temperature (Tg) 
The dispersions samples prepared from melt quenching process were subjected to 
heat cool heat cycle in MDSC experiments. The glass transition temperature event (Tg) 
from the first cycle was hard to detect due to the nature of very broad and 
undistinguished signal, a characteristic trait of Soluplus dispersions (data not shown). 
Hence, the Tg values were recorded from the thermograms of the second heating cycle 
for each set of dispersions. A single Tg event was observed in the second heating cycle 
across the composition range studied for both the systems, possibly signifying phase 
miscibility based on a single Tg rule. As the Tg values of neat amorphous NIF and FEL 
were close to each other, the experimental Tg values for the dispersions samples from 
both the systems were found to be similar. The experimental Tg values were compared to 
the predicted Tg values calculated from the Gordon-Taylor equation in order to 
understand the nature of deviations as shown in Figure 4.5. The predicted Gordon-Taylor 
curves were near identical to each other. It is apparent from the Figure 4.5 that both the 
systems exhibited negative deviation with regard to the predicted curves. In each system, 
almost identical magnitude of negative deviation was observed except for 10% Soluplus 
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sample with NIF. The deviation from the ideal behavior is generally considered as 
indicative of differences in the strength of homointeractions and heterointeractions 
between the components.18 A negative deviation could result from the stronger 
homointeractions leading to an increase in free volume upon mixing and hence a lower 
Tg value than predicted. A number of other systems have shown a similar behavior.
36, 37 
These empirical models have been used extensively but have their own limitations. 
Therefore, the results should be interpreted with caution, especially for systems 
exhibiting deviations. Nonetheless, in the present study Gordon-Taylor equation 
predicted the presence of specific intermolecular interactions between the components 
and would be further studied in subsequent sections. 
 
Figure 4.4. Binary phase diagram for (A) FEL:SOL and (B) NIF:SOL.  
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Figure 4.5. A plot showing experimental and predicted Tg as a function of Soluplus 
weight fraction. The red and green circles represent mean experimental Tg values from 
DSC second heating cycle for NIF:SOL and FEL:SOL respectively. The error bars 
denote the standard deviation. The broken lines represent the predicted Tg values from the 
Gordon-Taylor equation.  
 
To summarize the results discussed in this section, melting point depression data 
analysis yielded the Flory-Huggins interaction parameter and predicted the 
thermodynamic miscibility and solubility for both systems. Our results indicated that the 
interaction potential with Soluplus was higher with NIF and same for the solubility and 
miscibility. Despite several limitations associated with the melting point depression 
approach, a reasonable comparison could be drawn for both the systems. We ensured 
sufficient mixing between the drug and polymer via cryo-ground mixtures, giving each 
component a better chance for optimum interaction. In addition, the melting point 
temperature of both the drugs was higher than the Tg of Soluplus, allowing Soluplus to 
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exist in the supercooled liquid state and thereby ensuring better mixing and interaction. 
The thermodynamic miscibility between FEL/NIF and Soluplus is an important 
parameter to study but an equally important aspect to consider here is the kinetic mixing 
between them. The state of mixing between FEL/NIF and Soluplus will be investigated 
in the later section from SSNMR. The predictions derived from Gordon-Taylor equation 
were consistent in both the systems and possibly pointed to the presence of specific 
intermolecular interactions. 
4.3.4 FTIR Spectroscopy 
In order to understand the nature of underlying interactions between the drug and 
polymer, FTIR spectra were recorded for ASDs and compared with the pure 
components. Both FEL and NIF have hydrogen bond donor and acceptor groups in their 
structures. It has been shown in the literature that the amine group in the structure of FEL 
and NIF can participate in hydrogen bonding. Soluplus has potential sites in its structure 
to interact through hydrogen bonding as well. Hence, any changes in the peak position 
and shape in the FTIR spectrum relative to the pure components would provide evidence 
for any specific interactions such as hydrogen bonding. FTIR spectra of FEL:SOL and 
NIF:SOL system are presented in Figure 4.6. For amorphous FEL (Plot A), two peaks 
marked the NH stretching region: a main peak at 3331 cm-1 and a shoulder peak at 3415 
cm-1. These were assigned to a NH group bonded to the carbonyl group of adjacent 
molecule of FEL, and to a non-hydrogen bonded NH group, respectively. The FITR 
spectrum of amorphous NIF in the NH stretching region was characterized by similar 
peak positions (Plot B).38 With increasing SOL content, the hydrogen bonded NH peak 
became broader and a shoulder started to develop around 3290 cm-1 in the case of 
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FEL:SOL system. The shoulder peak increased in intensity with increase in SOL 
concentration and can be attributed to FEL-SOL hydrogen bonding interaction, wherein 
the amine group of FEL acts as a donor. In the case of NIF:SOL, similar trend was 
observed with increasing SOL weight %. In the carbonyl region (Plots C and D), the 
spectrum of pure Soluplus displayed two peaks assigned to ester carbonyl (1732 cm-1) 
and tertiary amide carbonyl (1632 cm-1).25 For hydrogen bonding to take place between 
FEL/NIF and Soluplus, either or both of these carbonyl groups can act as a proton 
acceptor leading to change in the peak positions in the carbonyl region. However, no 
direct evidence of any change for these peaks could be obtained because of heavy 
overlap from FEL and NIF absorbance peaks (Plots C and D). From FTIR analysis, it is 
clear that both FEL and NIF interacted in a similar fashion with Soluplus and formed 
possibly drug-polymer hydrogen bonds interactions. 
4.3.5 Solid-state NMR Spectroscopy 
In recent years, SSNMR has been used to analyze molecular interactions, 
homogeneity and phase behavior in ASDs on a molecular level.23 We utilized SSNMR to 
further elucidate the intermolecular interactions between FEL/NIF and Soluplus. The 13C 
CP/MAS spectra of the as received materials are displayed in Figure 4.7. The 
assignments of the resonances for crystalline FEL were reported previously in chapter 4, 
whereas for crystalline NIF the peaks were assigned based on previous literature 
reports.21 The spectrum of Soluplus consisted of resonances at 175.7 ppm from the 
carbonyl group of vinylcaprolactam ring, at 170.6 ppm due to carbonyl group of acetate 
and in the range of 22 to 72 ppm ascribed to aliphatic carbons. The comparison of 13C 
spectra of dispersions with the pure amorphous components is shown in Figure 4.8. It is 
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clear from the spectra of dispersions that melt quenching rendered samples amorphous as 
evident by broad resonances in contrast to sharp resonances seen for crystalline drugs. In 
the spectra of dispersion samples for both FEL:SOL and NIF:SOL, the intensity of 
Soluplus peaks decreased with decrease in Soluplus concentration and vice versa. In 
addition, the same trend was observed for drug peaks as its concentration varied. In 
general, the spectra of dispersion samples were superposition of the spectra of the pure 
amorphous components except in the carbonyl region, where some differences were 
observed. In the carbonyl region (160-180 ppm), some apparent differences in chemical 
shifts were seen. The carbonyl peak of Soluplus at 175.7 ppm showed a downward shift 
in the dispersion samples for both systems with decrease in Soluplus content. At 10% 
Soluplus loading, the peak resonated further downfield around 177.2 ppm for both the 
systems. This variation in chemical shift may indicate formation of hydrogen bonding 
between FEL/NIF and Soluplus. The carbonyl peak of 170.6 ppm from acetate functional 
group did not seem to shift to this extent and no apparent movement could be detected 
for this peak. In this case, the carbonyl group from vinylcaprolactam is a stronger proton 
acceptor than acetate group and hence participates in hydrogen bond formation. The 
strength of this interaction seems to be similar in both the systems as evident by near 
identical downfield shift behavior. The results seen here are in agreement with previous 
study conducted in Chapter 3, wherein acetate group interacted to a lesser extent in 
comparison to the pyrrolidone group. In addition, it is interesting to note here that a 
larger downfield shift was seen with Soluplus than PVP, which may signify that the 
acceptor strength of the carbonyl group of vinylcaprolactam moiety is stronger than the 
carbonyl group of pyrrolidone ring. 
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Figure 4.6. FTIR spectra for FEL:SOL (plots A, C) and NIF:SOL (plots B, D) samples. 
The NH stretching region (3150-3450 cm-1) and the carbonyl stretching region (1550-
1800 cm-1) are shown in plots (A, B) and (C, D) respectively.  
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Figure 4.7. Stacked plot for 13C CP/MAS Spectra of as received felodipine (top), as 
received nifedipine (middle) and Soluplus (bottom). Resonance assignments are done in 
reference to the numbering scheme used in Table 4.1.  
 
 
Figure 4.8. Stacked 13C CP/MAS spectra for dispersions samples (A) FEL-SOL system 
and (B) NIF-SOL system.  
 
 
 
 
126 
We have earlier seen in Chapter 3 that it was possible to quantify the hydrogen 
bonding interactions in the case of felodipine with polymers such as PVP, PVP/VP and 
PVAc. The same approach was adopted here with the goal of understanding how FEL 
and NIF interacted with Soluplus. From our previous study, it was shown that in 
amorphous FEL approximately 40% of molecules existed in hydrogen bonded (dimer) 
state and remaining 60% were non-hydrogen bonded (free). Similar analysis of the 
carbonyl region of amorphous NIF was performed in order to quantify the different 
states. Upon deconvolution, amorphous NIF carbonyl region was found to exhibit two 
populations: (i) hydrogen bonded (dimer) at 169.9 ppm and (ii) non-hydrogen bonded 
(free) at 167.5 ppm, constituting 29% and 71% respectively. Thus, a lesser degree of 
self-association was seen in amorphous NIF in comparison to amorphous FEL. The 
deconvolution exercise was also performed on dispersion samples to elucidate the 
changes in these two fractions. In the presence of Soluplus, drug-polymer hydrogen 
bonding is expected and that could change the ratio of “dimer” and “free” fractions in 
both systems. The carbonyl region was deconvoluted to obtain the underlying peaks 
areas. In the present study, we focused on the two peaks attributed to FEL/NIF, which 
represented the two states in which FEL/NIF carbonyl region existed. Hence, the 
percentage for the two populations were reported based on total FEL/NIF carbonyl peak 
areas. The results from this exercise are summarized in Figure 4.9 and a few common 
trends could be seen. With increase in Soluplus concentration, the percentage of “dimer” 
population decreases with concurrent increase in the percentage of “free” population for 
both the systems. This clearly suggest that FEL/NIF self-association gets disrupted in the 
presence of Soluplus and more free FEL/NIF becomes available to form drug-polymer 
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hydrogen bond. For both the systems, the “dimer” fraction declined gradually with 
increase in Soluplus concentration. The trends seen here suggested a similar interaction 
pattern existed in both the systems with some slight differences. Very interestingly, at 
any given Soluplus weight percent “free” NIF fraction was higher than the corresponding 
FEL fraction. One potential explanation is that NIF has a lower molecular weight than 
FEL, resulting in NIF hydrogen bonding with Soluplus to a greater extent than FEL. 
Thus, NIF presents higher ratio of donor to acceptor group relative to FEL on the molar 
basis. Furthermore, it was shown in Chapter 3 that the extent of hydrogen bonding in 
felodipine-polymer dispersions could be rank ordered as PVP>PVP/VA>PVAc. 
However, in the present study with Soluplus somewhat different behavior was seen 
where Soluplus was found to be less effective in terms of the extent of hydrogen bonding 
in comparison with those three polymers. For instance, at 50% PVP weight percent 
dimer fraction disappeared almost completely whereas in the case of Soluplus there was 
still a reasonable percentage detected. From the structure of Soluplus, it can be seen that 
it contains fewer R-C(O)-N-R2 (6.6 mmol/g) groups than PVP (9 mmol/g). In addition, 
steric considerations may also affect the availability of Soluplus donor groups to 
hydrogen bond with FEL. Considering these factors, Soluplus does not hydrogen bond 
with drugs like FEL or NIF as efficiently. 
The length scale of mixing in ASDs could also be studied using proton relaxation 
measurements detected through the 13C nucleus. By determining the proton relaxation 
times of individual components in an ASD in comparison to the proton relaxation times 
of neat components, it may be used to establish an upper limit of length scale of mixing. 
These experiments are based on spin diffusion phenomenon, which tend to average the 
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proton relaxation times to a single value in an intimately mixed system. In contrast in a 
non homogenous system, spin diffusion process is not as efficient, and therefore different 
protons relax independently of one another, giving rise to different relaxation profiles. 
Furthermore, the domains sizes ranging from a few angstroms to a few tens of 
nanometers can be estimated through these experiments, depending on the use of 
relaxation times of either 1H T1 or 
1H T1ρ. The main difference between 
1H T1 and 
1H T1ρ 
is that they are sensitive to motions on different time scales (MHz vs kHz).39 Therefore, 
1H T1 with a longer time scale provides information about domains over larger length 
scales than 1H T1ρ. Using this analysis, it is possible to study and characterize nano-
heterogenous structures on two domain sizes, which is very useful for systems like 
ASDs. Moreover, it is very important to use complementary techniques like DSC, which 
has been a tool to assess homogeneity in ASDs based on a single Tg rule, to help detect 
phase heterogeneity on a smaller scale. The detection of nanophases in ASDs is crucial 
for understanding the propensity to crystallize, and techniques like SSNMR can permit 
analysis of nano heterogeneities beyond the resolution limits of traditional techniques. 
The plots of 1H T1 and 
1H T1ρ for FEL:SOL system as a function Soluplus weight 
% are shown in Figure 4.10. For compositions ≥ 30% Soluplus loading, common 1H T1 
values for each component were obtained that were within the experimental error (Plot 
A). This implies that domain sizes for these compositions are smaller than the diffusion 
path length within the time 1H T1. For the compositions < 30% Soluplus loading, 
different 1H T1 values were recorded for each component within the error of 
measurement, which indicates an non-homogeneous system on the scale of the spin 
diffusion path length within the 1H T1 measurement size for these compositions. It is 
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evident from Figure 4.10 (Plot B) that different relaxation behavior was observed for both 
components for the 1H T1ρ measurements for all compositions, which strongly suggest at 
least some degree of non-homogeneity on 1H T1ρ length scale of mixing, although at 
higher Soluplus loadings, these heterogeneities get very small. Thus, heterogeneity was 
detected for these compositions on a smaller scale based on 1H T1ρ measurements. It is 
interesting to note that same trends are seen for NIF:SOL system, as evident from the 
plots in Figure 4.11. An examination of the experimental 1H T1 data showed similar 
relaxation behavior for compositions ≥ 30% Soluplus, whereas clear differences existed 
for samples with < 30% Soluplus loading (Plot A). As to the 1H T1ρ data in Figure 4.11 
(Plot B), non-identical 1HT1ρ relaxation times within experimental error were measured 
for both components across the composition range. This clearly indicates nano-
heterogeneities existing for these compositions on the length scale of the 1H T1ρ 
measurement. 
 
Figure 4.9. Bar graphs depicting the differences in “free” and “dimer” fractions for 
NIF:SOL system (green bars) and FEL:SOL system (pink bars).  
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Figure 4.10. 1HT1 (black squares) and 
1HT1ρ (red circles) plots for FEL:SOL system as a 
function of Soluplus weight percent. 
 
 
Figure 4.11. 1HT1 (black squares) and 
1HT1ρ (red circles) plots for NIF:SOL system as a 
function of Soluplus weight percent. 
 
The phase behavior of both the systems on a nanometric scale revealed some 
similarities as discussed in the paragraph above. Nonetheless, some small differences 
could be seen especially in the 1H T1ρ data. The degree of phase heterogeneity for both 
systems was more or less same based on the 1H T1 data, but larger degree of phase 
heterogeneity was estimated in the case of FEL:SOL system especially for the 
composition with 10% Soluplus loading. In our opinion, this can result from the 
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differences seen earlier for the extent of hydrogen bonding. We have shown in previous 
sections that NIF:SOL system was more extensively hydrogen bonded to Soluplus in 
comparison to FEL:SOL system, and this could influence the nature of nano-
heterogeneous domains with the matrix to some extent especially on a smaller scale. In 
addition, a useful approximate estimation of the upper limit of the domain size can be 
calculated based on the following equation: 
 
< 𝐿 >≅ (6𝐷1𝐻𝑇𝑖)
1
2 
(4.14) 
 
where <L> is the average diffusive path length for the effective spin diffusion, D is the 
spin diffusion coefficient and 1H Ti is the characteristic time over which spin diffusion 
takes place. Typically, value of D is assumed to be 10-12 cm2/s. Equating 1H Ti with 
either 1H T1 or 
1H T1ρ provides a reasonable estimation of domain sizes of nano 
heterogeneities. The results for domain sizes for ASDs of both the systems are listed in 
Table 4.4. The results from the Table 4.4 indicate that the domain sizes in both the 
systems were near identical for the compositions studied. It should be noted here that the 
calculation of domain sizes is based on the relaxation times of individual components. 
Hence, the extent of phase heterogeneity, which is based on the difference in the 
relaxation times of drug and polymer, does not always reflect in domain sizes. 
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Table 4.4. Domain sizes (nm) as calculated from SSNMR analysis. 
Composition (Drug:Polymer) NIF:SOL FEL:SOL 
50:50 2-35 2-35 
60:40 2-39 2-37 
70:30 2-40 2-37 
80:20 >40 >37 
90:10 >40 >37 
 
4.4 Conclusions 
In this chapter, the miscibility of two structurally similar molecules, felodipine 
and nifedipine, with Soluplus was studied in depth. The melting point depression 
approach was employed to study the thermodynamic miscibility for both the systems. 
The results from the melting point depression study indicated better miscibility of NIF 
with Soluplus in comparison to FEL. In addition, phase diagrams of temperature-
composition were successfully constructed for both the systems. The experimental Tg 
values for the compositions studied were compared to those predicted from the Gordon-
Taylor equation. It was found that both the system showed a similar pattern in terms of 
the deviations observed. The hydrogen bonding patterns were studied via FTIR and 
SSNMR analyses. It was revealed that both the drugs interacted with Soluplus via 
hydrogen bonding, and the preferred interaction site was the vinylcaprolactam moiety in 
Soluplus backbone. Furthermore, it was shown that NIF hydrogen bonded more 
extensively with Soluplus in comparison to FEL. The proton relaxation time 
measurements revealed the presence of heterogeneous domains in both the systems and 
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the upper limit of the domain sizes were also estimated. The analysis of the proton 
relaxation measurements indicated that higher extent of phase heterogeneity in FEL:SOL 
system. Overall, this study is important to understand the drug-polymer miscibility to 
rationally design ASDs formulations. 
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CHAPTER 5. MOLECULAR INTERACTIONS AND PHASE BEHAVIOR OF BINARY AND 
TERNARY AMORPHOUS SOLID DISPERSIONS OF KETOCONAZOLE  
5.1 Introduction 
In recent years amorphous solid dispersions (ASDs) have gained widespread 
attention to address the issue of poor bioavailability for poorly-water soluble drugs.1 This 
formulation strategy is a viable approach for BCS Class II and IV compounds but the 
inherent propensity of amorphous form to convert to the crystalline form poses a serious 
challenge to the bioavailability advantage that comes with it.2-4 Consequently, the role of 
polymers in overall stabilization of the system has been studied in great depth.5-7 It is now 
well recognized that polymers stabilize via two mechanisms: (a) increasing glass 
transition temperature (Tg) of the system, and (b) forming intermolecular drug-polymer 
interactions.8 Typically, ASDs have been formulated using one polymer in the matrix. In 
recent years, a new class of ternary ASDs has emerged, which can contain a mixture of 
two polymers.9-14  
In order to better understand the physicochemical properties of ternary ASDs, it is 
important to elucidate the phase behavior and molecular interactions present within the 
system. In contrast to a simple system like binary ASDs, presence of two polymers in 
ternary ASDs may strongly influence the overall phase mixing of the different 
components, and with it the physical stability of the system. Moreover, characterizing 
these intermolecular interactions is equally important because the interplay of various 
intermolecular species can impact phase homogeneity and hence the resultant stability of 
ternary ASDs. However, in depth details of intermolecular interactions and phase 
behavior are still not clear in ternary ASDs due to the limited amount of research done on 
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them. Based on the preceding discussion, it is apparent that there is a need to fully 
understand these complex systems on a molecular level.  
In the present study, we evaluated the physical stability of ketoconazole (KET), a 
BCS class II antifungal compound, in presence of different polymers for spray dried 
binary and ternary ASDs. Hydroxypropyl methylcellulose (HPMC) and polyacrylic acid 
(PAA) were chosen as polymeric carriers for this study. HPMC and PAA present 
different possibilities for drug-polymer interactions individually based on their chemical 
structures. Both the polymers have been previously studied as carriers for ASDs 
formulations.15,16 Mistry et al. studied the role of drug-polymer interactions on the 
molecular mobility of KET ASDs with polymers like PAA, poly (2-hydroxyethyl 
methacrylate) (PHEMA) and PVP. The authors demonstrated reduced mobility and a 
decrease extent of crystallization for ASDs containing PAA, which was attributed to the 
fact PAA interacted strongly with KET.17 Chen et al. correlated drug polymer-interaction 
and phase mixing with initial drug dissolution for KET ASDs with PVP, PVP/VA, 
HPMC or HPMCAS.18 Although both PAA and HPMC have used individually for KET 
ASDs, the combined use of these polymers has not been studied so far. This work 
presents a detailed solid-state characterization for KET ternary ASDs in comparison to 
individual binary ASDs. The specific goal of the current research is to investigate the 
impact of addition of a second polymer on the phase mixing and solid-state interaction 
patterns for KET in ternary ASDs at a molecular level. A detailed solid-state 
characterization approach was employed using several analytical techniques such as 
DSC, FT-IR spectroscopy and solid-state NMR spectroscopy. Finally, the physical 
stability of binary and ternary ASDs was evaluated by PXRD at two different conditions. 
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The findings of this comprehensive study can provide useful mechanistic insights into 
these systems and serve as a precedent for understanding the role of a second polymer on 
phase mixing and drug-polymer interactions, which is critical for the rational design of 
novel ternary ASDs. 
5.2 Experimental 
5.2.1 Materials 
Ketoconazole (KET; 99%) was purchased from BOC Sciences (Shirley, NY). 
HPMC (Pharmacoat 606) was a kind gift from Shin-Etsu Chemical Co., Ltd. (Tokyo, 
Japan). PAA (Mw ~ 1800) was purchased from Aldrich (St. Louis, USA). Polymer 
samples were stored in a vacuum desiccator over Drierite at room temperature. 
5.2.2 Preparation of Amorphous Materials 
Preparation of Amorphous Ketoconazole. Amorphous ketoconazole was 
prepared by melt quenching. The as-received sample was transferred to a Teflon beaker 
and heated in an oil bath at 160 ˚C until completely melted. The sample was then 
quench-cooled using liquid nitrogen, and the resulting glass was powdered using a 
mortar and pestle. Amorphous state was confirmed by PXRD, and all other 
characterizations were performed immediately. 
Preparation of KET:PAA Amorphous Solid Dispersions. ASDs of KET with 
PAA were prepared via spray drying with ProCept 4M8-Trix spray dryer (ProCept, 
Zelzate, Belgium) with N2 closed loop recirculation unit. A solution of drug and polymer 
were dissolved in 95:05 (v/v) mixture of methanol and water (5% w/v solids). Spray 
dryer conditions were as follows: N2 gas, medium cyclone, atomization pressure 0.35 
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bar, liquid flow rate 85 rpm, 0.8 mm bifluid nozzle, process gas flow 7.4 L/min, inlet 
temperature 85 ˚C. The resulting dispersions were dried in a vacuum desiccator over 
Drierite at room temperature overnight to remove any residual moisture. All dispersions 
samples confirmed amorphous by PXRD, and were stored in 20 mL glass scintillation 
vials in the freezer until analysed. 
Preparation of KET:HPMC and KET:PAA:HPMC Amorphous Solid 
Dispersions. Binary dispersions of KET with HPMC and ternay dispersions of KET, 
HPMC and PAA were prepared via spray drying with ProCept 4M8-Trix spray dryer 
(ProCept, Zelzate, Belgium) with N2 closed loop recirculation unit. A solution of drug 
and polymer were dissolved in a 75:25 mixture of ethanol and water (5% w/v solids). 
Spray dryer conditions were as follows: N2 gas, medium cyclone, atomization pressure 
0.35 bar, liquid flow rate 85 rpm, 0.8 mm bifluid nozzle, process gas flow 7.4 L/min, 
inlet temperature 105 ˚C. The resulting dispersions were dried in a vacuum desiccator 
over Drierite at room temperature overnight to remove any residual moisture. All 
dispersions samples confirmed amorphous by PXRD and were stored in 20 mL glass 
scintillation vials in the freezer until analysed. 
5.2.3 Differential Scanning Calorimetry  
DSC analyses were performed using a Q2000 (TA Instruments, New Castle, DE) 
equipped with a RCS90 refrigerated cooling system (TA Instruments; New Castle, DE). 
The instrument was calibrated for temperature and heat flow with an indium standard. 5-
7 mg of sample was loaded into an aluminum DSC pan with a hermetically sealed lid 
with one pinhole. All the dispersion samples were analyzed via heat-cool-heat cycle 
under nitrogen purge (50 mL/min). A typical thermal cycle consisted of following stages: 
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1) heating from 20 ˚C to 180 ˚C at 5 ˚C/min (primary heating); 2) isothermal for 5 min 
followed by cooling to -10 ˚C at 30 ˚C/min (cooling stage); 3) heating to 200 ˚C at 5 
˚C/min (secondary heating). For the heating cycles, a modulation amplitude of ± 0.5 ˚C 
was applied every 60 s to discern reversible thermal events. The first heating cycle was 
used to erase any thermal history of the sample and to get rid of any residual solvent. For 
each sample, measurements were done in duplicate. The data was analyzed by TA 
Universal Analysis software (version 4.7, TA Instruments, New Castle, DE). The value 
of Tg reported was the half height of the transition in the reversing heat flow signal. 
Theoretical Tg of the mixture was calculated using the Gordon-Taylor equation 
(eq. 5.1) in conjunction with the Simha-Boyer rule (eq. 5.2). 
 
𝑇𝑔 =  
𝑤1𝑇𝑔1 + 𝑘𝑤2𝑇𝑔2
𝑤1 + 𝑘𝑤2
 
(5.1) 
 
where w1 and w2 are the weight fractions and Tg1 and Tg2 are the glass transition 
temperatures (˚C) of each component. k is found by using eq. 5.2. 
 
𝑘 =  
𝜌1𝑇𝑔1
𝜌2𝑇𝑔2
 
(5.2) 
 
where ρ1 and ρ2 are the densities of each component. 
5.2.4 Fourier Transform Infrared Spectroscopy  
A Thermo Fisher Scientific Nicolet iS50 FT-IR (Thermo Fisher Scientific, 
Waltham, MA) with an attenuated total reflectance (ATR) attachment was used to collect 
FTIR spectra from 400 cm-1 to 4000 cm-1. Data were collected in 64 scans with a 
resolution of 4 cm-1 and a data spacing of 0.482 cm-1. Spectra were normalized and base 
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line corrected using Omnic software (Version 9.5, Thermo Fisher Scientific, Waltham, 
MA). 
5.2.5 Solid-state Nuclear Magnetic Resonance Spectroscopy 
13C SSNMR spectra were acquired using a Tecmag Redstone spectrometer 
(Tecmag Inc., Houston, TX) operating at approximately 300 MHz for 1H and 75 MHz 
for 13C. Samples were packed into 7.5 mm zirconia rotors and sealed with Teflon or Kel-
F end-caps (Revolution NMR LLC. Fort Collins, CO). One dimensional 13C spectra were 
acquired using cross polarization magic angle spinning (CP/MAS) at 4 kHz, using total 
sideband suppression (TOSS)19 and SPINAL6420. The 1H 90˚ pulse width was set to 4.5 
μs and contact time of 1.5 ms was used in all the measurements. The pulse delay for 1D 
experiments was 4 s and a total of 4096 scans were collected. The 13C chemical shift 
scale was referenced with the methyl peak of 3-methylglutaric acid, which was set to 
18.84 ppm.21 The relaxation times were detected via 13C nucleus, which facilitates 
identification of regions for respective components. Proton spin-lattice relaxation time in 
the laboratory frame (1H T1) were measured using a 
13C-detected saturation recovery 
pulse sequence with TOSS. 1H T1 were obtained by fitting integral-recovery time data by 
the following equation: 
 
𝑀(𝑡) = 𝑀0(1 − 𝑒
−
𝑡
𝑇1) 
(5.3) 
 
where M(t) is the peak intensity at delay time t, M0 is an amplitude parameter from the fit, 
and T1 is the obtained spin-lattice relaxation time in the laboratory frame. Proton 
relaxation times in the rotating frame (1H T1ρ) were measured by varying the spin lock 
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duration time after a 90˚ pulse. 1H T1ρ decay times were obtained by analyzing the 
integrated carbon signal exponentially according to the following equation: 
 
𝑀(𝑡) = 𝑀0𝑒
−
𝑡
𝑇1𝜌 
(5.4) 
 
where M(t) is the peak intensity and t is the spin-lock duration time. M0 is an amplitude 
parameter from the fit, and T1ρ is the fitted spin-lattice relaxation time in the rotating 
frame. All data fitting was done using GraphPad Prism (GraphPad Software, Inc., La 
Jolla, CA). The regions selective for drug and polymers were used to get the integrals. 
The region from 111-159 ppm was selective for KET, the regions 177-190 and 27-33 
ppm were non-overlapping for PAA, and the regions 57-65 and 99-105 ppm were unique 
for HPMC. These resolved areas are shown in highlighted boxes in Figure 5.7 (vide 
infra). 
5.2.6 Powder X-ray Diffraction 
PXRD patterns were collected on the Rigaku Miniflex 600 benchtop 
diffractometer (Rigaku Corporation, Tokyo, Japan), with Cu Kα radiation (40 kV x 15 
mA). The experiments were conducted at room temperature, between 2° to 50° 2θ at a 
scan speed of 2.0°/min and a step size of 0.02° 2θ under continuous mode. 
5.2.7 Physical Stability 
The physical stability of the binary and ternary dispersions was studied for 70% 
drug loading at two different stress conditions: 40 °C/75% RH and RT/94% RH. This 
drug loading was chosen to observe crystallization in samples in real time. The samples 
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were analyzed by PXRD at different time points (time 0, 1 week, 2 weeks, 1 month, 2 
months, 3 months, and 6 months). 
5.3 Results and Discussion 
5.3.1 Chemical Structures 
The chemical structures of compounds are shown in Figure 5.1. The model 
lipophilic drug, KET, belongs to the class of antifungal compounds. It is a weak base 
with two pKa values;  the imidazole ring (pKa = 6.51) and the piperazine ring (pKa = 
2.94).22 Its structure presents potential sites for intermolecular interactions such as acid-
base or hydrogen bonding interactions. PAA is a strong donor and medium acceptor, and 
has a carboxylic acid as its monomer with pKa of 4.75.
23 HPMC is a neutral cellulosic 
polymer, which has been extensively used as a polymeric matrix for ASDs.24 HPMC has 
many hydroxyl groups in its structure with capability of acting both as donor and 
acceptor. HPMC is devoid of any carbonyl groups and hence will act an excellent system 
with no interference in the carbonyl regions both for FTIR and SSNMR analyses. 
5.3.2 DSC Results 
For an accurate measurement of the Tg, amorphous KET was generated in situ 
inside DSC pan by heating the crystalline drug above its melting point, followed by 
quench cooling. Amorphous KET had a Tg of 47.0 °C, which is consistent with the 
previous reports.25 The polymers were amorphous in nature and displayed an average Tg 
of 99.9 °C and 145.5 °C for PAA and HPMC respectively. It is clear from the Tg values 
of neat materials that they are different from each other. This wider gap is desired when 
DSC is used to study phase homogeneity in ASDs. It is generally recommended that Tg 
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of individual components must be at least 10 °C apart in order to determine phase 
homogeneity via DSC.26 
Tg is an important index for assessing the physical stability and mobility of 
ASDs.27 We also evaluated the Tg values of binary and ternary ASDs as a function of 
composition by mDSC exposing the samples to a heat cool heat protocol. The results 
from the first heating cycle are shown in Figure 5.2. The binary systems of KET:PAA 
and KET:HPMC displayed a single Tg between the Tgs of individual components for all 
compositions, implying phase homogeneity. Similar trend was seen in the ternary 
samples. The Tg values obtained for KET:PAA were higher than for the KET:HPMC 
system. Thus, the rank ordering of the polymers based on effectiveness of the polymers 
to increase the Tg of KET is PAA>HPMC. Furthermore, 90:10 sample in all the systems 
displayed a melting endotherm, which possibly signifies the existence of drug-rich 
amorphous domains within the matrix. In the DSC analysis, it has been shown that the 
presence of a single Tg does not always indicate phase homogeneity.
28 Therefore, solid-
state NMR  was used to confirm phase homogeneity for these samples (vide infra). 
 
Figure 5.1. Chemical structures of (A) ketoconazole (KET) (B) PAA and (C) HPMC.  
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Figure 5.2. DSC thermograms from first heating cycle for (A) KET:PAA binary system 
(B) KET:HPMC binary system and (C) KET:PAA:HPMC ternary system. The 
composition of the samples is indicated by drug:polymer ratio on a weight basis: black 
for KET, gold for PAA and blue for HPMC.  
 
The thermal history of the sample generally affects the Tg of the system. In order 
to erase the thermal history of the sample, it is generally agreed to expose the sample to 
heat cool heat cycle in DSC. The Tg values from the second heating cycle yield more 
accurate values with sharper step change (shorter Tg widths). This is clearly depicted in 
the thermograms obtained from the second heating cycle in Figure 5.3. The Tg values 
thus obtained were slightly higher than the first heating cycle. This trend was most 
pronounced in KET:HPMC binary system. The change in the Tg values from the second 
heating cycle reflects the behavior of spray-dried samples in the DSC, where the samples 
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lose residual solvent following heating, and thus showing higher Tg values without any 
melting endotherms, in part due to better mixing. 
A number of equations are reported in the literature for predicting theoretical Tg 
values for drug-polymer mixtures.27 In the Figure 5.4, the Gordon-Taylor equation was 
used to generate the theoretical Tg curve lines, and the experimental values were drawn 
from the mean Tg values from the second heating cycle. Typically, the deviation positive 
or negative is suggestive of non-ideal mixing behavior between the drug and polymer, 
and has often been used to indicate the presence of specific intermolecular interactions. 
In addition, the direction and magnitude of deviation in these plots have been used to 
determine if homo or hetero interactions are dominating.29 The experimental Tg values 
for the samples with less than 50% drug loading could only be generated for binary 
KET:PAA system by preparing in situ dispersions inside the DSC pan from the 
respective physical mixtures. For systems containing HPMC, both binary and ternary, 
this approach could not be adopted, and therefore the experimental curves do not cover 
the entire composition range. 
In the binary KET:PAA system, a pronounced positive deviation was observed 
for the composition range from 10-90% drug loading. It is interesting to observe that the 
highest Tg value was noted for the composition 30:70 (105.5 °C), and the largest 
deviation between the experimental and theoretical Tg values was seen for the 
composition 50:50 (ΔTg = 32.7 °C). Similar positive deviations of experimental Tg 
values have been reported for the other drug-polymer systems like indomethacin-
eugragit and loperamide-PAA.30,31 This strong positive deviation shows that the drug-
polymer heterointeractions are stronger than drug-drug or polymer-polymer 
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homointeractions. Based on the basic nature of KET and the acidic nature of PAA, there 
is a possibility of ionic interaction. For salt formation to take place between acids and 
bases, it is generally accepted that the ΔpKa > 2.
32 If we compare the ΔpKa between KET 
(imidazole ring) and PAA, we get a value of 1.76. This value of ΔpKa does not satisfy 
the rule of thumb completely, but the strong positive deviation between the experimental 
and theoretical Tg values does point to partial proton transfer taking place in this 
scenario. Another potential interaction site is the carbonyl group of KET, which can take 
part in hydrogen bonding. It has been reported in literature that a specific interaction like 
strong hydrogen bonding can also result in positive deviation for systems like IMC-
PVA.33 In this case, it is difficult to ascertain using Tg data which interaction is 
responsible for this behavior, if we also take hydrogen bonding in account as a 
contributing interaction. 
In contrast to the KET-PAA binary system, the KET-HPMC binary system 
showed a negative deviation between the experimental and theoretical Tg values, as seen 
in Figure 5.4. The negative deviation could result from dominating drug-drug and/or 
polymer-polymer homo-interactions or to an increase in free volume upon mixing. 
Similar to the KET:PAA binary system, the largest deviation in Tg was observed for a 
50:50 composition (ΔTg = -28.2 °C). Other systems like curcumin-HPMC and 
felodipine-HPMC have also shown similar behavior.34,35 
It is interesting to note in the Figure 5.4 that the ternary system of KET-PAA-
HPMC showed positive deviation between the experimental and theoretical Tg values, 
similar to what was seen in the binary KET:PAA system. Again, the 50:50 composition 
resulted in the maximum deviation between the experimental and theoretical Tg values 
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(ΔTg = 16.0 °C), and more importantly, this value is almost half of what was seen in the 
binary KET:PAA system. Additionally, the overall deviation for ternary system was 
influenced by the positive deviation and the negative deviations effects of KET:PAA and 
KET:HPMC binary systems respectively, resulting in the experimental Tg values to lie in 
between the two curves. Although in ternary systems the amount of PAA is reduced to 
half on weight basis, a strong positive deviation was observed, especially for 
compositions < 80% KET, suggesting a similar interaction pattern existed, and probably 
interactions between KET-PAA outweighed the others. It is possible to observe negative 
deviations for ternary ASDs. Albadarin et al. observed negative deviation from the 
theoretical values in ternary dispersions of itraconazole with Soluplus and HPMCP.36 
 
Figure 5.3. DSC thermograms from second heating cycle for (A) KET:PAA binary 
system (B) KET:HPMC binary system and (C) KET:PAA:HPMC ternary system. The 
composition of the samples is indicated by drug:polymer ratio on a weight basis: black 
for KET, gold for PAA and blue for HPMC.  
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Figure 5.4. Mean experimental and theoretical Tg plotted as a function of weight fraction 
of KET for KET: PAA dispersions (red color), KET:HPMC dispersions (blue color) and 
KET:PAA:HPMC dispersions (green color). The dotted lines represent theoretical Tg 
values obtained from the Gordon-Taylor equation.  
 
5.3.3 FTIR Spectroscopy 
FTIR spectroscopy was used to study the intermolecular interactions between 
KET and each polymer in binary and ternary ASDs. FTIR plots for each system are 
depicted in Figure 5.5. The carbonyl region of the KET:PAA in the binary dispersions is 
shown in Figure 5.5 A. It has been already shown in the literature that pure PAA can self 
associate through hydrogen bonding, and exists in two forms: free and dimer.37 
Therefore, the spectrum of pure PAA is characterized by vibrations at 1737 cm-1 and 
1695 cm-1, attributed to free (non-hydrogen bonded) and dimer (hydrogen bonded), 
respectively. It has been suggested that KET is likely to interact with PAA via ionic 
interactions.17 In the present study, this is supported by the appearance of one new 
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specific peak at 1544 cm-1, assigned to asymmetric stretching vibration of the carboxylate 
group. This new peak becomes more pronounced in samples with greater than or equal to 
30% PAA. The formation of the carboxylate ion should also reveal a peak around 1400 
cm-1 arising from symmetric stretching vibration of the carboxylate group. This peak was 
hard to discern in the spectra due to strong absorption peaks of both KET and PAA. This 
is in good agreement with the spectrum of the sodium salt of PAA, which shows two 
prominent peaks corresponding to the carboxylate asymmetric stretching at 1549 cm-1 
and carboxylate symmetric stretching at 1399 cm-1 (Figure 5.6). Nie et al. have reported 
similar results for carboxylate group formation resulting from ionic interaction between 
HPMCP and clofazimine.38 Additional evidence for proton transfer can be found in the 
region of 2200-3400 cm-1 (Figure 5.5 B). Pure PAA displays a characteristic broad 
absorption band at 3040 cm-1 for O-H stretching. A broad shoulder peak around 2530 cm-
1 appeared in KET:PAA dispersions samples assigned to +N-H stretch formed upon the 
protonation of the imidazole group in KET. Furthermore, a hypsochromic shift of dimer 
peak of PAA from 1695 cm-1 to 1716 cm-1 was observed in the dispersions indicating 
disruption of dimers giving rise to new fraction of free carboxylic acid. 
Another interesting finding can be seen in the 1300-1800 cm-1 region (Figure 5.5 
A). The amorphous KET showed C=O stretching band at 1640 cm-1. In the presence of 
PAA, a shoulder around 1607 cm-1 appeared in the dispersion samples with greater than 
or equal to 20% PAA. The intensity of this extra vibration band at 1607 cm-1 increased 
with increase in polymer loading. This phenomenon may be an indication of presence of 
a new species of KET carbonyl group. Generally, hydrogen bonding results in a shift to 
lower wave numbers. This shift to lower wavenumbers from 1640 cm-1 to 1607 cm-1 is 
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possibly pointing to the formation of a hydrogen bond, where the carbonyl group of KET 
can act as an acceptor and the carboxylic acid group of PAA as a donor. No changes 
could be seen in the O-H stretching region of PAA due to overlapping bands. At this 
stage, it is logical to hypothesize that the hydrogen bonding could also be a possible 
mode of interaction between KET and PAA and more evidence is needed to support this 
hypothesis.  
In the case of KET: HPMC binary dispersions, no evidence of any interaction 
could be derived from FTIR spectra. As shown in the Figure 5.5 C, HPMC caused no 
change in the peak corresponding to the carbonyl group of KET in the region of 1550-
1800 cm-1. Additionally, the O-H stretch region in KET:HPMC samples was difficult to 
discern due to the presence of multiple overlapping absorption bands (Figure 5.5 D). 
Basically, the FTIR spectra of this binary system were linear addition of the pure 
amorphous components weighted by each component amount. This observation is 
consistent with the findings from Chen et al.18 The authors pointed out that KET is poorly 
miscible with HPMC based on the weak Flory-Huggins interaction parameter (positive χ 
value), which collectively indicate the absence of any specific interactions between KET 
and HPMC. 
The results for FTIR spectra of ternary ASDs of KET:PAA:HPMC are shown in 
Figure 5.5 (plots E and F). The ternary ASDs retain spectral features from binary 
KET:PAA ASDs except for some minor differences. The dimer peak of PAA shifted to 
higher wavenumbers similar to binary KET:PAA ASDs. The carboxylate peak around 
1544 cm-1 became less intense in comparison to KET:PAA samples likely because of 
less amount of PAA present in ternary samples. It is noteworthy to mention that the peak 
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intensity of hydrogen bonded carbonyl group of KET (1607 cm-1) decreased in the 
ternary ASDs. Likewise, the +N-H stretch peak around 2530 cm-1 became less 
pronounced for ternary ASDs. In the case of ternary dispersions, the possibility of two 
polymers interacting with each other needs to be taken into the account. In order to 
explore this scenario, polymer blends with different weight ratios of PAA and HPMC 
were studied via FTIR. From the Figure 5.7, it is clearly evident that in the presence of 
HPMC there is loss of PAA dimers. At 80% HPMC weight ratio, the dimer peak 
intensity is drastically reduced. The disruption of PAA dimer fraction could be a result of 
intermolecular interactions between HPMC and PAA or simply due to a dilution effect. 
If these two species were to interact on a molecular level via hydrogen bonding, a shift to 
a lower wavenumbers is anticipated. The FTIR spectra of these polymer blends do not 
seem to suggest such an occurrence. In fact, the dimer peak of PAA (1695 cm-1) moved 
to higher wavenumbers as the weight fraction of HPMC is increased. For polymer blends 
it is likely that PAA and HPMC are not involved in strong interactions, and therefore in 
ternary ASDs there are no other competing interaction present. The interaction pattern in 
the ternary ASDs seems to suggest that interaction between KET and PAA is still 
favored in the presence of HPMC. 
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Figure 5.5. FTIR spectra of pure KET, pure PAA and dispersions showing the carbonyl 
stretching region and the single bond region for KET:PAA binary system (plots A and 
B), KET:HPMC binary system (plots C and D) and KET:PAA:HPMC ternary system 
(plots E and F).  
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Figure 5.6. FTIR spectrum of PAA and its sodium salt. The peaks ~ 1549 cm-1 and 1399 
cm-1 found in sodium salt of PAA are attributed to asymmetric and symmetric stretching 
vibration of the carboxylate group respectively. 
 
 
Figure 5.7. Comparison of FTIR spectra of PAA, HPMC and their spray dried blends. In 
presence of HPMC, the intensity of dimer peak (~1695 cm-1) decreases and moves to 
higher wavenumbers as the weight fraction of HPMC increases. Spectrum of 50:50 
physical mixture of PAA and HPMC is shown as a reference. 
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5.3.4 Solid-state NMR spectroscopy 
5.3.4.1 13C CP/MAS Experimental Results 
In recent years, SSNMR has been used as a part of analysis for ASDs for its 
unique capability to provide atomic level information on intermolecular interactions and 
phase homogeneity.39-41 In order to understand holistically the system under study and to 
complement routine analysis techniques, SSNMR experiments utilizing CP/MAS and 
spin diffusion were included. Figure 5.8 shows 13C SSNMR spectra of the raw materials. 
The spectrum of crystalline KET consisted of sharp resonances typical of crystalline 
materials. The peaks were assigned according to the numbering scheme used in the 
structure. There is one molecule in each asymmetric unit in the crystal structure based on 
one peak for each carbon atom found in the spectrum. In contrast, amorphous KET 
displayed broader peaks suggestive of a disordered state. The carbonyl carbon centered 
around 169 ppm is of interest to probe any possible interactions with polymers for 
hydrogen bonding. In addition, other potential sites of interest are the carbon signals in 
the imidazole ring, which appear in the aromatic region (110-150 ppm), to investigate 
any ionic interactions. The polymers exhibited amorphous nature as confirmed by 
relatively broad signals in Figure 5.8. Pure HPMC does not have any carbonyl signal. It is 
useful to note that the carbonyl region of PAA consisted of two peaks; one main peak of 
182.6 ppm and the shoulder peak at 177.2 ppm. These two peaks corresponded to dimer 
and free fractions. Upon deconvolution of the region, the respective contribution of the 
peaks in terms of percentage was quantified. It was estimated that dimer and free 
fractions were 44% and 56% respectively. 
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It is important of compare the molar ratio of donor to acceptor groups with respect 
to acidic and basic groups in both binary KET:PAA and ternary KET:PAA:HPMC 
systems for the drug loadings under study. The molecular weights of KET (531.43 g/mol) 
and monomer unit of PAA (72.06 g/mol) were used in Figure 5.9. For the composition 
range between 50-80% drug loadings, the ratio of donor/acceptor functionalities 
exceeded 1. Also, the theoretical composition of 1:1 molar ratio was calculated to be 
88.11% KET on weight basis. In comparison to binary system, the molar ratios for 
ternary system were half in values for each composition, considering PAA amount 
reduced to half and there were no acidic groups in HPMC. The 78.71% weight fraction of 
KET corresponded to 1:1 molar stoichiometry of KET:PAA in ternary compositions. 
Thus, in theory below 88.11% and 78.71% weight of KET all imidazole groups should be 
protonated in binary and ternary ASDs respectively, if there is no steric hindrance.  
13C CPMAS spectra of the binary KET-PAA dispersions at various drug loadings 
are shown in Figure 5.10 A. The spectra displayed broader Gaussian resonances, which 
confirmed their amorphous character. No significant changes were observed in the 
spectra except in the carbonyl region. On analysis of the carbonyl region (160-190 ppm) 
some interesting spectral features were noted. Firstly, there is a change in the intensity of 
the dimer peak across the range of drug loadings as evident in Figure 5.11 A. This 
suggests that there is loss of PAA dimers resulting from an interaction with KET. As 
pointed by the FTIR analysis, KET and PAA can form ionic bonds, resulting in the 
formation of carboxylate ion. In the carbonyl sub spectra given here, no apparent peaks 
were observed which could be attributed to carboxylate ion formation. In order to 
confirm the peak position of the carboxylate group, we compared the 13C spectrum of 
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sodium salt of PAA with pure PAA in Figure 5.12. It was shown that carboxylate ion 
resonated further downfield around 186 ppm. Since this region in our samples did not 
reveal any direct changes, an ionic interaction is likely to be hidden there. Very 
interestingly, there is a new peak around 172 ppm, which is more resolved in dispersions 
from 50 to 70 % and shifted further upfield as KET loading increased to 90% as seen in 
Figure 5.11 A. This peak was found to be absent in the spectrum of 50:50 physical 
mixture of amorphous KET and PAA (Figure 5.13). We hypothesize that this peak is due 
to the hydrogen bonding of the carbonyl group of KET with PAA. From the molar ratio 
calculations we know that there is an excess of PAA present for compositions ≤ 88.11%, 
which most likely makes this hydrogen bond a possibility. In addition, this also supports 
our earlier hypothesis for the 1607 cm-1 peak in FTIR analysis. It is clear from the 
analysis of the carbonyl region that there are possibly two different fractions contributing 
to the KET carbonyl intensities: hydrogen-bonded (H-bonded) and non-hydrogen bonded 
(Non H-bonded) species.  
13C CP/MAS spectra of the binary KET:HPMC dispersions are displayed in 
Figure 5.10 B. No change in chemical shift was observed in any region for the 
dispersions samples in comparison with the pure components, and no evidence of any 
interaction could be found. There was no spectral inference from HPMC in the carbonyl 
region, and the respective peaks of KET and HPMC increased/decreased depending on 
the composition. This is also in good agreement with the findings of FTIR analysis. 
The possibility of PAA interacting with HPMC was again explored with SSNMR 
as presented in Figure 5.14. The differences could be seen in the carbonyl region for 
PAA:HPMC spray blends at various weight ratios. In presence of HPMC, the dimer 
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fraction goes down and correspondingly the free fraction increases. For the 80:20 
HPMC:PAA blend, the dimer fraction decreased to 7 % from 44% in pure PAA while 
the free fraction increased form 56% to 93%. No change in the chemical shift was 
observed. These changes confirm the absence of any strong interaction between PAA 
and HPMC. This is consistent with the FTIR results reported earlier, and confirms that in 
the ternary system these two polymers most likely do not interact. 
From the spectra of ternary KET:PAA:HPMC dispersions, the followings 
spectral features were noted from Figures 5.10 C and 5.11 B. As shown in Figure 5.10 C, 
similar trends were seen in ternary samples as with the binary KET:PAA system, and 
only the carbonyl region revealed some changes. Again, as depicted in Figure 5.11 B, the 
peak attributed to hydrogen-bonded KET (~172 ppm) clearly existed and PAA dimer 
peak (~182 ppm) intensity decreased with increasing drug load, implying the 
disappearance of dimers due to the disruption of self-association of PAA. Meanwhile, 
the peak associated with the free fraction of KET (~169 ppm) become more resolved in 
spectra with higher drug loads. It was difficult to compare the carbonyl regions of binary 
KET:PAA and ternary KET:PAA:HPMC systems in terms of quantification of various 
species that existed because of an extensive peak overlap. 
In order to understand the carbonyl region of binary KET:PAA and ternary 
KET:PAA:HPMC systems, a detailed deconvolution exercise was performed. In the 
present study, we fitted the respective sub spectra (160-190 ppm) with five peaks using 
an iterative least-square peak fitting method with Gaussian-Lorentzian function (Figure 
5.15). The five peaks criteria satisfied the existence of various species in KET and PAA. 
The three out of five peaks belonged to PAA carbonyl portion: carboxylate (~186 ppm), 
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dimer (~182 ppm) and free (~177 ppm) while the other two constituted the two carbonyl 
species of KET: H-bonded (~172 ppm) and non H-bonded (~169 ppm). For the fitting 
procedure, the chemical shift and line width were kept locked for all the samples. By 
dividing the corresponding areas with the total area and multiplying with 100, we 
obtained the respective area percentage of each species. The progression of the area 
percentages from the various species for binary KET:PAA and ternary 
KET:PAA:HPPMC samples as the function of KET weight % is illustrated Figures 5.16. 
We will first focus on the changes observed for PAA species for the both systems. It is 
clear from Figure 5.16 that the area percentage of the PAA peaks decreased with 
increasing drug load for both the systems. Also, the area percentages of all PAA peaks in 
the binary samples (Plot A) were higher than those in the ternary samples (Plot B) for the 
same KET weight percentage. This is expected because there is less PAA present in the 
ternary samples. The decrease in the free PAA fraction was more gradual in the binary 
system in comparison to the ternary system, where at 90% KET content the area reduced 
to more than 50%. Interestingly, the dimer fraction reduced to almost the same 
percentage in both the systems at the 90% drug load, even though the binary 50:50 
composition had almost twice the amount present. Furthermore, the carboxylate peak did 
not contribute significantly to the total area, which is suggestive of the fact that, for these 
compositions, hydrogen bonding is the dominating interaction. 
On the other hand, some interesting trends were observed for the area percentages 
of the KET peaks as shown in Figure 5.16. First, the higher amount of non H-bonded 
peak was found in the ternary systems for each composition (Plot B). Second, the area 
percentages of non-H bonded peak increased when moving from 50 to 90 % KET content 
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for both the systems. For the H-bonded peak in the binary system (Plot A), there was an 
increase in the peak area when moving from 50 to 70% KET, reaching the maximum 
value, after which it decreased. In contrast, in the ternary samples (Plot B) the area 
percentage decreased gradually for compositions up to 80% KET content before an 
abrupt reduction at 90% KET composition. The plots in Figure 5.16 compare the area 
percentages obtained from the deconvolution procedure, but in order to make comparison 
for the interaction patterns between the binary and ternary systems, it is necessary to 
further treat the area percentages and normalize them based on the total area of either 
groups: KET carbonyl group and PAA carbonyl group. 
Figure 5.17 compares the percentages of the various species of PAA and KET for 
both binary and ternary systems as computed on the basis of total KET/PAA carbonyl 
area. These plots summaries the deconvolution exercise in a clearer fashion and a few 
conclusions could be drawn. For total PAA carbonyl fraction (Plot A), contribution of 
each species was in the given order: Free>Dimer>Carboxylate for both the systems. 
Overall, higher percentages were seen for carboxylate and dimer fractions in the binary 
system than in the ternary system. Meanwhile, more free PAA was present in the ternary 
system. The ratio of free to dimer fractions increased with KET percent content in both 
the systems. On the other hand, for total KET carbonyl fraction (Plot B), the higher 
percentage of KET was H-bonded in binary system than in ternary system for each 
composition. The ratio of non-H bonded to H-bonded fractions increased for both the 
systems with increasing drug content, and a steeper increase was seen for the ternary 
system. In summary, it can be concluded that the binary samples had more ionic and 
hydrogen bonding interactions vs. ternary samples. Nevertheless, the ternary samples still 
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had a similar interaction pattern with only half the amount of PAA present. This analysis 
is also consistent with the results seen in the FTIR section. The low intensity of 
carboxylate peak in the FTIR spectra could now be attributed to the less amount being 
present. In addition, the peak attributed to H-bonded carbonyl of KET was more 
pronounced for samples with lower drug loads, which is due to a higher fraction of KET 
carbonyl being H-bonded for those compositions. We are not aware of any similar studies 
being conduced earlier where comparison could be established between the molecular 
interaction pattern for binary and ternary ASDs.  
 
Figure 5.8. Comparison of 13C CP/MAS spectra of (A) crystalline KET (B) amorphous 
KET (C) PAA and (D) HPMC. 
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Figure 5.9. Donor to acceptor molar ratio calculated for binary KET:PAA and ternary 
KET:PAA:HPMC as a function of weight percent of KET. The cross point on the curve 
represent the theoretical 1:1 molar ratio in each case.  
 
 
Figure 5.10. Comparison of 13C CP/MAS spectra of (A) crystalline KET (B) amorphous 
KET (C) PAA and (D) HPMC. 
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Figure 5.11. 13C CP/MAS sub spectra in the carbonyl region (160-190 ppm) for (A) 
KET:PAA binary dispersions and (B) KET:PAA:HPMC ternary dispersions. The shaded 
box shows how peak around 172 ppm shifts upfield with increase in drug loading. 
 
 
Figure 5.12. 13CP/MAS SSNMR spectra of PAA and sodium salt of PAA. The main 
peak in the carbonyl region of sodium salt resonated around ~186 ppm.  
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Figure 5.13. 13CP/MAS spectra of 50:50 KET:PAA binary dispersion (red) and 50:50 
KET:PAA physical mixture (purple). The shoulder peak around 172 ppm is visible in 
dispersion sample but absent in physical mixture. Spectra of PAA and amorphous KET is 
included as a reference. 
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Figure 5.14. 13CP/MAS spectra of spray dried blends of PAA and HPMC at various 
ratios. 
 
 
 
Figure 5.15. Deconvolution of the carbonyl region of (A) binary KET:PAA samples and 
(B) ternary KET:PAA:HPMC samples. The fitted peaks are shown in blue; the sum of the 
fit is shown in yellow; the residual is shown in red. 
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Figure 5.16. Plots of % peak area for various species as a function of KET weight % 
obtained from deconvolution of the carbonyl region from SSNMR spectra for (A) 
KET:PAA binary system and (B) KET:PAA:HPMC ternary system. The black and gold 
curves belong to KET and PAA species respectively.  
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Figure 5.17. Plots depicting comparison of various species in binary and ternary systems 
calculated for total (A) PAA carbonyl fraction and (B) KET carbonyl fraction as a 
function of KET weight%.  
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5.3.4.2 15N CP/MAS Spectra Analysis 
15N SSNMR experiments were performed in order to further understand the acid-
base interactions between KET and PAA. 15N is known to have both a very low 
magnetogyric ratio and natural abundance, which makes it very less sensitive and 
therefore time consuming to analyze. Another challenge that comes with 15N spectra of 
amorphous materials is the presence of broader resonances, which makes detection more 
complicated, and this becomes more aggravated in the presence of excipients, which can  
further reduce the signal intensity due to dilution. However, even with these challenges, 
15N data collected in our study did reveal some important features regarding the local 
nitrogen environment of KET. The 15N spectra of samples are compared in Figure 5.18. 
Given the time it took to acquire each spectrum (~3-4 days), only one composition close 
to the 1:1 molar ratio was selected (80:20 composition on weight basis for both the 
systems). In the spectrum of amorphous KET, four resonances could be detected.  The 
peak at 259 ppm was attributed to the imidazole N34 nitrogen in KET. In the dispersion 
samples, no variation in chemical shifts of other resonances was observed except for 
nitrogen N34. The nitrogen N34 peak shifted upfield ~16 ppm and ~ 19 ppm in binary 
and ternary samples, respectively, and this change in chemical shift is suggestive of 
proton transfer or salt formation. Similar results have been reported by Lubach et al. for 
indomethacin and eudragit system, where ~16 ppm shift relative to polymer was noted 
for a 70% dispersion sample.42 In another study, similar change in chemical shift of 
amorphous lapatinib was observed when formulated with HPMCP, resulting from 
tionization of drug.43 This exercise supports the results obtained from FTIR and 13C 
 
 
167 
SSNMR experiments and further provides evidence for the presence of ionic interaction 
between KET and PAA.  
5.3.4.3 Investigation of Phase Homogeneity by SSNMR 
In order to further understand the homogeneity of dispersions at a nanometric 
level, 13C-detected proton relaxation experiments were performed. Two different kinds of 
proton relaxation measurements were included: spin-lattice relaxation time in the 
laboratory frame (1H T1), and in the rotating frame (
1H T1ρ). The relaxation parameter 
1H 
T1 studies homogeneity on larger domain sizes than 
1H T1ρ, since for solids 
1H T1 >> 
1H 
T1ρ. Typically, for an intimately-mixed system, identical relaxation behavior is seen for 
individual components due to spin diffusion. If not, different relaxation values are seen 
for each component. A common 1H T1 value signifies mixing to a scale of about 20-50 
nm, whereas a common 1H T1ρ value denotes mixing to a scale of about 2-5 nm. For 
reference, the proton relaxation times for the individual components are given in Table 
5.1. The relaxation times for the KET:PAA binary system are shown in Figure 5.19 
(plots A and D). Each composition showed a single relaxation 1H T1 and T1ρ value within 
the error of measurement, suggesting that dispersions are homogenous to a calculated 
domain size of <2 nm. The plots of relaxation times for KET:HPMC binary system are 
shown in Figure 5.19 (plots B and E). It can be found that near identical relaxation 
values are obtained for 1H T1 and T1ρ for composition up to 80% drug load, indicating 
phase homogeneity on a scale less than 3 nm. Whereas sample with 90% drug started to 
show signs of nano heterogeneity as confirmed by slight differences seen for 1H T1 and 
T1ρ relaxation times, with an estimated domain size of > 40 nm. The relaxation times for 
ternary KET:PAA:HPMC system are shown in Figure 5.19 (plots C and F). A similar 
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relaxation behavior was observed in the case of 1H T1 and T1ρ for all three components 
up to 80% drug load, but some phase heterogeneity detected at 90% drug load with PAA. 
Therefore, for ternary samples, a homogeneous domain size of < 3 nm and > 40 nm was 
estimated for samples up to 80% drug load and 90% drug load respectively. To 
summarize these results, no drastic differences were observed between the ternary and 
binary systems in terms of phase homogeneity. In addition, the results provide further 
insight into molecular level mixing on a smaller scale of resolution than DSC. 
 
Figure 5.18. 15N CPMAS SSNMR spectra of (A) amorphous KET, (B) 80:20 KET:PAA 
binary dispersion and (C) 80:10:10 KET:PAA:HPMC ternary dispersion.  
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Figure 5.19. Comparison of 1HT1 (plots A, C, E) and 
1HT1ρ (plots B, D and F) for drug 
and polymer(s) components. The relaxation times for KET, PAA, HPMC are shown in 
black, orange and blue bars respectively. Plots A, C and E belong to 1HT1 relaxation 
times for binary KET:PAA system, binary KET:HPMC system and ternary 
KET:PAA:HPMC system respectively. Plots B, D and F belong to 1HT1ρ relaxation times 
for binary KET:PAA system, binary KET:HPMC system and ternary KET:PAA:HPMC 
system respectively. 
 
Table 5.1. Proton relaxation times of as received and amorphous KET along with 
polymers PAA and HPMC. 
 
Proton 
Relaxation 
Time 
Ketoconazole Polymers 
As received Amorphous PAA HPMC 
T
1
 (s) 13.88±0.11 5.32±0.24 1.45±0.04 1.35±0.02 
T
1ρ
 (ms) 52.71±0.76 4.30±0.07 8.58±0.07 12.53±0.10 
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5.3.5 Physical Stability 
Physical stability of the 70:30 composition from each system was evaluated at 
two different conditions, RT/94% RH and 40 °C/75% RH for up to six months. PXRD 
was used to determine the point of initial crystallization. PXRD patterns of the binary and 
ternary ASDs stored at RT/94% RH are shown in Figure 5.20 (plots A, B and C) for a 
period of 6 months. The binary system with HPMC crystallized the fastest, displaying 
signs of crystallization at the 1 week time point. In contrast, the binary system with PAA 
remained physically stable at RT/94% RH over a period of 6 months with no signs of 
crystallization. However, the composition of ternary system was shown to perform 
robustly at these conditions for up to 2 months, when it started to show early signs of 
crystallization, and crystallized thereafter.  
The plots of PXRD data for binary and ternary ASDs at 40 °C/75% RH are 
illustrated in Figure 5.20 (plots D, E and F). At 40 °C/75% RH, the binary dispersion 
with HPMC again crystallized the fastest with crystallization being detected from 1 week 
onwards. Very interestingly, the binary dispersion with PAA and the ternary dispersion 
retained their amorphous state throughout the period of 6 months, with no diffraction 
peaks being visible at this condition. This finding suggested that replacing 50% of 
HPMC with PAA in the binary composition could significantly improve the physical 
stability. 
From the stability analysis, it was revealed that HPMC did not alone inhibit 
crystallization at both conditions. This could be explained by lack of any specific 
interactions within the system, which made this binary system the most susceptible to 
crystallization. Also, we found that HPMC was not as effective as PAA in increasing the 
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Tg of the ASDs, which also contributed towards poor stability of this binary system at 
both conditions. As compared with the HPMC binary system, the PAA binary system did 
outperform in terms of rendering the system physically stable at both conditions. This 
behavior of PAA is consistent with the ability of PAA to form stronger interactions with 
KET and higher enhancement in the Tg. Even though PAA is more hygroscopic than 
HPMC, that did not result in crystallization. Similarly, Weuts et al. found that PAA 
could maintain loperamide in the amorphous state and give a stable dissolution profile at 
different storage conditions.31 In the case of ternary dispersions samples, adding HPMC 
did not disrupt KET:PAA interactions drastically nor cause any significant reduction in 
Tg as revealed from the DSC study. Our detailed SSNMR comparison of binary PAA 
system and ternary system did reveal that there are some differences in how these two 
systems interact on a molecular level. It is clear that the 70:30 ternary dispersion had less 
ionic and H-bonding interactions than the counterpart binary system, and this explains 
the somewhat poor performance, particularly at RT/94% RH. Otherwise, those 
disparities still translated to better physical stability in comparison with binary HPMC 
system. 
Our results are very encouraging in a way that they provide support for the use of 
binary polymer combinations to optimize the performance of ASDs. We have now shown 
using HPMC alone as a matrix could result in poor physical stability but using a binary 
combination of PAA and HPMC could help achieve a desired level of physical stability. 
From dissolution point of view, we have seen from reports in literature that by 
incorporating a cellulosic polymer in the system could help prolong supersaturation.44 
Hence, this combination of PAA and HPMC could potentially give a balanced dissolution 
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profile with better physical stability. This aspect is something that we are currently 
exploring. We also have to keep in mind that the approach of combining polymers might 
not always works as shown by Meng et al.45 The authors reported that the ternary 
dispersion of itraconazole with carbopol and povidone demonstrated poor physical 
stability and drug release behavior when compared to individual polymer based binary 
dispersions. Nonetheless, ternary ASDs require a detailed solid-state characterization 
from a molecular perspective to select polymer combinations rationally in order to 
optimize the overall performance. 
 
Figure 5.20. PXRD patterns of stability binary and ternary dispersions for (A) KET:PAA 
(B) KET:HPMC and (C) KET:PAA:HPMC stored at RT/94% RH. The plots of stability 
samples stored at 40 °C/75% RH are shown in (D) KET:PAA (E) KET:HPMC and (F) 
KET:PAA:HPMC. Crystalline KET is included as a reference. 
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5.4 Conclusions 
In current study, we have evaluated the molecular interaction patterns in binary 
and ternary ASDs of KET using various solid-state characterization techniques. From 
DSC analysis, a large positive deviation was observed for KET:PAA binary and 
KET:PAA:HPMC ternary systems, whereas KET:HPMC binary system showed negative 
deviation. Our spectroscopic data from FTIR and 13C SSNMR showed that PAA 
interacted with KET via ionic and hydrogen bonding interactions both in binary and 
ternary ASDs. Moreover, spectral evidence can be found for lack of any specific 
interactions between KET and HPMC. The results from 15N SSNMR analysis further 
provided evidence for an ionic interaction between KET and PAA. Through a detailed 
13C SSNMR deconvolution study, it was established that the binary KET:PAA system 
had a higher prevalence of ionic and hydrogen bonds than the ternary KET:PAA:HPMC 
system. This serves as one successful example of establishing a comparison between the 
binary and ternary ASDs from a molecular perspective. ASDs were found to be 
homogenous on a nanometric level using proton relaxation measurements for both the 
binary and ternary systems. A stronger interaction in binary KET:PAA and ternary 
KET:PAA:HPMC systems translated to better stability at different storage conditions. In 
summary, this study also established a proof of concept for the approach of combining a 
second interacting polymer to a non-interacting drug-polymer matrix to achieve better 
physical stability. We believe our results are valuable contribution to the growing field of 
ternary ASDs, and provide a better understanding of how to design ternary ASDs with 
optimum performance. 
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CHAPTER 6. IMPACT OF HPMCAS GRADE ON PHASE BEHAVIOR OF ITRACONAZOLE 
SOLID DISPERSIONS: EFFECT OF PREPARATION METHOD  
6.1 Introduction 
In this chapter, we will discuss the role of different grades of hydroxypropyl 
methylcellulose acetate succinate (HPMCAS) on the phase behavior of itraconazole 
(ITZ) dispersions. In recent years, HPMCAS has been identified as one of the most 
effective cellulose based polymers especially for manufacturing spray dried dispersions 
(SDDs).1,2 HPMCAS has some unique characteristics that makes it amenable for spray 
drying process.3 They are listed below: 
(1) It possesses a high Tg in its unionized state. The high Tg reduces the drug mobility 
and results in excellent physical stability of HPMCAS based dispersions. 
(2) It has good solubility in volatile organic solvents like acetone and methanol, 
thereby permitting economical and controllable processing for manufacturing 
SDDs. 
(3) At any pH above 5, the polymer becomes at least partially ionized, which causes 
the charge to develop and minimizes the formation of large polymer aggregates 
and stabilizes the drug-polymer colloids.  
(4) Its amphiphilic nature permits poorly water-soluble drugs to interact with the 
hydrophobic regions while the hydrophilic region allows these structures to 
remain as stable colloids in aqueous medium. 
Commercially, HPMCAS is available in three grades, designated as –L, -M, and 
–H as listed in Table 6.1. These grades have different percentages of substituents: 
methoxy, hydroxypropoxyl, acetate and succinate. Spray drying is a conventional 
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method for the preparation of amorphous solid dispersions, but from a practical 
standpoint, it is best to have techniques that can be used to predict the properties of the 
spray-dried dispersion prior to the actual spray drying process.4 Recently, cast films have 
been explored to anticipate the feasibility of samples prepared using methods such as 
spray drying and hot melt extrusion.5,6 For instance, Durante et al. employed a predictive 
model to estimate the miscibility of ITZ with different polymers for cast films and 
SDDs.7 In this study, the authors could rank order the polymers (Eudragit 
EPO<<PVP/VA< HPMCAS-MG) in terms of miscibility and their results reflected the 
same trends between films and SDDs. In this study, the utility of films have been 
investigated for a model system consisting of ITZ and different grades of HPMCAS in 
order to anticipate the viability of large-scale processes such as spray drying. This study 
was a collaborative effort between the Munson group and Prof. Polli’s group at 
University of Maryland. The film and spray dried samples were prepared at University of 
Maryland, whereas detailed solid-state characterization was performed at University of 
Kentucky, with a special focus on SSNMR spectroscopy. 
The first objective of this chapter was to assess the impact of different grades of 
HPMCAS on the phase behavior of ITZ dispersions. Secondly, the role of preparation 
method on the phase mixing of the drug with polymer was also evaluated. In addition, 
long-term accelerated stability studies (40 °C/75 % RH) were conducted to evaluate the 
physical stability of film and spray dried samples. Only the results gathered at University 
of Kentucky are presented here. Chemical structures are shown in Figure 6.1. 
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6.2 Experimental 
6.2.1 Preparation Method 
Preparation of Amorphous Itraconazole. Amorphous ITZ was prepared by in 
situ by melt quenching inside the spinning NMR rotor. Sample was packed into 7.5 mm 
zirconia rotors with Teflon or Kel-F end caps (Revolution NMR, LLC., Fort Collins, 
CO). The rotor was heated in the NMR probe equipped with a variable-temperature 
accessory stack (Varian, Palo Alto, CA) at 175 ˚C for approximately 10 min while 
spinning at 4 kHz. The rotor was then rapidly cooled to room temperature to generate 
amorphous ITZ. 
Preparation of film samples. HPMCAS films were cast by dissolving each of 
the three grades of HPMCAS in a 2:1 (w/w) mixture of dichloromethane and methanol. 
ITZ was then added to the solutions to constitute 10, 20 and 30% (w/w) of the total solid 
content in the solution. The total solid concentration in the final solutions was kept at 
10% (w/w). Solutions were then poured into round 50 mL aluminum pans (121 mm 
diameter x 5 mm height) at 50 g per pan and evaporated for 45 min. The pans were 
transferred to a drying oven and dried at 40 °C for over 12 hr. The film samples were 
then stored in a desiccating cabinet (RH < 5%) and subsequently milled into flakes by 
trituration. 
Preparation of Spray dried samples. Spray drying was performed using a 
Buchi B-290 spray dryer (Buchi Corporation; New Castle, DE) in the closed-loop mode. 
Solutions identical to those used for film casting were pumped into the atomizer at a rate 
of 16 g/min. The inlet and outlet temperatures were 100 °C and 56 °C, respectively. 
Spray drying process parameters (i.e. inlet temperature, percent solids, pump rate, 
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atomizing gas pressure) had been previously examined to yield above methods. The 
spray dried powder (i.e. SDDs) were collected and dried for an additional 12 hr at 40 °C 
and stored in a desiccating cabinet (RH < 5%). 
6.2.2 Solid-State NMR Spectroscopy 
13C SSNMR spectra were acquired using a Tecmag Redstone spectrometer 
(Tecmag Inc., Houston, TX) operating at approximately 300 MHz for 1H and 75 MHz 
for 13C. Samples were packed into 7.5 mm zirconia rotors and sealed with Teflon or Kel-
F end-caps (Revolution NMR LLC. Fort Collins, CO). One dimensional 13C spectra were 
acquired using cross polarization magic angle spinning (CP/MAS) at 4 kHz, using total 
sideband suppression (TOSS)8 and SPINAL649 decoupling. The 1H 90˚ pulse width was 
set to 4.5 μs and contact time of 1.5 ms was used in all the measurements. The pulse 
delay for 1D experiments was 4 s and a total of 4096 scans were collected. The 13C 
chemical shift scale was referenced with the methyl peak of 3-methylglutaric acid, which 
was set to 18.84 ppm.10 
The maximum peak intensity for the chemical shift regions selective to ITZ and 
HPMCAS resonances were used to obtain relaxation times (details in Results and 
Discussion section). The relaxation times were detected via 13C nucleus, which facilitates 
identification of regions for respective components. Proton spin-lattice relaxation time in 
the laboratory frame (1H T1) were measured using a 
13C-detected saturation recovery 
pulse sequence with TOSS. Relaxation times were obtained by fitting intensity-recovery 
time data by the following equation: 
 
𝑀(𝑡) = 𝑀0(1 − 𝑒
−
𝑡
𝑇1) 
(6.1) 
 
 
178 
where M(t) is the peak intensity at delay time t, M0 is an amplitude parameter from the 
fit, and T1 is the obtained spin-lattice relaxation time. Proton relaxation times in the 
rotating frame (1H T1ρ) were measured by varying the spin lock duration time after a 90˚ 
pulse. The T1ρ decay times were obtained by analyzing the integrated carbon signal 
intensity exponentially according to the following equation: 
 
𝑀(𝑡) = 𝑀0𝑒
−
𝑡
𝑇1𝜌 
(6.2) 
 
where M(t) is the peak intensity and t is the spin-lock duration time. M0 is an amplitude 
parameter from the fit, and T1ρ is the fitted spin-lattice relaxation time in the rotating 
frame. All data fitting was done using GraphPad Prism (GraphPad Software, Inc., La 
Jolla, CA). 
6.2.3 Powder X-ray Diffraction 
PXRD patterns were collected on the Rigaku Miniflex 600 benchtop 
diffractometer (Rigaku Corporation, Tokyo, Japan), with Cu Kα radiation (40 kV x 15 
mA). The experiments were conducted at room temperature, between 2° to 50° 2θ at a 
scan speed of 2.0 °/min and a step size of 0.02° 2θ under continuous mode. 
6.2.4 Vapor Sorption 
Moisture sorption isotherms of pure components and dispersions were measured 
by an automated water sorption analyser (Q5000SA, TA instruments, New Castle, DE). 
The neat samples were initially dried at 0% relative humidity (RH) at 25 °C for 180 min 
with equilibrium criterion of < 0.001% w/w change for 15 min. The samples were then 
exposed to different RH conditions from 10 to 90% at 25 °C with 10% step increase. The 
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maximum dwell time of 180 min was used with the same equilibrium criterion. The 
dispersion samples were subjected to constant RH of 75% at 40 °C until equilibrated 
after initial drying at 0% RH with a dm/dt window of weight change % < 0.001 over 15 
min. 
6.3 Results and Discussion 
6.3.1 13C CP/MAS Solid-state NMR Spectra 
The 13C CP/MAS spectra of as-received ITZ and amorphous ITZ are shown in 
Figure 6.2. The crystalline ITZ could be easily distinguished from amorphous ITZ based 
on sharp and narrow resonances seen in the 13C spectra. The amorphous form is 
characterized by broader signals characteristic of disordered state. The peak at 152 ppm 
corresponds to the carbonyl group (C=O) in the amorphous ITZ. The 13C CP/MAS 
spectra for the polymers are displayed in Figure 6.2. All the three grades of HPMCAS 
were found to be amorphous. The HPMCAS grades were devoid of aromatic resonances 
as shown in Figure 6.2. It is interesting to note the differences in peak shapes for 
different grades of HPMCAS in the carbonyl region (160-180 ppm). Upon deconvolution 
of the region, the area could be resolved into two peaks (~173 ppm and ~170 ppm). 
These two peaks correspond to succinate and acetate ester functionalities, respectively, 
although it should be noted that the succinate moiety has an equal contribution to 
succinate and acetate peak, due to its partial ester structure. The analysis also yielded 
respective percentages of these moieties as displayed in Figure 6.3. L grade has the 
highest succinate to acetate ratio among three grades, which explains why the carbonyl 
peak is apparently the most downfield in L grade. The other aliphatic resonances were 
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measured to be similar in ppm in all the three grades, although the peak at ~28 ppm is 
due to the succinate component, and its intensity changes with succinate concentration. 
The dispersions samples were prepared via two approaches: rotary evaporation 
and spray drying. The samples obtained from rotary evaporation were termed “film” 
samples. The 13C CP/MAS spectra of film samples formulated with HPMCAS grades are 
shown in Figure 6.4. For the spectra of dispersions with HPMCAS, samples up to 20% 
drug loading were amorphous in nature whereas the samples with 30% ITZ showed the 
presence of some amount of residual crystallinity. The degree of crystallinity could be 
quantified for different grades of HPMCAS. The region between 90-115 ppm was 
deconvoluted and the peak at 109 ppm was attributed to the crystalline ITZ fraction. The 
degree of crystallinity was calculated using following equation: 
 
∅𝐼𝑇𝑍 = 100 ∗
𝑃109
𝑃′109
 
(6.3) 
 
where P109 is the peak intensity for 109 ppm signal in the sample and P’109 is the peak 
intensity of 109 ppm signal of pure crystalline ITZ. The degree of crystallinity was rank 
ordered as H>M>L (Table 6.3; initial condition). Thus, the highest crystallinity was 
associated with H grade. And, the same trend was seen from DSC analysis (data not 
shown). In the case of the spray-dried samples, it was evident from Figure 6.5 that 
samples were completely amorphous for all the drug loadings. The spray-dried 
dispersions were better than the film samples in this regard, as they were devoid of any 
residual crystallinity. The spray drying process is generally regarded as more efficient in 
rendering the samples amorphous than the rotary evaporation as it ensures better mixing 
of the drug and polymer. 
 
 
181 
Three regions between resonances 9-14 ppm, 45-55 ppm and 111-159 ppm were 
selective for ITZ (shown in pink shaded boxes in Figures 6.4 and 6.5), while two regions 
between peaks 80-90 ppm and 160-180 ppm served as non-overlapping areas for 
HPMCAS (shown in green shaded boxes in Figures 6.4 and 6.5). These selective regions 
were used in proton relaxation measurements to follow the relaxation behavior of ITZ 
and HPMCAS in the samples (vide infra). In addition, any variation in chemical shift for 
any peak in the spectra was also noted. HPMCAS has proton donors and acceptors in its 
structure whereas ITZ has proton acceptors (Figure 6.1). Therefore, there is a likelihood 
of hydrogen bond formation between the respective donors and acceptor functionalities 
in the drug and polymer. It has been observed that any change in chemical shifts could 
potentially result from H-bonding.11 The carbonyl region of HPMCAS did not show any 
significant changes for both film and spray dried samples. In addition, any variation in 
the carbonyl peak (~152 ppm) of ITZ was difficult to detect due to presence of multiple 
peaks in the same region. Therefore, no direct evidence of hydrogen bonding or any 
specific interaction could be obtained from the 13C CP/MAS spectra.  
Table 6.1. Composition of different grades of HPMCAS (wt %). 
Substituent 
HPMCAS 
L Grade M Grade H Grade 
Methoxyl Content  20-24 21-25 22-26 
Hydroxypropoxyl 
Content 
5-9 5-9 6-10 
Acetyl Content 5-9 7-11 10-14 
Succinoyl Content 14-18 10-14 4-8 
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Figure 6.1. Chemical structures of itraconazole (left) and HPMCAS (right). 
 
 
Figure 6.2. SSNMR spectra from bottom to top include crystalline ITZ, amorphous ITZ 
and HPMCAS grades-H, L and M. 
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Figure 6.3. Deconvolution of the carbonyl region (160-180 ppm) in SSNMR spectra for 
HPMCAS grades. The fitting of succinate and acetate peaks is shown in black and blue 
respectively; the sum of the species is shown in magenta; the residual difference between 
the experimental and fitted peaks is shown in orange. 
 
 
 
 
 
 
 
 
 
 
 
 
 
184 
 
 
 
Figure 6.4. Stacked 13C CP/MAS spectra for ITZ film samples formulated with (A) 
HPMCAS H grade, (B) HPMCAS L grade and (C) HPMCAS M grade. Green and pink 
shaded boxes represent HPMCAS and ITZ specific regions respectively.  
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Figure 6.5. Stacked 13C CP/MAS spectra for ITZ spray dried dispersion samples 
formulated with (A) HPMCAS H grade, (B) HPMCAS L grade and (C) HPMCAS M 
grade. Green and pink shaded boxes represent HPMCAS and ITZ specific regions 
respectively. 
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6.3.2 Phase Homogeneity Using Proton Relaxation Measurements 
In order to understand phase mixing on a nanometric scale, proton relaxation 
measurements were employed, which consisted of measuring spin-lattice relaxation 
times in the laboratory frame 1H T1, and in the rotating frame 
1H T1ρ. The relaxation 
behavior of ITZ and HPMCAS was resolved via 13C resonances. These parameters can 
provide valuable insights regarding the phase mixing between the drug and the polymer 
on two different length scales of mixing. The relaxation time constants 1H T1 and 
1H T1ρ 
are sensitive to motions in MHz range and kHz range, respectively. Because the 1H T1 
times are 2-3 orders of magnitude longer than 1H T1ρ times, 
1H T1 is averaged out to 
larger distances (20-50 nm) than 1H T1ρ (2-5 nm). The relaxation times of pure materials 
are shown in Table 6.2. Generally, amorphous materials show shorter 1H T1 and 
1H T1ρ 
relaxation times in comparison to their crystalline counterparts owing to greater mobility. 
In the case of ITZ, the amorphous sample is characterized by shorter 1H T1 time whereas 
the opposite behavior is seen for 1H T1ρ. For HPMCAS grades, 
1H T1 times were 
measured to be less than 2 s. It is interesting to note that 1H T1ρ time was measured 
longest for the H grade. Meanwhile, both L and M grade showed almost identical 1H T1ρ 
times. Greater differences were observed in 1H T1ρ times between amorphous ITZ and 
HPMCAS. 
Dispersion samples showed differences in relaxation time of ITZ and HPMCAS, 
corresponding to some degree of phase heterogeneity between the drug and the polymer. 
For a perfectly homogenous system, drug and polymer would show identical relaxation 
times. Therefore, any differences observed in the relaxation behavior of the drug and 
polymer would result from phase heterogeneity or non-uniform distribution of drug and 
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polymer in the matrix. The plots of 1H T1 differential between ITZ and different grades 
of HPMCAS are shown in Figure 6.6 for the film and spray dried samples. It is evident 
from the Figure 6.6 (Plot A) that no significant differences were seen up to 20% ITZ 
loading, whereas the sample with 30% loading started to show some differences, 
resulting in a larger differential value for the film samples. The extent of phase 
heterogeneity on 1H T1 scale of mixing could be ranked ordered as H>M>L. However, 
for the spray-dried samples no such trend could be seen for any drug loading, and all the 
samples were found to be homogenous on 1H T1 scale of mixing (Plot B). The plots of 
1H T1ρ differential between ITZ and different grades of HPMCAS are displayed in Figure 
6.7 for film and spray dried samples. On smaller domains (Plot A), the film samples 
were clearly phase non homogeneous at 30% drug loading, and same extent of phase 
separation was observed (H>M>L). In contrast, the spray dried samples (Plot B) were 
completely phase mixed showing no differences in differential values within 95% 
confidence intervals.  
In summary, the film samples were homogenous up to 20% drug loading, 
whereas 30% sample showed signs of phase hetereogeneity on both the domains. In the 
case of 30% ITZ sample, the extent of phase heterogeneity was found to be different for 
different grades of HPMCAS (L grade being best). This is also supported from the 
residual crystallinity analysis. It was shown that better mixing between ITZ and 
HPMCAS could be established through spray drying. And, all the three grades exhibited 
similar performance for spray dried samples and no phase heterogeneity was seen. 
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6.3.3 Determination of Domain Sizes 
Proton relaxation measurements can also be used to estimate the upper limit of 
the length scale of mixing because these processes are governed by spin diffusion. The 
equation used to obtain semi quantitative information about domain size is given by: 
 𝐿2 = 6𝐷𝑇𝑖 (6.4) 
 
where D is the spin diffusion coefficient, which depends on the average proton to proton 
distance as well as a dipolar interaction. It has a typical value of 10-12 cm2/s.12,13 Ti is the 
relaxation time, T1 or T1ρ. Using this approach, the domains sizes were estimated to be < 
3 nm for all the samples except 30% ITZ film samples. In the case of 30% ITZ film 
samples, domain sizes were estimated be >30 nm, 2-30 nm and >30 nm for H, L and M 
grades respectively. These samples were known to show some degree of phase 
heterogeneity and hence their larger domain sizes. 
 
Table 6.2. 1H T1 and T1ρ values along with the standard errors associated with fit for ITZ 
(as-received and amorphous) and HPMCAS grades measured via 13C resonances. 
Proton 
Relaxation 
Time 
Itraconazole Polymers 
As received Amorphous H Grade L Grade M Grade 
1H T
1
 (s) 3.34±0.08 1.57±0.02 1.76±0.07 1.93±0.05 1.80±0.04 
1H T
1ρ
 (ms) 2.88±0.07 3.65±0.05 7.63±0.19 5.99±0.10 5.97±0.25 
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Figure 6.6. Absolute difference in 1H T1 values between ITZ and HPMCAS grades for 
A) film and B) spray dried samples as a function of ITZ weight percent. The error bars 
represent the 95% confidence interval associated with the fit. The dashed line signifies 
the zero difference line. The green, red and blue diamond symbols represent HPMCAS 
H, L and M grades respectively.  
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Figure 6.7. Absolute difference in 1H T1ρ values between ITZ and HPMCAS grades for 
A) film and B) spray dried samples as a function of ITZ weight percent. The error bars 
represent the 95% confidence interval associated with the fit. The dashed line signifies 
the zero difference line. The green, red and blue diamond symbols represent HPMCAS 
H, L and M grades respectively.  
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6.3.4 Physical Stability 
The physical stability of amorphous materials is very important because of their 
propensity to crystallize. It is therefore common to study the behavior of ASDs at 
accelerated stability conditions wherein the role of humidity and elevated temperature is 
evaluated. The stability study was carried out for the 30% ITZ loading (film and spray 
dried samples) at 40 °C/75% RH in open vials for a period of 6 months, and the samples 
were examined via SSNMR and PXRD. PXRD data showed no change in spray-dried 
samples over time (Figure 6.8). The spray-dried samples remained amorphous up to 6 
months, with no detection of crystallinity for all of the grades of HPMCAS. It is also 
noteworthy to point that SSNMR analysis of spray-dried samples revealed the same 
trend. No changes were observed in the 13C CPMAS spectra of the spray-dried samples 
(Figure 6.9). The 1H T1 and 
1H T1ρ relaxation data indicated that stability spray-dried 
samples did not phase separate over time at these conditions, and there was no significant 
change in the differential values of the relaxation times (Figure 6.10). In the case of film 
stability samples, no further crystallization was observed by qualitative analysis from 
PXRD (Figure 6.11). Also, 13C CP/MAS spectra of stability samples did not reveal any 
new crystalline peaks except for the previously reported peak at ~109 ppm (Figure 6.12). 
In addition, it is surprising to observe that there was reduction in measured apparent 
crystallinity over time for these samples as calculated by SSNMR (Table 6.3). This kind 
of behavior is counterintuitive, as it is known that moisture can promote phase separation 
and/or crystallization in amorphous materials.14 At this point, we can speculate that this 
trend can result from changes induced by RH equilibrated samples in SSNMR spectra. 
Nonetheless, this needs further investigation to ascertain if this behavior is real or not. 
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The relaxation data also suggest no further phase separation took place and the 
differential values for both 1H T1 and 
1H T1ρ did not change drastically over a period of 6 
months (Figure 6.13). Both the systems were found to be robust at these conditions. 
From the isothermal moisture sorption experiments, it can be seen that pure 
HPMCAS grades did not absorb a significant amount of moisture, and maximum % 
weight again was under 10% at the highest RH (Figure 6.14). The polymers could be 
rank ordered for hygroscopicity from highest to lowest moisture being L>M>H. H grade 
has highest acetate/succinate ratio, which makes it the most hydrophobic in the series. In 
addition, amorphous ITZ was very hydrophobic, with less than 2% water absorbed at 
90% RH. The moisture uptake by stability samples was under 3% from TGA analysis for 
all the time points (data not shown). HPMCAS has a high Tg under dry conditions. The 
Tg values of as prepared samples with 30% drug loading were measured to be above 100 
°C (data not shown). When exposed to higher RH conditions, there is smaller decrease in 
Tg of HPMCAS when compared to typical water-soluble polymers owning to its 
hydrophobic nature and therefore less moisture uptake. As a result, the stability samples 
still had Tg values well above the storage temperature of 40 °C (data not shown). Overall, 
drug mobility remains low, which in part explains why the samples exhibited long-term 
kinetic physical stability under standard accelerated stability conditions. Similar results 
were observed in a study done by Chakravarty et al.15 Their results pointed out that the 
long-term physical stability could be achieved using HPMCAS as the polymeric matrix 
for spray dried dispersions.  
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6.4 Conclusions 
In this study, a detailed SSNMR characterization was conducted on ITZ film and 
spray dried samples. SSNMR analysis revealed that spray drying resulted in intimate 
mixing between ITZ and HPMCAS. The film samples were found to contain residual 
crystallinity at 30% drug load. In addition, the extent of phase heterogeneity was found 
to be HPMCAS grade dependent (H>M>L). The stability data suggested that the 
components of both sets of dispersions remain phase mixed as studied by proton 
relaxation times. Overall, this characterization study is important in understanding the 
performance of different grades of HPMCAS and how the method of preparation can 
dictate kinetic mixing between the components for rational development of ASDs. 
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Figure 6.8. PXRD patterns of stability spray dried samples at 40 °C/75% RH for (A) H 
Grade (B) L Grade and (C) M Grade. 
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Figure 6.9. Stacked plots for SSNMR spectra of crystalline ITZ, amorphous ITZ and 
spray dried stability samples at 40 °C/75 % RH for (A) H grade (B) L grade and (C) M 
grade. 
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Figure 6.10. Absolute difference in 1H T1 (plots (A-C); green bars) and 
1H T1ρ (plots (D-
E); blue bars) values between ITZ and HPMCAS spray dried stability samples (40 °C/75 
% RH) for a period of 6 months. The error bars represent the 95% confidence interval 
associated with the fit. 
 
Table 6.3. Comparison of percent crystallinity for different time periods for 30% ITZ 
film stability sample (40 °C/75 %RH) as measured by SSNMR. 
Time H Grade M Grade L Grade 
Initial 22.7 15.4 12.0 
3 Months 15.1 11.2 9.2 
6 Months 16.0 11.0 7.7 
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Figure 6.11. PXRD patterns of stability film samples at 40 °C/75% RH for (A) H Grade 
(B) L Grade and (C) M Grade. 
 
 
198 
 
 
 
Figure 6.12. Stacked plots for SSNMR spectra of crystalline ITZ, amorphous ITZ and 
film samples at 40 °C/75 % RH for (A) H grade (B) L grade and (C) M grade. 
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Figure 6.13. Absolute difference in 1H T1 (plots (A-C); green bars) and 
1H T1ρ (plots (D-
E); blue bars) values between ITZ and HPMCAS film stability samples (40 °C/75 % RH) 
for a period of 6 months. The error bars represent the 95% confidence interval associated 
with the fit.  
 
 
Figure 6.14. Moisture sorption isotherms of ITZ, amorphous ITZ and HPMCAS grades. 
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CHAPTER 7.  SUMMARY AND FUTURE DIRECTIONS 
7.1 Summary 
The central theme of this thesis research revolves around understanding the phase 
homogeneity in ASDs. Throughout this thesis work, phase homogeneity and drug-
polymer interactions were studied using SSNMR spectroscopy and other analytical 
techniques. Various model systems were evaluated to gain molecular level understanding 
of the factors controlling phase homogeneity and the physical stability of ASDs. As a 
first step in Chapter 1, we provided the literature survey on the classification of ASDs, 
the preparation methods, the solid-state characterization techniques, and the factors 
affecting physical stability. Chapter 2 was aimed at providing the basic understanding of 
SSNMR principles along with its advantages and limitations. Various experimental 
features like cross polarization (CP), magic angle spinning (MAS) and high power 
proton decoupling were presented. Special attention was given to the applications of 
SSNMR spectroscopy in the field of ASDs. The applicability of proton relaxation times 
(1H T1 and 
1H T1ρ) in evaluating sub nanometric phase homogeneity and their advantages 
over thermal analysis were highlighted. In addition, the usefulness of SSNMR for 
understanding the type, extent and strength of intermolecular drug-polymer interactions 
was discussed. 
Chapter 3 presented a case study on the role of hydrogen bonding on the phase 
homogeneity of felodipine melt quenched dispersions with three different polymers, 
PVP, PVP/VA and PVAc. In the first part of the study, a comparative assessment of 
phase homogeneity involving DSC and SSNMR analyses was conducted on the model 
systems. In the second part of the study, the strength and extent hydrogen bonding 
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interactions were quantified using SSNMR 13C CP/MAS spectra. Using a new approach, 
it was possible to quantify various species present in amorphous felodipine and its 
dispersions without the need of doing 15N SSNMR based experiments. More precisely, in 
amorphous felodipine 40% and 60% of molecules were categorized as “dimer” and 
“free” respectively. It was shown that polymers capable of forming hydrogen bonding 
interactions disrupted the existing drug-drug interactions resulting in drug-polymer 
hydrogen bonding interactions. The strength and extent of hydrogen bonding interactions 
were rank ordered as PVP>PVP/VA>PVAc. Our results suggested that the phase 
homogeneity was governed by the strength and extent of hydrogen bonding between the 
drug-polymer. Moreover, it was demonstrated how SSNMR was useful in understanding 
and characterizing the presence of nano heterogeneities.  
It is crucial to understand the thermodynamic miscibility between the drug and 
polymer to formulate a stable ASD system. We therefore thoroughly investigated and 
compared the relationship between thermodynamic miscibility and phase homogeneity in 
two structurally similar molecules, felodipine and nifedipine in Chapter 4. Soluplus was 
selected as a model polymer. The melting point depression approach was used to 
estimate the Flory-Huggins interaction parameter for the two systems understudy. Our 
analysis revealed that nifedipine had higher miscibility with Soluplus, when compared to 
felodipine. A similar analysis of hydrogen bonding interactions was performed on both 
the systems, where tendencies of felodipine and nifedipine to interact with Soluplus were 
compared. It was found that nifedipine was more extensively hydrogen bonded to 
Soluplus than felodipine, while both the drugs had a similar strength of hydrogen 
bonding interaction. Following the insight into the phase homogeneity of both the 
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systems, it was shown that nano domains existed within both the systems with felodipine 
dispersions slightly more heterogeneous.  
Conventionally, ASDs have been formulated as a binary matrix but in recent 
years a new class of ASDs have emerged, where generally a second polymer is added to 
the formulation. Having the presence of a second polymer necessitates a comprehensive 
solid-state characterization in order to study the intermolecular interactions and phase 
behavior on a molecular level. With this goal in mind, ketoconazole was selected as a 
model drug and hydroxypropyl methyl cellulose (HPMC) and polyacrylic acid (PAA) 
were chosen as polymeric carriers. Binary ketoconazole dispersions with HPMC lacked 
any specific interactions, whereas binary ketoconazole PAA dispersions and ternary 
ketoconazole PAA and HPMC showed spectroscopic evidence for ionic and hydrogen 
bonding interactions. The 13C SSNMR deconvolution study established a comparison for 
molecular interactions between the binary and ternary dispersions, with the binary 
ketoconazole PAA system showing higher prevalence of ionic and hydrogen bonds than 
the ternary ketoconazole HPMC PAA system. Moreover, binary and ternary ASDs were 
found to be homogenous on a nanometric level, implying the presence of a second 
polymer did not impact the phase homogeneity. In addition, a stronger interaction in 
binary ketoconazole PAA and ternary ketoconazole HPMC PAA system translated to 
better physical stability at different storage conditions. Overall, this study provided a 
detailed molecular level characterization of binary and ternary ASDs in order to design 
ASDs formulation with optimum performance. 
In Chapter 6, the impact of grade of hydroxypropyl methyl cellulose acetate 
succinate (HPMCAS) on the phase behavior of itraconazole dispersions was 
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investigated. The samples were prepared via different approaches: film casting versus 
spray drying. SSNMR analysis revealed substantial differences in the phase behavior of 
dispersions prepared by these two methods. For “film” samples, residual crystallinity 
was detected at drug loadings of > 20 % and found to be dependent on the HPMCAS 
grade, with H grade showing the highest crystallinity. Additionally, it was evident from 
the proton relaxation measurements that “film” samples were homogenous up to 20% 
itraconazole loading, whereas the sample with 30% itraconazole concentration started to 
show the presence of phase heterogeneity and its extent could be rank ordered as 
H>M>L. In contrast, the spray dried samples were amorphous and measured to be 
homogenous for all the drug loadings. Both “film” and spray dried samples were 
observed to be robust at accelerated stability conditions and did not show any further 
changes in phase homogeneity, implying that HPMCAS was efficient in decreasing drug 
mobility and keeping the drug kinetically stable. It was an important study to elucidate 
the phase behavior of different grades of HPMCAS along with the effect of preparation 
methods. 
7.2 Future Directions 
Throughout this dissertation, the proton relaxation measurements have been 
employed to study the phase homogeneity of ASDs on different model systems. Though 
such measurements have been proven to be quite useful, a detailed understanding and 
appreciation of the differences seen for different model compounds and carriers is much 
desired. Based on our experience working with different model systems, future studies 
should involve studying the various factors, which can potentially influence such 
measurements. It is worth giving a thought why do different APIs and polymers have 
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such different proton relaxation times? Besides, is it possible to relate the differences 
with some molecular properties? The proton relaxation measurements give a good 
estimation of upper limit of domain sizes. In Chapter 3, we have seen how domain sizes 
vary with the composition and polymer type. It was agreed that the extent of phase 
homogeneity is governed on the nature of hydrogen bonding between the drug and 
polymer. As a next logical step, it would be interesting to see some sort of correlation 
between the domain sizes and the onset of crystallization. Moreover, the impact of 
moisture on domain sizes could potentially be explored to predict the relative physical 
stability of ASDs. Usually, the domain sizes are reported to indicate the extent of phase 
homogeneity. Another relevant question is what is the real physical meaning of 
“domains” and how do they impact the overall phase behavior of ASDs. Moreover, the 
impact of moisture on domain sizes could potentially be explored to predict the relative 
physical stability of ASDs.  
Specific interactions like hydrogen bonding have been studied in depth through 
13C CP/MAS experiments in this thesis work. Some model systems showed the variation 
in chemical shifts as a response to the changes induced by hydrogen bonding (Chapter 3 
and 4), whereas systems involving HPMCAS didn’t directly reveal the presence of 
hydrogen bonding as seen in Chapter 7. In order to collect more evidence for specific 
interactions, two-dimensional experiments such as 1H-X CP/MAS HETCOR should also 
be explored. As a next step for the quantification hydrogen bonding in ASDs systems, it 
would be interesting to incorporate models like “Painter Coleman association model” 
and compare the SSNMR data to FTIR and Raman spectroscopy. Additionally, as an 
extension to the studies done in this thesis work, where compositions ranging from 50 % 
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to 90 % w/w drug were studied, it would be helpful to explore the other compositions as 
well.  
Ternary ASDs are new emerging field in ASDs research, where more scientific 
understanding is needed. Interestingly, we were able to present a detailed solid-state 
characterization and compared the physical stability of binary and ternary ASDs. 
However, the influence of a second polymer on dissolution characteristics needs further 
exploration. Moreover, it would also be interesting to develop any correlation between 
the phase homogeneity and dissolution characteristics. Finally, the study on ternary 
ASDs could be extended on other model drugs and polymer combinations. Along those 
lines, studying surfactants as a part of ternary ASDs could possibly open new avenues 
for research. 
 
 
 
 
REFERENCES  
Chapter 1 
(1) Buckley, S. T.; Fischer, S. M.; Fricker, G.; Brandl, M. Eur. J. Pharm. Sci. 2012, 45, 
235. 
(2) Bosselmann, S.; Williams III, R. O. Formulating Poorly Water Soluble Drugs, 
Springer: 2012. 
(3) Amidon, G. L.; Lennernäs, H.; Shah, V. P.; Crison, J. R. Pharm. Res. 1995, 12, 413. 
(4) Food; Administration, D. Food and Drug Administration, 2000. 
(5) Smithey, D.; Gao, P.; Taylor, L. AAPS News Magazine 2013, 16, 11. 
(6) Stegemann, S.; Leveiller, F.; Franchi, D.; De Jong, H.; Lindén, H. Eur. J. Pharm. Sci. 
2007, 31, 249. 
(7) Di, L.; Fish, P. V.; Mano, T. Drug Discovery Today 2012, 17, 486. 
(8) Ali, S.; Kolter, K. Am. Pharm. Rev., dec 2012. 
(9) Griffin, B. Am. Pharm. Rev 2012, 15. 
(10) Di, L.; Kerns, E. H.; Carter, G. T. Curr. Pharm. Des. 2009, 15, 2184. 
(11) Hörter, D.; Dressman, J. Adv. Drug. Delivery Rev. 2001, 46, 75. 
(12) Kawabata, Y.; Wada, K.; Nakatani, M.; Yamada, S.; Onoue, S. Int. J. Pharm. 2011, 
420, 1. 
(13) Kaushal, A. M.; Gupta, P.; Bansal, A. K. Crit. Rev. Ther. Drug Carrier Syst. 2004, 
21. 
(14) Van den Mooter, G. Drug Discovery Today: Technol. 2012, 9, e79. 
(15) Hancock, B. C.; Parks, M. Pharm. Res. 2000, 17, 397. 
(16) Huang, L.-F.; Tong, W.-Q. T. Adv. Drug. Delivery Rev. 2004, 56, 321. 
(17) Laitinen, R.; Löbmann, K.; Strachan, C. J.; Grohganz, H.; Rades, T. Int. J. Pharm. 
2013, 453, 65. 
(18) Serajuddin, A. T. M. J. Pharm. Sci. 1999, 88, 1058. 
(19) Vasconcelos, T.; Sarmento, B.; Costa, P. Drug Discovery Today 2007, 12, 1068. 
(20) Al-Obaidi, H.; Buckton, G. AAPS PharmSciTech 2009, 10, 1172. 
(21) Ito, A.; Watanabe, T.; Yada, S.; Hamaura, T.; Nakagami, H.; Higashi, K.; Moribe, 
K.; Yamamoto, K. Int. J. Pharm. 2010, 383, 18. 
(22) Hancock, B. C.; Zografi, G. J. Pharm. Sci 1997, 86, 1. 
 
 
207 
(23) W.Y. Lee, T.; A. Boersen, N.; Hui, H. W.; Chow, S. F.; Wan, K. Y.; H.L. Chow, A. 
Curr. Pharm. Des. 2014, 20, 303. 
(24) Bhattacharya, S.; Suryanarayanan, R. J. Pharm. Sci. 2009, 98, 2935. 
(25) Chiou, W. L.; Riegelman, S. J. Pharm. Sci. 1971, 60, 1281. 
(26) Sekiguchi, K.; Obi, N. Chem. Pharm. Bull. 1961, 9, 866. 
(27) Vo, C. L.-N.; Park, C.; Lee, B.-J. Eur. J. Pharm. Biopharm. 2013, 85, 799. 
(28) Patil, H.; Tiwari, R. V.; Repka, M. A. AAPS PharmSciTech 2016, 17, 20. 
(29) Crowley, M. M.; Zhang, F.; Repka, M. A.; Thumma, S.; Upadhye, S. B.; Kumar 
Battu, S.; McGinity, J. W.; Martin, C. Drug Dev. Ind. Pharm. 2007, 33, 909. 
(30) Brough, C.; Williams, R. Int. J. Pharm. 2013, 453, 157. 
(31) Ellenberger, D. J.; Miller, D. A.; Williams, R. O. AAPS PharmSciTech 2018, 19, 
1933. 
(32) Janssens, S.; De Zeure, A.; Paudel, A.; Van Humbeeck, J.; Rombaut, P.; Van den 
Mooter, G. Pharm. Res. 2010, 27, 775. 
(33) Paudel, A.; Worku, Z. A.; Meeus, J.; Guns, S.; Van den Mooter, G. Int. J. Pharm. 
2013, 453, 253. 
(34) Srinarong, P.; de Waard, H.; Frijlink, H. W.; Hinrichs, W. L. J. Expert. Opin. Drug 
Delivery 2011, 8, 1121. 
(35) Serajuddin, A. T. J. Pharm. Sci. 1999, 88, 1058. 
(36) Baird, J. A.; Taylor, L. S. Adv. Drug Delivery Rev. 2012, 64, 396. 
(37) Coleman, N. J.; Craig, D. Q. M. Int. J. Pharm. 1996, 135, 13. 
(38) Reading, M.; Luget, A.; Wilson, R. Thermochim. Acta 1994, 238, 295. 
(39) Knopp, M. M.; Löbmann, K.; Elder, D. P.; Rades, T.; Holm, R. Eur. J. Pharm. Sci. 
2016, 87, 164. 
(40) Newman, A.; Engers, D.; Bates, S.; Ivanisevic, I.; Kelly, R. C.; Zografi, G. J. 
Pharm. Sci 2008, 97, 4840. 
(41) Schneider, H. A. Makromol. Chem. 1988, 189, 1941. 
(42) Ford, J. L.; Mann, T. E. Adv. Drug. Delivery Rev. 2012, 64, 422. 
(43) Stodghill, S. P. Am. Pharm. Rev. 2010, 13, 29. 
(44) Bates, S.; Zografi, G.; Engers, D.; Morris, K.; Crowley, K.; Newman, A. Pharm. 
Res. 2006, 23, 2333. 
(45) Bøtker, J. P.; Karmwar, P.; Strachan, C. J.; Cornett, C.; Tian, F.; Zujovic, Z.; 
Rantanen, J.; Rades, T. Int. J. Pharm. 2011, 417, 112. 
 
 
208 
(46) Chauhan, A.; Chauhan, P. J. Anal. Bioanal. Tech. 2014, 5, 1. 
(47) Colthup, N.; Daly, L.; Wiberley, S.; Introduction to Infrared and Raman 
Spectroscopy, Academic Press: San Diego, 1990. 
(48) Jeffrey, G. A.; Jeffrey, G. A. An Introduction to Hydrogen Bonding, Oxford 
University Press: New York, 1997. 
(49) Lin, S.-Y.; Lin, H.-L.; Chi, Y.-T.; Huang, Y.-T.; Kao, C.-Y.; Hsieh, W.-H. Int. J. 
Pharm. 2015, 496, 457. 
(50) Weuts, I.; Van Dycke, F.; Voorspoels, J.; De Cort, S.; Stokbroekx, S.; Leemans, R.; 
Brewster, M. E.; Xu, D.; Segmuller, B.; Turner, Y. Z. A.; Roberts, C. J.; Davies, M. C.; 
Qi, S.; Craig, D. Q. M.; Reading, M. J. Pharm. Sci. 2011, 100, 260. 
(51) Coates, J.; Rintoul, L.; Fredericks, P. In Analytical Instrumentation Handbook, 3rd 
ed; CRC Press, 2004. 
(52) Févotte, G.; Calas, J.; Puel, F.; Hoff, C. Int. J. Pharm. 2004, 273, 159. 
(53) Vogt, F. G.; Williams, G. R. Pharm. Res. 2012, 29, 1866. 
(54) Padilla, A. M.; Chou, S. G.; Luthra, S.; Pikal, M. J. J. Pharm. Sci 2011, 100, 1362. 
(55) Brouwers, J.; Brewster, M. E.; Augustijns, P. J. Pharm. Sci 2009, 98, 2549. 
(56) Ruckenstein, E.; Djikaev, Y. S. Adv. Colloid Interface Sci. 2005, 118, 51. 
(57) Jungblut, S.; Dellago, C. Eur. Phys. J. E 2016, 39, 77. 
(58) Hoffman, J. D. J. Chem. Phys. 1958, 29, 1192. 
(59) Gerges, J.; Affouard, F. J. Phys. Chem. B 2015, 119, 10768. 
(60) Mullin, J.; Crystallization, Elsevier Science, 2001. 
(61) Schmelzer, J. W. P. J. Non-Cryst. Solids 2008, 354, 269. 
(62) Shah, N.; Sandhu, H.; Choi, D. S.; Chokshi, H.; Malick, A. W. Amorphous Solid 
Dispersions. Theory and Practice, Springer, 2014. 
(63) Janssens, S.; Van den Mooter, G. J. Pharm. Pharmacol. 2009, 61, 1571. 
(64) Yu, L. Adv. Drug. Delivery Rev. 2001, 48, 27. 
(65) Gordon, M.; Taylor, J. S. J. Appl. Chem. 1952, 2, 493. 
(66) Simha, R.; Boyer, R. J. Chem. Phys. 1962, 37, 1003. 
(67) Couchman, P.; Karasz, F. Macromolecules 1978, 11, 117. 
(68) Fox, T. G. Bull. Am. Phys. Soc. 1956, 1, 123. 
(69) Hancock, B. C.; Zografi, G. Pharm. Res. 1994, 11, 471. 
(70) Yang, Z.; Han, C. D. Macromolecules 2008, 41, 2104. 
 
 
209 
(71) Marsac, P. J.; Konno, H.; Taylor, L. S. Pharm. Res. 2006, 23, 2306. 
(72) Taylor, L. S.; Zografi, G. Pharm. Res. 1997, 14, 1691. 
(73) Gupta, P.; Thilagavathi, R.; Chakraborti, A. K.; Bansal, A. K. Mol. Pharmaceutics 
2005, 2, 384. 
(74) Matsumoto, T.; Zografi, G. Pharm. Res. 1999, 16, 1722. 
(75) Song, Y.; Zemlyanov, D.; Chen, X.; Nie, H.; Su, Z.; Fang, K.; Yang, X.; Smith, D.; 
Byrn, S.; Lubach, J. W. Mol. Pharmaceutics 2015, 13, 483. 
(76) Kestur, U. S.; Van Eerdenbrugh, B.; Taylor, L. S. CrystEngComm 2011, 13, 6712. 
(77) Rumondor, A. C. F.; Marsac, P. J.; Stanford, L. A.; Taylor, L. S. Mol. 
Pharmaceutics 2009, 6, 1492. 
(78) Marsac, P. J.; Shamblin, S. L.; Taylor, L. S. Pharm. Res. 2006, 23, 2417. 
(79) Flory, P. J. Principles of polymer chemistry 1953, 495. 
(80) Lin, D.; Huang, Y. Int. J. Pharm. 2010, 399, 109. 
(81) Tian, Y.; Booth, J.; Meehan, E.; Jones, D. S.; Li, S.; Andrews, G. P. Mol. 
Pharmaceutics 2013, 10, 236. 
(82) Newman, A. Pharmaceutical Amorphous Solid Dispersions, John Wiley & Sons, 
2015. 
Chapter 2 
(1) Mirau, P. A. J. Magn. Reson. 1992, 96, 480. 
(2) Tishmack, P. A.; Bugay, D. E.; Byrn, S. R. J. Pharm. Sci 2003, 92, 441. 
(3) Stoven, V.; Lallemand, J. Y.; Abergel, D.; Bouaziz, S.; Delsuc, M. A.; Ekondzi, A.; 
Guittet, E.; Laplante, S.; Le Goas, R.; Malliavin, T.; Mikou, A.; Reisdorf, C.; Robin, M.; 
van Heijenoort, C.; Yang, Y. Biochimie 1990, 72, 531. 
(4) Kaplan, O.; Cohen, J. S. Trends. Pharmacol. Sci. 1990, 11, 398. 
(5) Geppi, M.; Mollica, G.; Borsacchi, S.; Veracini, C. A. Appl. Spectrosc. Rev. 2008, 43, 
202. 
(6) Harris, R. K. J. Pharm. Pharmacol. 2007, 59, 225. 
(7) Harris, R. K.; Hodgkinson, P.; Larsson, T.; Muruganantham, A. J. Pharm. Biomed. 
Anal. 2005, 38, 858. 
(8) Monti, G. A.; Chattah, A. K.; Linck, Y. G. Annual Reports on NMR Spectroscopy, 
Academic Press, 2014. 
(9) Bugay, D. E. Pharm. Res. 1993, 10, 317. 
(10) Paudel, A.; Geppi, M.; Van den Mooter, G. J. Pharm. Sci 2014, 103, 2635. 
 
 
210 
(11) Berendt, R. T.; Sperger, D. M.; Munson, E. J.; Isbester, P. K. Trends Anal. Chem. 
2006, 25, 977. 
(12) Pham, T. N.; Watson, S. A.; Edwards, A. J.; Chavda, M.; Clawson, J. S.; Strohmeier, 
M.; Vogt, F. G. Mol. Pharmaceutics 2010, 7, 1667. 
(13) Schaefer, J.; Stejskal, E. O.; Buchdahl, R. Macromolecules 1975, 8, 291. 
(14) Schaefer, J.; Stejskal, E. O.; Buchdahl, R. Macromolecules 1977, 10, 384. 
(15) Andrew, E. R.; Bradbury, A.; Eades, R. G. Nature 1959, 183, 1802. 
(16) Dixon, W. T.; Schaefer, J.; Sefcik, M. D.; Stejskal, E. O.; McKay, R. A. J. Magn. 
Reson.(1969) 1982, 49, 341. 
(17) Pines, A.; Gibby, M. G.; Waugh, J. S. Chem. Phys. Lett. 1972, 15, 373. 
(18) Pines, A. J. Chem. Phys. 1973, 59, 569. 
(19) Knicker, H. Org. Geochem. 2011, 42, 867. 
(20) Yuan, X.; Xiang, T.-X.; Anderson, B. D.; Munson, E. J. Mol. Pharmaceutics 2015, 
12, 4518. 
(21) Urbanova, M.; Sturcova, A.; Kredatusova, J.; Brus, J. Int. J. Pharm. 2015, 478, 464. 
(22) Policianova, O.; Brus, J.; Hruby, M.; Urbanova, M.; Zhigunov, A.; Kredatusova, J.; 
Kobera, L. Mol. Pharmaceutics 2014, 11, 516. 
(23) Bovey, F. A.; Mirau, P. A. NMR of Polymers, Academic Press, 1996. 
(24) Yuan, X.; Sperger, D.; Munson, E. J. Mol. Pharmaceutics 2013, 11, 329. 
(25) Newman, A.; Engers, D.; Bates, S.; Ivanisevic, I.; Kelly, R. C.; Zografi, G. J. 
Pharm. Sci 2008, 97, 4840. 
(26) Tongyin, Y.; Mingming, G. Prog. Polym. Sci. 1990, 15, (6), 825-908. 
(27) Aso, Y.; Yoshioka, S.; Miyazaki, T.; Kawanishi, T. Chem. Pharm. Bull. 2009, 57, 
61. 
(28) Song, Y.; Yang, X.; Chen, X.; Nie, H.; Byrn, S.; Lubach, J. W. Mol. Pharmaceutics 
2015, 12, 857. 
(29) Tatton, A. S.; Pham, T. N.; Vogt, F. G.; Iuga, D.; Edwards, A. J.; Brown, S. P. 
CrystEngComm 2012, 14, 2654. 
(30) Tatton, A. S.; Pham, T. N.; Vogt, F. G.; Iuga, D.; Edwards, A. J.; Brown, S. P. Mol. 
Pharmaceutics 2013, 10, 999. 
(31) Vogt, F. G.; Yin, H.; Forcino, R. G.; Wu, L. Mol. Pharmaceutics 2013, 10, 3433. 
(32) Offerdahl, T. J.; Salsbury, J. S.; Dong, Z.; Grant, D. J. W.; Schroeder, S. A.; 
Prakash, I.; Gorman, E. M.; Barich, D. H.; Munson, E. J. J. Pharm. Sci. 2005, 94, 2591. 
 
 
211 
(33) Tan, I.; Flanagan, B. M.; Halley, P. J.; Whittaker, A. K.; Gidley, M. J. 
Biomacromolecules 2007, 8, 885. 
(34) Lefort, R.; De Gusseme, A.; Willart, J. F.; Danède, F.; Descamps, M. Int. J. Pharm. 
2004, 280, 209. 
Chapter 3 
(1) He, Y.; Ho, C. J. Pharm. Sci 2015. 
(2) Laitinen, R.; Löbmann, K.; Strachan, C. J.; Grohganz, H.; Rades, T. Int. J. Pharm. 
2013, 453, (1), 65-79. 
(3) Brough, C.; Williams, R. Int. J. Pharm. 2013, 453, (1), 157-166. 
(4) Van den Mooter, G. Drug Discovery Today: Technol. 2012, 9, (2), e79-e85. 
(5) Yu, L. Adv. Drug. Delivery Rev. 2001, 48, (1), 27-42. 
(6) Chiou, W. L.; Riegelman, S. J. Pharm. Sci 1971, 60, (9), 1281-1302. 
(7) Vo, C. L.-N.; Park, C.; Lee, B.-J. Eur. J. Pharm. Biopharm. 2013, 85, (3), 799-813. 
(8) Qi, S.; Moffat, J. G.; Yang, Z. Mol. Pharmaceutics 2013, 10, (3), 918-930. 
(9) Qian, F.; Huang, J.; Hussain, M. A. J. Pharm. Sci 2010, 99, (7), 2941-2947. 
(10) Baird, J. A.; Taylor, L. S. Adv. Drug. Delivery Rev. 2012, 64, (5), 396-421. 
(11) Konno, H.; Taylor, L. S. J. Pharm. Sci. 2006, 95, (12), 2692. 
(12) Karavas, E.; Ktistis, G.; Xenakis, A.; Georgarakis, E. Drug Dev. Ind. Pharm. 2005, 
31, (6), 473-489. 
(13) Ahlneck, C.; Zografi, G. Int. J. Pharm. 1990, 62, (2), 87-95. 
(14) Newman, A.; Nagapudi, K.; Wenslow, R. Ther. Delivery 2015, 6, (2), 247. 
(15) Newman, A.; Engers, D.; Bates, S.; Ivanisevic, I.; Kelly, R. C.; Zografi, G. J. 
Pharm. Sci. 2008, 97, (11), 4840-4856. 
(16) Bikiaris, D.; Papageorgiou, G. Z.; Stergiou, A.; Pavlidou, E.; Karavas, E.; Kanaze, 
F.; Georgarakis, M. Thermochim. Acta 2005, 439, (1), 58-67. 
(17) Qian, F.; Huang, J.; Zhu, Q.; Haddadin, R.; Gawel, J.; Garmise, R.; Hussain, M. Int. 
J. Pharm. 2010, 395, (1), 232-235. 
(18) Lodge, T. P.; Wood, E. R.; Haley, J. C. J. Polym. Sci. Part B: Polym. Phys. 2006, 
44, 756. 
(19) Padilla, A. M.; Ivanisevic, I.; Yang, Y.; Engers, D.; Bogner, R. H.; Pikal, M. J. 
Pharm. Sci. 2011, 100, (1), 206-222. 
(20) Ricarte, R. G.; Lodge, T. P.; Hillmyer, M. A. Mol. Pharmaceutics 2015, 12, 983. 
 
 
212 
(21) Lauer, M. E.; Grassmann, O.; Siam, M.; Tardio, J.; Jacob, L.; Page, S.; Kindt, J. H.; 
Engel, A.; Alsenz, J. Pharm. Res. 2011, 28, (3), 572-584. 
(22) Li, N.; Gilpin, C. J.; Taylor, L. S. Mol. Pharmaceutics 2017, 14, (5), 1691-1705. 
(23) Paudel, A.; Geppi, M.; Van den Mooter, G. J. Pharm. Sci. 2014, 103, (9), 2635-
2662. 
(24) Ueda, K.; Higashi, K.; Moribe, K. Mol. Pharmaceutics 2016, 13, 852. 
(25) Song, Y.; Yang, X.; Chen, X.; Nie, H.; Byrn, S.; Lubach, J. W. Mol. Pharmaceutics 
2015, 12, (3), 857-866. 
(26) Calahan, J. L.; Azali, S. C.; Munson, E. J.; Nagapudi, K. Mol. Pharmaceutics 2015, 
12, (11), 4115-4123. 
(27) Yuan, X.; Sperger, D.; Munson, E. J. Mol. Pharmaceutics 2013, 11, (1), 329-337. 
(28) Pham, T. N.; Watson, S. A.; Edwards, A. J.; Chavda, M.; Clawson, J. S.; Strohmeier, 
M.; Vogt, F. G. Mol. Pharmaceutics 2010, 7, (5), 1667-1691. 
(29) Schmidt-Rohr, K.; Spiess, H. W., Multidimensional Solid-State NMR and Polymers, 
Elsevier, 2012. 
(30) Clauss, J.; Schmidt-Rohr, K.; Spiess, H. W. Acta Polym. 1993, 44, (1), 1. 
(31) Litvinov, V. M.; Guns, S.; Adriaensens, P.; Scholtens, B. J. R.; Quaedflieg, M. P.; 
Carleer, R.; Van den Mooter, G. Mol. Pharmaceutics 2012, 9, (10), 2924-2932. 
(32) Aso, Y.; Yoshioka, S.; Miyazaki, T.; Kawanishi, T.; Tanaka, K.; Kitamura, S.; 
Takakura, A.; Hayashi, T.; Muranushi, N. Chem. Pharm. Bull. 2007, 55, (8), 1227. 
(33) Yang, F.; Su, Y.; Zhang, J.; DiNunzio, J.; Leone, A.; Huang, C.; Brown, C. D. Mol. 
Pharmaceutics 2016, 13, (10), 3494-3505. 
(34) Nie, H.; Su, Y.; Zhang, M.; Song, Y.; Leone, A.; Taylor, L. S.; Marsac, P. J.; Li, T.; 
Byrn, S. R. Mol. Pharmaceutics 2016, 13, (11), 3964-3975. 
(35) Yuan, X.; Xiang, T.-X.; Anderson, B. D.; Munson, E. J. Mol. Pharmaceutics 2015, 
12, (12), 4518-4528. 
(36) Policianova, O.; Brus, J.; Hruby, M.; Urbanova, M.; Zhigunov, A.; Kredatusova, J.; 
Kobera, L. Mol. Pharmaceutics 2014, 11, (2), 516-530. 
(37) Ng, Y. C.; Yang, Z. Y.; McAuley, W. J.; Qi, S. Eur. J. Pharm. Biopharm. 2013. 
(38) Konno, H.; Taylor, L. S. J. Pharm. Sci. 2006, 95, 2692. 
(39) Gupta, P.; Thilagavathi, R.; Chakraborti, A. K.; Bansal, A. K. Mol. Pharmaceutics 
2005, 2, (5), 384. 
(40) Maniruzzaman, M.; Morgan, D. J.; Mendham, A. P.; Pang, J.; Snowden, M. J.; 
Douroumis, D. Int. J. Pharm. 2013, 443, (1–2), 199. 
(41) Zhu, Q.; Taylor, L. S.; Harris, M. T. Mol. Pharmaceutics 2010, 7, (4), 1291-1300. 
 
 
213 
(42) Rumondor, A. C. F.; Marsac, P. J.; Stanford, L. A.; Taylor, L. S. Mol. 
Pharmaceutics 2009, 6, (5), 1492. 
(43) Marsac, P. J.; Konno, H.; Taylor, L. S. Pharm. Res. 2006, 23, 2306. 
(44) Al-Obaidi, H.; Buckton, G. AAPS PharmSciTech 2009, 10, (4), 1172-1177. 
(45) Sun, M.; Wu, C.; Fu, Q.; Di, D.; Kuang, X.; Wang, C.; He, Z.; Wang, J.; Sun, J. Int. 
J. Pharm. 2016, 503, (1), 238-246. 
(46) Lin, S.-Y.; Lin, H.-L.; Chi, Y.-T.; Huang, Y.-T.; Kao, C.-Y.; Hsieh, W.-H. Int. J. 
Pharm. 2015, 496, (2), 457-465. 
(47) Paudel, A.; Nies, E.; Van den Mooter, G. Mol. Pharmaceutics 2012, 9, (11), 3301-
3317. 
(48) Dixon, W. T.; Schaefer, J.; Sefcik, M. D.; Stejskal, E. O.; McKay, R. A. J. Magn. 
Reson. 1982, 49, (2), 341. 
(49) Fung, B. M.; Khitrin, A. K.; Ermolaev, K. J. Magn. Reson. 2000, 142, (1), 97. 
(50) Barich, D. H.; Gorman, E. M.; Zell, M. T.; Munson, E. J. Solid State Nucl. Magn. 
Reson. 2006, 30, (3–4), 125. 
(51) Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; 
Cheeseman, J. R.; Scalmani, G.; Barone, V.; Mennucci, B.; Petersson, G. A.; Nakatsuji, 
H.; Caricato, M.; Li, X.; Hratchian, H. P.; Izmaylov, A. F.; Bloino, J.; Zheng, G.; 
Sonnenberg, J. L.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, 
M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Vreven, T.; Montgomery Jr., J. A.; 
Peralta, J. E.; Ogliaro, F.; Bearpark, M.; Heyd, J. J.; Brothers, E.; Kudin, K. N.; 
Staroverov, V. N.; Kobayashi, R.; Normand, J.; Raghavachari, K.; Rendell, A.; Burant, J. 
C.; Iyengar, S. S.; Tomasi, J.; Cossi, M.; Rega, N.; Millam, J. M.; Klene, M.; Knox, J. E.; 
Cross, J. B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; 
Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Martin, R. L.; 
Morokuma, K.; Zakrzewski, V. G.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.; 
Dapprich, S.; Daniels, A. D.; Farkas, Ö.; Foresman, J. B.; Ortiz, J. V.; Cioslowski, J.; 
Fox, D. J. Gaussian 09, Gaussian, Inc: Wallingford, CT, 2009. 
(52) Becke, A. D. J. Chem. Phys. 1993, 98, (7), 5648-52. 
(53) Krishnan, R.; Binkley, J. S.; Seeger, R.; Pople, J. A. J. Chem. Phys. 1980, 72, 650-4. 
(54) Chen, H.; Lin, C.; Chen, G.; Lai, G.; Zhao, S. Huaxue Yanjiu 2006, 17, (4), 6-9. 
(55) Hariharan, P. C.; Pople, J. A Theor. Chim. Acta 1973, 28, 213-22. 
(56) Baerends, E. J.; Ellis, D. E.; Ros, P. Chemical Physics 1973, 2, (1), 41-51. 
(57) Knopp, M. M.; Löbmann, K.; Elder, D. P.; Rades, T.; Holm, R. Eur. J. Pharm. Sci. 
2016, 87, (Supplement C), 164-173. 
(58) W.Y. Lee, T.; A. Boersen, N.; Hui, H. W.; Chow, S. F.; Wan, K. Y.; H.L. Chow, A. 
Curr. Pharm. Des. 2014, 20, (3), 303-324. 
 
 
214 
(59) Schneider, H. A. Makromol. Chem. 1988, 189, (8), 1941. 
(60) Bhugra, C.; Telang, C.; Schwabe, R.; Zhong, L. Mol. Pharmaceutics 2016, 13, (9), 
3326-3333. 
(61) Latosińska, J. N. Chem. Phys. Lett. 2008, 463, (1), 195-200. 
(62) Dempah, K. E.; Lubach, J. W.; Munson, E. J. Mol. Pharmaceutics 2017, 14, (3), 
856-865. 
(63) Sperger, D. M.; Fu, S.; Block, L. H.; Munson, E. J. J. Pharm. Sci. 2011, 100, (8), 
3441-3452. 
(64) Geppi, M.; Mollica, G.; Borsacchi, S.; Veracini, C. A. Appl. Spectrosc. Rev. 2008, 
43, (3), 202-302. 
(65) Guo, M. Trends Polym. Sci. 1996, 4, (7), 238-244. 
(66) Bovey, F. A.; Mirau, P. A., NMR of Polymers, Academic Press, 1996. 
(67) Tongyin, Y.; Mingming, G. Prog. Polym. Sci. 1990, 15, (6), 825-908. 
(68) Xiang, T.-X.; Anderson, B. D. J. Pharm. Sci. 2017, 106, (3), 803-816. 
(69) Konno, H.; Taylor, L. S. J. Pharm. Sci. 2006, 95, (12), 2692-2705. 
(70) Song, Y.; Wang, L.; Yang, P.; Wenslow, R. M.; Tan, B.; Zhang, H.; Deng, Z. J. 
Pharm. Sci. 2013, 102, (6), 1915-1923. 
(71) Kestur, U. S.; Taylor, L. S. CrystEngComm 2010, 12, (8), 2390-2397. 
(72) Wegiel, L. A.; Mauer, L. J.; Edgar, K. J.; Taylor, L. S. J. Pharm. Sci. 2013, 102, (1), 
171-184. 
(73) Jeffrey, G. A.; An Introduction to Hydrogen Bonding, Oxford University Press, 
1997. 
 
Chapter 4 
(1) Janssens, S.; Van den Mooter, G. J. Pharm. Pharmacol. 2009, 61, 1571. 
(2) Newman, A.; Engers, D.; Bates, S.; Ivanisevic, I.; Kelly, R. C.; Zografi, G. J. Pharm. 
Sci. 2008, 97, (11), 4840-4856. 
(3) Serajuddin, A. T. J. Pharm. Sci. 1999, 88, (10), 1058. 
(4) Van den Mooter, G. Drug Discovery Today: Technol. 2012, 9, (2), e79-e85. 
(5) He, Y.; Ho, C. J. Pharm. Sci. 2015. 
(6) Marsac, P. J.; Konno, H.; Taylor, L. S. Pharm. Res. 2006, 23, 2306. 
(7) W.Y. Lee, T.; A. Boersen, N.; Hui, H. W.; Chow, S. F.; Wan, K. Y.; H.L. Chow, A. 
Curr. Pharm. Des. 2014, 20, (3), 303-324. 
 
 
215 
(8) Li, N.; Taylor, L. S. Mol. Pharmaceutics 2016, 13, 1123. 
(9) Higashi, K.; Hayashi, H.; Yamamoto, K.; Moribe, K. Int. J. Pharm. 2015, 494, (1), 9-
16. 
(10) Li, N.; Gilpin, C. J.; Taylor, L. S. Mol. Pharmaceutics 2017, 14, (5), 1691-1705. 
(11) Tian, Y.; Booth, J.; Meehan, E.; Jones, D. S.; Li, S.; Andrews, G. P. Mol. 
Pharmaceutics 2013, 10, 236. 
(12) Zhao, Y.; Inbar, P.; Chokshi, H. P.; Malick, A. W.; Choi, D. S. J. Pharm. Sci. 2011, 
100, (8), 3196. 
(13) Calahan, J. L.; Azali, S. C.; Munson, E. J.; Nagapudi, K. Mol. Pharmaceutics 2015, 
12, (11), 4115-4123. 
(14) Marsac, P. J.; Shamblin, S. L.; Taylor, L. S. Pharm. Res. 2006, 23, (10), 2417-2426. 
(15) Djuris, J.; Nikolakakis, I.; Ibric, S.; Djuric, Z.; Kachrimanis, K. Eur. J. Pharm. 
Biopharm. 2013, 84, (1), 228. 
(16) Dalsania, S.; Sharma, J.; Munjal, B.; Bansal, A. K. Pharm. Res. 2018, 35, (2), 29. 
(17) Donnelly, C.; Tian, Y.; Potter, C.; Jones, D. S.; Andrews, G. P. Pharm. Res. 2015, 
32, (1), 167-179. 
(18) Baird, J. A.; Taylor, L. S. Adv. Drug Delivery Rev. 2012, 64, 396. 
(19) Qian, F.; Huang, J.; Zhu, Q.; Haddadin, R.; Gawel, J.; Garmise, R.; Hussain, M. Int. 
J. Pharm. 2010, 395, 232. 
(20) Pham, T. N.; Watson, S. A.; Edwards, A. J.; Chavda, M.; Clawson, J. S.; Strohmeier, 
M.; Vogt, F. G. Mol. Pharmaceutics 2010, 7, (5), 1667-1691. 
(21) Yang, F.; Su, Y.; Zhang, J.; DiNunzio, J.; Leone, A.; Huang, C.; Brown, C. D. Mol. 
Pharmaceutics 2016, 13, (10), 3494-3505. 
(22) Policianova, O.; Brus, J.; Hruby, M.; Urbanova, M.; Zhigunov, A.; Kredatusova, J.; 
Kobera, L. Mol. Pharmaceutics 2014, 11, (2), 516-530. 
(23) Paudel, A.; Geppi, M.; Van den Mooter, G. J. Pharm. Sci. 2014, 103, (9), 2635-
2662. 
(24) Gerges, J.; Affouard, F. J. Phys. Chem. B 2015, 119, (33), 10768-10783. 
(25) Lin, S.-Y.; Lin, H.-L.; Chi, Y.-T.; Huang, Y.-T.; Kao, C.-Y.; Hsieh, W.-H. Int. J. 
Pharm. 2015, 496, (2), 457-465. 
(26) Stanković, M.; Frijlink, H. W.; Hinrichs, W. L. J. Drug Discovery Today 2015, 20, 
(7), 812-823. 
(27) Krevelen, D. W.; Van Krevelen, D., Properties of Polymers: Their Correlation with 
Chemical Structure, their Numerical Estimation and Prediction from Additive Group 
Contributions, Elsevier: Amsterdam, 1990. 
 
 
216 
(28) Schneider, H. A.  The Gordon-Taylor equation. Makromol. Chem. 1988, 189, (8), 
1941. 
(29) Dixon, W. T.; Schaefer, J.; Sefcik, M. D.; Stejskal, E. O.; McKay, R. A. J. Magn. 
Reson. 1982, 49, (2), 341. 
(30) Fung, B. M.; Khitrin, A. K.; Ermolaev, K. J. Magn. Reson. 2000, 142, (1), 97. 
(31) Barich, D. H.; Gorman, E. M.; Zell, M. T.; Munson, E. J. Solid State Nucl. Magn. 
Reson. 2006, 30, (3–4), 125. 
(32) Greenhalgh, D. J.; Williams, A. C.; Timmins, P.; York, P. J. Pharm. Sci. 1999, 88, 
(11), 1182-1190. 
(33) Lu, J.; Cuellar, K.; Hammer, N. I.; Jo, S.; Gryczke, A.; Kolter, K.; Langley, N.; 
Repka, M. A. Drug Dev. Ind. Pharm. 2016, 42, (3), 485-496. 
(34) Qian, F.; Huang, J.; Hussain, M. A. J. Pharm. Sci. 2010, 99, (7), 2941. 
(35) Lin, D.; Huang, Y.  A thermal analysis method to predict the complete phase 
diagram of drug–polymer solid dispersions. Int. J. Pharm. 2010, 399, (1–2), 109. 
(36) Konno, H.; Taylor, L. S. J. Pharm. Sci. 2006, 95, 2692. 
(37) Shamblin, S. L.; Taylor, L. S.; Zografi, G. J. Pharm. Sci. 1998, 87, (6), 694-701. 
(38) Tang, X. C.; Pikal, M. J.; Taylor, L. S. Pharm. Res. 2002, 19, (4), 477-483. 
(39) Geppi, M.; Mollica, G.; Borsacchi, S.; Veracini, C. A. Appl. Spectrosc. Rev. 2008, 
43, (3), 202-302. 
 
Chapter 5 
(1) Vasconcelos, T.; Sarmento, B.; Costa, P. Drug Discovery Today 2007, 12, 1068. 
(2) Vo, C. L.-N.; Park, C.; Lee, B.-J. Eur. J. Pharm. Biopharm. 2013, 85, 799. 
(3) Smithey, D.; Gao, P.; Taylor, L. AAPS News Magazine 2013, 16, 11. 
(4) W.Y. Lee, T.; A. Boersen, N.; Hui, H. W.; Chow, S. F.; Wan, K. Y.; H.L. Chow, A. 
Curr. Pharm. Des. 2014, 20, 303. 
(5) Policianova, O.; Brus, J.; Hruby, M.; Urbanova, M.; Zhigunov, A.; Kredatusova, J.; 
Kobera, L. Mol. Pharmaceutics 2014, 11, 516. 
(6) Maniruzzaman, M.; Morgan, D. J.; Mendham, A. P.; Pang, J.; Snowden, M. J.; 
Douroumis, D. Int. J. Pharm. 2013, 443, 199. 
(7) Calahan, J. L.; Azali, S. C.; Munson, E. J.; Nagapudi, K. Mol. Pharmaceutics 2015, 
12, 4115. 
(8) Janssens, S.; Van den Mooter, G. J. Pharm. Pharmacol. 2009, 61, 1571. 
 
 
217 
(9) Janssens, S.; Nagels, S.; De Armas, H. N.; D’autry, W.; Van Schepdael, A.; Van den 
Mooter, G. Eur. J. Pharm. Biopharm. 2008, 69, 158. 
(10) Goddeeris, C.; Willems, T.; Van den Mooter, G. Eur. J. Pharm. Sci. 2008, 34, 293. 
(11) Al-Obaidi, H.; Buckton, G. AAPS PharmSciTech 2009, 10, 1172. 
(12) Al-Obaidi, H.; Ke, P.; Brocchini, S.; Buckton, G. Int. J. Pharm. 2011, 419, 20. 
(13) Ziaee, A.; Albadarin, A. B.; Padrela, L.; Faucher, A.; O'Reilly, E.; Walker, G. Eur. 
J. Pharm. Biopharm. 2017, 120, 43. 
(14) Xie, T.; Taylor, L. S. J Pharm Sci. 2017, 106, 100. 
(15) Rumondor, A. C. F.; Ivanisevic, I.; Bates, S.; Alonzo, D. E.; Taylor, L. S. Pharm. 
Res. 2009, 26, 2523. 
(16) Wegiel, L. A.; Mauer, L. J.; Edgar, K. J.; Taylor, L. S. J. Pharm. Sci. 2013, 102, 
171. 
(17) Mistry, P.; Mohapatra, S.; Gopinath, T.; Vogt, F. G.; Suryanarayanan, R. Mol. 
Pharmaceutics 2015, 12, 3339. 
(18) Chen, Y.; Wang, S.; Wang, S.; Liu, C.; Su, C.; Hageman, M.; Hussain, M.; Haskell, 
R.; Stefanski, K.; Qian, F. Pharm. Res. 2016, 33, 2445. 
(19) Dixon, W. T.; Schaefer, J.; Sefcik, M. D.; Stejskal, E. O.; McKay, R. A. J. Magn. 
Reson. 1982, 49, 341. 
(20) Fung, B. M.; Khitrin, A. K.; Ermolaev, K. J. Magn. Reson. 2000, 142, 97. 
(21) Barich, D. H.; Gorman, E. M.; Zell, M. T.; Munson, E. J. Solid State Nucl. Magn. 
Reson. 2006, 30, 125. 
(22) Männistö, P. T.; Mäntylä, R.; Nykänen, S.; Lamminsivu, U.; Ottoila, P. Antimicrob. 
Agents Chemother.1982, 21, 730. 
(23) Lee, J. W.; Kim, S. Y.; Kim, S. S.; Lee, Y. M.; Lee, K. H.; Kim, S. J. J. Appl. Polym. 
Sci. 1999, 73, 113. 
(24) Vo, C. L.-N.; Park, C.; Lee, B.-J. Eur. J. Pharm. Biopharm. 2013, 85, 799. 
(25) Van den Mooter, G.; Wuyts, M.; Blaton, N.; Busson, R.; Grobet, P.; Augustijns, P.; 
Kinget, R. Eur. J. Pharm. Sci. 2001, 12, 261. 
(26) Newman, A. W.; Byrn, S. R. Drug Discovery Today 2003, 8, 898. 
(27) Baird, J. A.; Taylor, L. S. Adv. Drug. Delivery Rev. 2012, 64, 396. 
(28) Qian, F.; Huang, J.; Zhu, Q.; Haddadin, R.; Gawel, J.; Garmise, R.; Hussain, M. Int. 
J. Pharm. 2010, 395, 232. 
(29) Baghel, S.; Cathcart, H.; O'Reilly, N. J. J. Pharm. Sci. 2016, 105, 2527. 
 
 
218 
(30) Liu, H.; Zhang, X.; Suwardie, H.; Wang, P.; Gogos, C. G. J. Pharm. Sci. 2012, 101, 
2204. 
(31) Weuts, I.; Kempen, D.; Verreck, G.; Peeters, J.; Brewster, M.; Blaton, N.; Van den 
Mooter, G. Eur. J. Pharm. Sci. 2005, 25, 387. 
(32) Childs, S. L.; Stahly, G. P.; Park, A. Mol. Pharmaceutics 2007, 4, 323. 
(33) Ueda, H.; Aikawa, S.; Kashima, Y.; Kikuchi, J.; Ida, Y.; Tanino, T.; Kadota, K.; 
Tozuka, Y. J. Pharm. Sci. 2014, 103, 2829. 
(34) Konno, H.; Taylor, L. S. J. Pharm. Sci. 2006, 95, 2692. 
(35) Meng, F.; Trivino, A.; Prasad, D.; Chauhan, H. Eur. J. Pharm. Sci. 2015, 71, 12. 
(36) Albadarin, A. B.; Potter, C. B.; Davis, M. T.; Iqbal, J.; Korde, S.; Pagire, S.; 
Paradkar, A.; Walker, G. Int. J. Pharm. 2017, 532, 603. 
(37) Dong, J.; Ozaki, Y.; Nakashima, K. Macromolecules 1997, 30, 1111. 
(38) Nie, H.; Su, Y.; Zhang, M.; Song, Y.; Leone, A.; Taylor, L. S.; Marsac, P. J.; Li, T.; 
Byrn, S. R. Mol. Pharmaceutics. 2016, 13, 3964. 
(39) Paudel, A.; Geppi, M.; Van den Mooter, G. J. Pharm. Sci. 2014, 103, 2635. 
(40) Pham, T. N.; Watson, S. A.; Edwards, A. J.; Chavda, M.; Clawson, J. S.; Strohmeier, 
M.; Vogt, F. G. Mol. Pharmaceutics 2010, 7, 1667. 
(41) Yuan, X.; Xiang, T.-X.; Anderson, B. D.; Munson, E. J. Mol. Pharmaceutics 2015, 
12, 4518. 
(42) Lubach, J. W.; Hau, J. Pharm. Res. 2018, 35, 65. 
(43) Song, Y.; Yang, X.; Chen, X.; Nie, H.; Byrn, S.; Lubach, J. W. Mol. Pharmaceutics 
2015, 12, 857. 
(44) Xie, T.; Taylor, L. S. Pharm. Res. 2016, 33, 739. 
(45) Meng, F.; Meckel, J.; Zhang, F. Eur. J. Pharm. Sci. 2017, 106, 413. 
 
Chapter 6 
(1) Curatolo, W.; Nightingale, J. A.; Herbig, S. M. Pharm. Res. 2009, 26, 1419. 
(2) Al-Obaidi, H.; Buckton, G. AAPS PharmSciTech 2009, 10, 1172. 
(3) Friesen, D. T.; Shanker, R.; Crew, M.; Smithey, D. T.; Curatolo, W. J.; Nightingale, J. 
A. S. Mol. Pharmaceutics 2008, 5, 1003. 
(4) Huang, Y.; Dai, W. G. Acta Pharm. Sin. B 2014, 4, 18. 
(5) Parikh, T.; Gupta, S. S.; Meena, A. K.; Vitez, I.; Mahajan, N.; Serajuddin, A. T. M. J. 
Pharm. Sci 2015, 104, 2142. 
 
 
219 
(6) Weuts, I.; Van Dycke, F.; Voorspoels, J.; De Cort, S.; Stokbroekx, S.; Leemans, R.; 
Brewster, M. E.; Xu, D.; Segmuller, B.; Turner, Y. T. A.; Roberts, C. J.; Davies, M. C.; 
Qi, S.; Craig, D. Q. M.; Reading, M. J. Pharm. Sci. 2011, 100, 260. 
(7) Duarte, Í.; Santos, J. L.; Pinto, J. F.; Temtem, M. Pharm. Res. 2015, 32, 222. 
(8) Dixon, W. T.; Schaefer, J.; Sefcik, M. D.; Stejskal, E. O.; McKay, R. A. J. Magn. 
Reson. 1982, 49, 341. 
(9) Fung, B. M.; Khitrin, A. K.; Ermolaev, K. J. Magn. Reson. 2000, 142, 97. 
(10) Barich, D. H.; Gorman, E. M.; Zell, M. T.; Munson, E. J. Solid State Nucl. Magn. 
Reson. 2006, 30, 125. 
(11) Tongyin, Y.; Mingming, G. Prog. Polym. Sci. 1990, 15, 825. 
(12) Aso, Y.; Yoshioka, S.; Miyazaki, T.; Kawanishi, T.; Tanaka, K.; Kitamura, S.; 
Takakura, A.; Hayashi, T.; Muranushi, N. Chem. Pharm. Bull. 2007, 55, 1227. 
(13) Bovey, F. A.; Mirau, P. A. NMR of Polymers, Academic Press, 1996. 
(14) Rumondor, A. C. F.; Marsac, P. J.; Stanford, L. A.; Taylor, L. S. Mol. 
Pharmaceutics 2009, 6, 1492. 
(15) Chakravarty, P.; Lubach, J. W.; Hau, J.; Nagapudi, K. Int. J. Pharm. 2017, 519, 44. 
 
 
 
 
 
VITA 
Kanika Sarpal 
EDUCATION 
2009 – 2011 M.S. Pharm (Pharmaceutics) 
 National Institute of Pharmaceutical Education and Research (N.I.P.E.R), 
S.A.S Nagar, India  
2005 – 2009 B. Pharmacy  
 University Institute of Pharmaceutical Sciences, Panjab University, 
Chandigarh, India  
HONORS AND AWARDS 
2018  International Pharmaceutical Excipient Council (IPEC) Foundation Graduate 
Student Award  
2018  American Association of Pharmaceutical Sciences (AAPS) Best Poster Abstract 
Award 
2018  AAPS Travelship Award  
2018  Small Molecule NMR Conference Scholarship 
2018  Pharmaceutical Sciences Excellence in Graduate Achievement Fellowship 
2018 2nd Prize, Rho Chi Research Day at University of Kentucky  
2017  American Association of Indian Pharmaceutical Scientists (AAiPS) Graduate  
Student Award 
2017  Small Molecule NMR Conference Scholarship 
2016  1st Prize, Poster presentation at Globalization of Pharmaceutics Education  
Network Conference 
2015  3rd Prize, Podium talk at Pharmaceutics Graduate Student Research Meeting  
 
PUBLICATIONS 
K. Sarpal, Y.B. Pawar and A. K. Bansal. Self-emulsifying drug delivery systems: A strategy to 
improve oral bioavailability. CRIPS. Vol. 11, No. 3, Jul-Sept 2010. 
K. Sarpal, S. Delaney, G. Zhang and E. Munson. Phase Behavior of Amorphous Solid 
Dispersions of Felodipine: Homogeneity and Drug-Polymer Interactions. (manuscript submitted). 
K. Sarpal, C. Tower and E. Munson. An Investigation into Molecular Interactions and Phase 
Behavior of Binary and Ternary Amorphous Solid dispersions of Ketoconazole (manuscript to be 
submitted). 
M. Honick, K. Sarpal, A Alayoubi, A. Zidan, S. Hoag, R. Hollenbeck, E. Munson, and J Polli. 
Utility of Films to Anticipate Properties of Amorphous Itraconazole Spray Dried Dispersions. 
(manuscript submitted). 
